|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197845|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-07-18 22:13:01.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740583|^|A|^|REGISTERED|^|SPECIFIC_ACTIVITY|^|Potency Assay (Cell Based)|^|TM100001721|^|1|^|10|^|2012-07-18 22:13:01.0|^|TM100001721v4.0/07Jun2012|^|NB74138 p1|^|CRO-017-01|^|13-JUL-2012|^|17131541|^|0|^|A|^|T|^|Relative Potency|^|Relative Potency|^|Relative Potency|^|86|^|86|^|%|^|86|^||^|T|^|T|^|55 - 158% potency relative to reference material|^|ZANY|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197845|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-07-18 22:13:01.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740583|^|A|^|REGISTERED|^|SPECIFIC_ACTIVITY|^|Potency Assay (Cell Based)|^|TM100001721|^|1|^|10|^|2012-07-18 22:13:01.0|^|TM100001721v4.0/07Jun2012|^|NB74138 p1|^|CRO-017-01|^|13-JUL-2012|^|17131542|^|0|^|A|^|T|^|Specific Activity|^|Specific Activity|^|Specific Activity|^|859|^|859|^|U/mg|^|859|^||^|T|^|T|^|550 - 1580 U/mg|^|ZANY|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740573|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052|^|1|^|1|^|2012-06-14 10:10:22.0|^|TM100002052 Version 3.0/13-Apr-2012|^|NB73112 P3|^|CRO-017-02|^|05-JUN-2012|^|17131475|^|0|^|A|^|T|^|Appearance|^|Visual appearance|^|Visual appearance|^|White cake essentially free from visible particulates|^|White cake essentially free from visible particulates|^||^||^||^|T|^|T|^|White cake essentially free from visible particulates|^|BYRNEJ18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740574|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reduced)|^|TM100001851|^|1|^|10|^|2012-06-14 10:53:22.0|^|TM100001851 Version 3.0 30May2012|^|NB73091 P1-11|^|CRO-017-02|^|08-JUN-2012|^|20004943|^|0|^|A|^|T|^|LOQ|^|LOQ|^|LOQ|^|0.3|^|0.3|^||^|0.3|^||^|T|^|T|^||^|DEEGAO01|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740574|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reduced)|^|TM100001851|^|1|^|10|^|2012-06-14 10:53:22.0|^|TM100001851 Version 3.0 30May2012|^|NB73091 P1-11|^|CRO-017-02|^|08-JUN-2012|^|17131480|^|0|^|A|^|T|^|Sum HC and LC|^|Heavy Chain + Light Chain|^|Heavy Chain + Light Chain|^|99.3|^|99.3|^|%|^|99.3|^||^|T|^|T|^|>= 95.0% IgG as heavy + light chain|^|JEFFEL02|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740574|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reduced)|^|TM100001851|^|1|^|10|^|2012-06-14 10:53:22.0|^|TM100001851 Version 3.0 30May2012|^|NB73091 P1-11|^|CRO-017-02|^|08-JUN-2012|^|17131481|^|0|^|A|^|T|^|Percent Fragment|^|Fragments|^|Fragments|^|0.4|^|0.4|^|%|^|0.4|^||^|T|^|T|^|Report Results|^|DEEGAO01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740575|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|7|^|2012-06-14 08:22:02.0|^|TM100002052 v3 13 Apr 2012|^|NB73111 p7-9|^|CRO-017-02|^|11-JUN-2012|^|17131486|^|0|^|A|^|T|^|Color Hue|^|Color Hue|^|Color Hue|^|B|^|B|^||^||^||^|T|^|T|^||^|BYRNEJ18|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740575|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|7|^|2012-06-14 08:22:02.0|^|TM100002052 v3 13 Apr 2012|^|NB73111 p7-9|^|CRO-017-02|^|11-JUN-2012|^|17131487|^|0|^|A|^|T|^|Color Intensity|^|Color Intensity|^|Color Intensity|^|9|^|9|^||^|9|^||^|T|^|T|^||^|BYRNEJ18|^|F|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740575|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|7|^|2012-06-14 08:22:02.0|^|TM100002052 v3 13 Apr 2012|^|NB73111 p7-9|^|CRO-017-02|^|11-JUN-2012|^|17131488|^|0|^|A|^|T|^|Color|^|Coloration|^|Coloration|^|<=B9|^|<=B9|^||^||^||^|T|^|T|^|Not more intensely colored than level 5 of the color standard|^|BYRNEJ18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740572|^|A|^|REGISTERED|^|CONCENTRATION_UV|^|Protein Concentration (UV)|^|TM100001683, TMC0085|^|1|^|9|^|2012-06-14 10:22:16.0|^|TM100001683 V5 15Nov2011|^|NB73092 P1-14|^|CRO-017-02|^|05-JUN-2012|^|17131469|^|0|^|A|^|T|^|Protein Concentration|^|Protein Concentration - rep|^|Protein Concentration - rep|^|21.1|^|21.1|^|mg/mL|^|21.1|^||^|T|^|T|^||^|JEFFEL02|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740572|^|A|^|REGISTERED|^|CONCENTRATION_UV|^|Protein Concentration (UV)|^|TM100001683, TMC0085|^|1|^|9|^|2012-06-14 10:22:16.0|^|TM100001683 V5 15Nov2011|^|NB73092 P1-14|^|CRO-017-02|^|05-JUN-2012|^|17131470|^|0|^|A|^|T|^|Protein Concentration - Average|^|Protein Concentration|^|Protein Concentration|^|21.1|^|21.1|^|mg/mL|^|21.1|^||^|T|^|T|^|Report Results|^|JEFFEL02|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740576|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2012-06-19 14:55:41.0|^|TM100001681 Version 3.0/30-May-2012|^|73093 P11|^|CRO-017-02|^|08-JUN-2012|^|17131493|^|0|^|A|^|T|^|Peak 1 (% Area)|^|% Acidic Peaks - rep|^|% Acidic Peaks - rep|^|23.5|^|23.5|^|%|^|23.5|^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740576|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2012-06-19 14:55:41.0|^|TM100001681 Version 3.0/30-May-2012|^|73093 P11|^|CRO-017-02|^|08-JUN-2012|^|17131494|^|0|^|A|^|T|^|Peak 1 (% Area) - Average|^|% Acidic Peaks|^|% Acidic Peaks|^|23.5|^|23.5|^|%|^|23.5|^||^|T|^|T|^|17.0 - 33.0%|^|ROCHEP02|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740576|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2012-06-19 14:55:41.0|^|TM100001681 Version 3.0/30-May-2012|^|73093 P11|^|CRO-017-02|^|08-JUN-2012|^|17131495|^|0|^|A|^|T|^|Peak 2 (% Area)|^|% Main Peak - rep|^|% Main Peak - rep|^|58.9|^|58.9|^|%|^|58.9|^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740576|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2012-06-19 14:55:41.0|^|TM100001681 Version 3.0/30-May-2012|^|73093 P11|^|CRO-017-02|^|08-JUN-2012|^|17131496|^|0|^|A|^|T|^|Peak 2 (% Area) - Average|^|% Main Peak|^|% Main Peak|^|58.9|^|58.9|^|%|^|58.9|^||^|T|^|T|^|>= 50.0%|^|ROCHEP02|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740576|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2012-06-19 14:55:41.0|^|TM100001681 Version 3.0/30-May-2012|^|73093 P11|^|CRO-017-02|^|08-JUN-2012|^|17131497|^|0|^|A|^|T|^|Peak 3 (% Area)|^|% Basic Peaks - rep|^|% Basic Peaks - rep|^|17.6|^|17.6|^|%|^|17.6|^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740576|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2012-06-19 14:55:41.0|^|TM100001681 Version 3.0/30-May-2012|^|73093 P11|^|CRO-017-02|^|08-JUN-2012|^|17131498|^|0|^|A|^|T|^|Peak 3 (% Area) - Average|^|% Basic Peaks|^|% Basic Peaks|^|17.6|^|17.6|^|%|^|17.6|^||^|T|^|T|^|7.0 - 24.0%|^|ROCHEP02|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740577|^|A|^|ADDITIONAL|^|MAB_OXIDATION|^|Lys-C Digest|^|TM100001849|^|1|^|9|^|2012-06-14 08:11:48.0|^|TM100001849 v2 30 May 2012|^|NB73094 p15|^|CRO-017-02|^|07-JUN-2012|^|17131503|^|0|^|A|^|T|^|Peak 1 (Relative Area %)|^|Oxidation at Fc-Met-1|^|Oxidation at Fc-Met-1|^|1.2|^|1.2|^|%|^|1.2|^||^|T|^|T|^||^|BYRNEJ18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740579|^|A|^|REGISTERED|^|PARTICULATE_BIO|^|Appearance (Visible Particulates)|^|TM100002052|^|1|^|4|^|2012-06-14 08:27:29.0|^|TM100002052 v3 13 Apr 2012|^|NB73111 p2|^|CRO-017-02|^|11-JUN-2012|^|17131514|^|0|^|A|^|T|^|Particles|^|Visible particulates|^|Visible particulates|^|FREE|^|Essentially Free of Visible Particles|^||^||^||^|T|^|T|^|Essentially Free of Visible Particles|^|BYRNEJ18|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740580|^|A|^|REGISTERED|^|PH|^|pH|^|M00125|^|1|^|4|^|2012-06-14 10:05:40.0|^|M00125 Version 2.0 07May2012|^|NB73095 P1-6|^|CRO-017-02|^|11-JUN-2012|^|17131519|^|0|^|A|^|T|^|pH|^|pH - rep|^|pH - rep|^|5.9|^|5.9|^||^|5.9|^||^|T|^|T|^||^|JEFFEL02|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740580|^|A|^|REGISTERED|^|PH|^|pH|^|M00125|^|1|^|4|^|2012-06-14 10:05:40.0|^|M00125 Version 2.0 07May2012|^|NB73095 P1-6|^|CRO-017-02|^|11-JUN-2012|^|17131520|^|0|^|A|^|T|^|pH - Average|^|pH|^|pH|^|5.9|^|5.9|^||^|5.9|^||^|T|^|T|^|6.0 +/- 0.5|^|JEFFEL02|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740581|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2012-06-14 10:16:17.0|^|TM100001683 Version 5.0/15-Nov-2011|^|NB73112 P5|^|CRO-017-02|^|05-JUN-2012|^|17131525|^|0|^|A|^|T|^|Minutes|^|Minutes|^|Minutes|^|5|^|5|^|min|^|5|^||^|T|^|T|^||^|ROCHEP02|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740581|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2012-06-14 10:16:17.0|^|TM100001683 Version 5.0/15-Nov-2011|^|NB73112 P5|^|CRO-017-02|^|05-JUN-2012|^|17131526|^|0|^|A|^|T|^|Seconds|^|Seconds|^|Seconds|^|28|^|28|^|s|^|28|^||^|T|^|T|^||^|ROCHEP02|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740581|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2012-06-14 10:16:17.0|^|TM100001683 Version 5.0/15-Nov-2011|^|NB73112 P5|^|CRO-017-02|^|05-JUN-2012|^|17131527|^|0|^|A|^|T|^|Rounding Interval|^|Rounding Interval|^|Rounding Interval|^|NA|^|Not available|^||^||^||^|T|^|T|^||^|ROCHEP02|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740581|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2012-06-14 10:16:17.0|^|TM100001683 Version 5.0/15-Nov-2011|^|NB73112 P5|^|CRO-017-02|^|05-JUN-2012|^|17131528|^|0|^|A|^|T|^|Total Time|^|Total Time|^|Total Time|^|328|^|328|^|s|^|328|^||^|T|^|T|^||^|ROCHEP02|^|F|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740581|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2012-06-14 10:16:17.0|^|TM100001683 Version 5.0/15-Nov-2011|^|NB73112 P5|^|CRO-017-02|^|05-JUN-2012|^|17131529|^|0|^|A|^|T|^|Reconstitution Time|^|Reconstitution Time|^|Reconstitution Time|^|5 min 28 sec|^|5 min 28 sec|^||^||^||^|T|^|T|^|Report Results|^|ROCHEP02|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740582|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777|^|1|^|10|^|2012-06-14 10:02:59.0|^|TM100001777 Version 3.0/30-May-2012|^|NB73096 P10|^|CRO-017-02|^|07-JUN-2012|^|17131534|^|0|^|A|^|T|^|Peak 1 (% Area)|^|Monomer|^|Monomer|^|99.2|^|99.2|^|%|^|99.2|^||^|T|^|T|^|>= 95.0%|^|ROCHEP02|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740582|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777|^|1|^|10|^|2012-06-14 10:02:59.0|^|TM100001777 Version 3.0/30-May-2012|^|NB73096 P10|^|CRO-017-02|^|07-JUN-2012|^|17131535|^|0|^|A|^|T|^|Peak 2 (% Area)|^|HMMS|^|HMMS|^|0.6|^|0.6|^|%|^|0.6|^||^|T|^|T|^|<= 5.0%|^|ROCHEP02|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740582|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777|^|1|^|10|^|2012-06-14 10:02:59.0|^|TM100001777 Version 3.0/30-May-2012|^|NB73096 P10|^|CRO-017-02|^|07-JUN-2012|^|17131536|^|0|^|A|^|T|^|Peak 3 (% Area)|^|LMMS|^|LMMS|^|0.2|^|0.2|^|%|^|0.2|^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740584|^|A|^|REGISTERED|^|TURBIDITY|^|Appearance (Clarity)|^|TM100002052|^|1|^|2|^|2012-06-14 08:36:08.0|^|TM100002052 v3 13 Apr 2012|^|NB73111 p3-7|^|CRO-017-02|^|11-JUN-2012|^|17131548|^|0|^|A|^|T|^|Turbidity - Rep|^|Turbidity - Rep|^|Turbidity - Rep|^|4.79|^|5|^|NTU|^|5|^||^|T|^|T|^||^|BYRNEJ18|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197851|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-23 11:04:41.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740584|^|A|^|REGISTERED|^|TURBIDITY|^|Appearance (Clarity)|^|TM100002052|^|1|^|2|^|2012-06-14 08:36:08.0|^|TM100002052 v3 13 Apr 2012|^|NB73111 p3-7|^|CRO-017-02|^|11-JUN-2012|^|17131549|^|0|^|A|^|T|^|Turbidity|^|Turbidity|^|Turbidity|^|4.79|^|5|^|NTU|^|5|^||^|T|^|T|^|<= 18 NTU|^|BYRNEJ18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197865|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-22 21:40:06.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740578|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2012-06-22 21:40:06.0|^|TM000001405 v2.0|^|126456-138|^|Pfizer, QC, St. Louis, MO, US|^|22-JUN-2012|^|17302651|^|0|^|A|^|T|^|LOQ|^|LOQ|^|LOQ|^|0.2|^|0.2|^||^|0.2|^||^|T|^|T|^||^|MAREAS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197865|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-22 21:40:06.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740578|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2012-06-22 21:40:06.0|^|TM000001405 v2.0|^|126456-138|^|Pfizer, QC, St. Louis, MO, US|^|22-JUN-2012|^|17302652|^|0|^|A|^|T|^|Manual Entry - Moisture - Replicate|^|Manual Entry - Moisture - Replicate|^|Manual Entry - Moisture - Replicate|^|0.2|^|0.2|^|%|^|0.2|^||^|T|^|T|^||^|MAREAS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197865|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-22 21:40:06.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740578|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2012-06-22 21:40:06.0|^|TM000001405 v2.0|^|126456-138|^|Pfizer, QC, St. Louis, MO, US|^|22-JUN-2012|^|17131508|^|0|^|A|^|T|^|Moisture - Rep|^|Moisture - Rep|^|Moisture - Rep|^|0.2|^|NMT 0.2|^|%|^||^||^|T|^|T|^||^|MAREAS|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_01|^|1 Month|^|1|^||^|2012-05-04 00:00:00.0|^|2012-06-04 00:00:00.0|^||^|196066|^|A|^|197865|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-05-31 00:03:41.0|^|2012-11-26 22:09:57.0|^|2012-11-26 22:09:57.0|^|2012-06-22 21:40:06.0|^|2013-10-22 11:52:06.0|^|T|^|T|^|2013-10-22 11:52:11.0|^|740578|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2012-06-22 21:40:06.0|^|TM000001405 v2.0|^|126456-138|^|Pfizer, QC, St. Louis, MO, US|^|22-JUN-2012|^|17131509|^|0|^|A|^|T|^|Moisture|^|Moisture|^|Moisture|^|0.2|^|NMT 0.2|^|%|^||^||^|T|^|T|^|<= 2%|^|MAREAS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769664|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052|^|1|^|1|^|2012-08-10 09:33:52.0|^|TM100002052 v3 13 Apr 2012|^|NB73112 p10-12|^|CRO-017-02|^|03-AUG-2012|^|17652524|^|0|^|A|^|T|^|Appearance|^|Visual appearance|^|Visual appearance|^|White cake essentially free from visible particulates|^|White cake essentially free from visible particulates|^||^||^||^|T|^|T|^|White cake essentially free from visible particulates|^|BYRNEJ18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769666|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reduced)|^|TM100001851|^|1|^|10|^|2012-08-14 09:43:37.0|^|TM100001851 Version 3.0 30-May-2012|^|73091 P18|^|CRO-017-02|^|09-AUG-2012|^|20004949|^|0|^|A|^|T|^|LOQ|^|LOQ|^|LOQ|^|0.3|^|0.3|^||^|0.3|^||^|T|^|T|^||^|DEEGAO01|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769666|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reduced)|^|TM100001851|^|1|^|10|^|2012-08-14 09:43:37.0|^|TM100001851 Version 3.0 30-May-2012|^|73091 P18|^|CRO-017-02|^|09-AUG-2012|^|17652535|^|0|^|A|^|T|^|Sum HC and LC|^|Heavy Chain + Light Chain|^|Heavy Chain + Light Chain|^|99.7|^|99.7|^|%|^|99.7|^||^|T|^|T|^|>= 95.0% IgG as heavy + light chain|^|ROCHEP02|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769666|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reduced)|^|TM100001851|^|1|^|10|^|2012-08-14 09:43:37.0|^|TM100001851 Version 3.0 30-May-2012|^|73091 P18|^|CRO-017-02|^|09-AUG-2012|^|17652536|^|0|^|A|^|T|^|Percent Fragment|^|Fragments|^|Fragments|^|0.3|^|NMT 0.3|^|%|^||^||^|T|^|T|^|Report Results|^|DEEGAO01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769667|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|7|^|2012-08-14 13:09:41.0|^|TM100002052 v3 13 Apr 2012|^|NB74373 p11-14|^|CRO-017-02|^|10-AUG-2012|^|17652541|^|0|^|A|^|T|^|Color Hue|^|Color Hue|^|Color Hue|^|B|^|B|^||^||^||^|T|^|T|^||^|BYRNEJ18|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769667|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|7|^|2012-08-14 13:09:41.0|^|TM100002052 v3 13 Apr 2012|^|NB74373 p11-14|^|CRO-017-02|^|10-AUG-2012|^|17652542|^|0|^|A|^|T|^|Color Intensity|^|Color Intensity|^|Color Intensity|^|9|^|9|^||^|9|^||^|T|^|T|^||^|BYRNEJ18|^|F|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769667|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|7|^|2012-08-14 13:09:41.0|^|TM100002052 v3 13 Apr 2012|^|NB74373 p11-14|^|CRO-017-02|^|10-AUG-2012|^|17652543|^|0|^|A|^|T|^|Color|^|Coloration|^|Coloration|^|<=B9|^|<=B9|^||^||^||^|T|^|T|^|Not more intensely colored than level 5 of the color standard|^|BYRNEJ18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769668|^|A|^|REGISTERED|^|CONCENTRATION_UV|^|Protein Concentration (UV)|^|TM100001683, TMC0085|^|1|^|9|^|2012-08-14 09:36:18.0|^|TM100001683 Version 5.0 15-Nov-2011|^|73092 P24|^|CRO-017-02|^|03-AUG-2012|^|17652548|^|0|^|A|^|T|^|Protein Concentration|^|Protein Concentration - rep|^|Protein Concentration - rep|^|23.3|^|23.3|^|mg/mL|^|23.3|^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769668|^|A|^|REGISTERED|^|CONCENTRATION_UV|^|Protein Concentration (UV)|^|TM100001683, TMC0085|^|1|^|9|^|2012-08-14 09:36:18.0|^|TM100001683 Version 5.0 15-Nov-2011|^|73092 P24|^|CRO-017-02|^|03-AUG-2012|^|17652549|^|0|^|A|^|T|^|Protein Concentration - Average|^|Protein Concentration|^|Protein Concentration|^|23.3|^|23.3|^|mg/mL|^|23.3|^||^|T|^|T|^|Report Results|^|ROCHEP02|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769669|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2012-08-10 14:27:17.0|^|TM100001681 V3.0 Effective 30 May 2012|^|NB73093 p20-26|^|CRO-017-02|^|08-AUG-2012|^|17652554|^|0|^|A|^|T|^|Peak 1 (% Area)|^|% Acidic Peaks - rep|^|% Acidic Peaks - rep|^|23.2|^|23.2|^|%|^|23.2|^||^|T|^|T|^||^|DEEGAO01|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769669|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2012-08-10 14:27:17.0|^|TM100001681 V3.0 Effective 30 May 2012|^|NB73093 p20-26|^|CRO-017-02|^|08-AUG-2012|^|17652555|^|0|^|A|^|T|^|Peak 1 (% Area) - Average|^|% Acidic Peaks|^|% Acidic Peaks|^|23.2|^|23.2|^|%|^|23.2|^||^|T|^|T|^|17.0 - 33.0%|^|DEEGAO01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769669|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2012-08-10 14:27:17.0|^|TM100001681 V3.0 Effective 30 May 2012|^|NB73093 p20-26|^|CRO-017-02|^|08-AUG-2012|^|17652556|^|0|^|A|^|T|^|Peak 2 (% Area)|^|% Main Peak - rep|^|% Main Peak - rep|^|57.9|^|57.9|^|%|^|57.9|^||^|T|^|T|^||^|DEEGAO01|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769669|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2012-08-10 14:27:17.0|^|TM100001681 V3.0 Effective 30 May 2012|^|NB73093 p20-26|^|CRO-017-02|^|08-AUG-2012|^|17652557|^|0|^|A|^|T|^|Peak 2 (% Area) - Average|^|% Main Peak|^|% Main Peak|^|57.9|^|57.9|^|%|^|57.9|^||^|T|^|T|^|>= 50.0%|^|DEEGAO01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769669|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2012-08-10 14:27:17.0|^|TM100001681 V3.0 Effective 30 May 2012|^|NB73093 p20-26|^|CRO-017-02|^|08-AUG-2012|^|17652558|^|0|^|A|^|T|^|Peak 3 (% Area)|^|% Basic Peaks - rep|^|% Basic Peaks - rep|^|18.8|^|18.8|^|%|^|18.8|^||^|T|^|T|^||^|DEEGAO01|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769669|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2012-08-10 14:27:17.0|^|TM100001681 V3.0 Effective 30 May 2012|^|NB73093 p20-26|^|CRO-017-02|^|08-AUG-2012|^|17652559|^|0|^|A|^|T|^|Peak 3 (% Area) - Average|^|% Basic Peaks|^|% Basic Peaks|^|18.8|^|18.8|^|%|^|18.8|^||^|T|^|T|^|7.0 - 24.0%|^|DEEGAO01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769670|^|A|^|ADDITIONAL|^|MAB_OXIDATION|^|Lys-C Digest|^|TM100001849|^|1|^|9|^|2012-08-10 08:53:14.0|^|TM100001849 v2 30 May 2012|^|NB73094 p21-29|^|CRO-017-02|^|08-AUG-2012|^|17652564|^|0|^|A|^|T|^|Peak 1 (Relative Area %)|^|Oxidation at Fc-Met-1|^|Oxidation at Fc-Met-1|^|2.3|^|2.3|^|%|^|2.3|^||^|T|^|T|^||^|BYRNEJ18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769671|^|A|^|REGISTERED|^|PARTICULATE_BIO|^|Appearance (Visible Particulates)|^|TM100002052|^|1|^|4|^|2012-08-14 13:12:29.0|^|TM100002052 v3 13 Apr 2012|^|NB74373 p3-4|^|CRO-017-02|^|10-AUG-2012|^|17652569|^|0|^|A|^|T|^|Particles|^|Visible particulates|^|Visible particulates|^|FREE|^|Essentially Free of Visible Particles|^||^||^||^|T|^|T|^|Essentially Free of Visible Particles|^|BYRNEJ18|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769671|^|A|^|REGISTERED|^|PARTICULATE_BIO|^|Appearance (Visible Particulates)|^|TM100002052|^|1|^|4|^|2012-08-14 13:12:29.0|^|TM100002052 v3 13 Apr 2012|^|NB74373 p3-4|^|CRO-017-02|^|10-AUG-2012|^|17790651|^|0|^|A|^|T|^|Visible Particulates|^|Visible Particulates|^|Visible Particulates|^|FREE|^|Essentially free from visible particulates|^||^||^||^|T|^|T|^||^|BYRNEJ18|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769672|^|A|^|REGISTERED|^|PH|^|pH|^|M00125|^|1|^|4|^|2012-08-14 12:16:29.0|^|M00125 v2 07 May 2012|^|NB73095 p7-11|^|CRO-017-02|^|13-AUG-2012|^|17652574|^|0|^|A|^|T|^|pH|^|pH - rep|^|pH - rep|^|5.9|^|5.9|^||^|5.9|^||^|T|^|T|^||^|BYRNEJ18|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769672|^|A|^|REGISTERED|^|PH|^|pH|^|M00125|^|1|^|4|^|2012-08-14 12:16:29.0|^|M00125 v2 07 May 2012|^|NB73095 p7-11|^|CRO-017-02|^|13-AUG-2012|^|17652575|^|0|^|A|^|T|^|pH - Average|^|pH|^|pH|^|5.9|^|5.9|^||^|5.9|^||^|T|^|T|^|6.0 +/- 0.5|^|BYRNEJ18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769673|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2012-08-10 09:43:14.0|^|TM100001683 v5 15 Nov 2011|^|NB 73112 P13|^|CRO-017-02|^|03-AUG-2012|^|17652580|^|0|^|A|^|T|^|Minutes|^|Minutes|^|Minutes|^|4|^|4|^|min|^|4|^||^|T|^|T|^||^|BYRNEJ18|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769673|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2012-08-10 09:43:14.0|^|TM100001683 v5 15 Nov 2011|^|NB 73112 P13|^|CRO-017-02|^|03-AUG-2012|^|17652581|^|0|^|A|^|T|^|Seconds|^|Seconds|^|Seconds|^|50|^|50|^|s|^|50|^||^|T|^|T|^||^|BYRNEJ18|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769673|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2012-08-10 09:43:14.0|^|TM100001683 v5 15 Nov 2011|^|NB 73112 P13|^|CRO-017-02|^|03-AUG-2012|^|17652582|^|0|^|A|^|T|^|Rounding Interval|^|Rounding Interval|^|Rounding Interval|^|NA|^|Not available|^||^||^||^|T|^|T|^||^|BYRNEJ18|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769673|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2012-08-10 09:43:14.0|^|TM100001683 v5 15 Nov 2011|^|NB 73112 P13|^|CRO-017-02|^|03-AUG-2012|^|17652583|^|0|^|A|^|T|^|Total Time|^|Total Time|^|Total Time|^|290|^|290|^|s|^|290|^||^|T|^|T|^||^|BYRNEJ18|^|F|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769673|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2012-08-10 09:43:14.0|^|TM100001683 v5 15 Nov 2011|^|NB 73112 P13|^|CRO-017-02|^|03-AUG-2012|^|17652584|^|0|^|A|^|T|^|Reconstitution Time|^|Reconstitution Time|^|Reconstitution Time|^|4 min 50 sec|^|4 min 50 sec|^||^||^||^|T|^|T|^|Report Results|^|BYRNEJ18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769674|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777|^|1|^|10|^|2012-09-04 14:03:58.0|^|TM100001777 V 3.0 30 May 2012|^|NB 73096 p 27|^|CRO-017-02|^|09-AUG-2012|^|17652589|^|0|^|A|^|T|^|Peak 1 (% Area)|^|Monomer|^|Monomer|^|98.9|^|98.9|^|%|^|98.9|^||^|T|^|T|^|>= 95.0%|^|DEEGAO01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769674|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777|^|1|^|10|^|2012-09-04 14:03:58.0|^|TM100001777 V 3.0 30 May 2012|^|NB 73096 p 27|^|CRO-017-02|^|09-AUG-2012|^|17652590|^|0|^|A|^|T|^|Peak 2 (% Area)|^|HMMS|^|HMMS|^|0.8|^|0.8|^|%|^|0.8|^||^|T|^|T|^|<= 5.0%|^|DEEGAO01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769674|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777|^|1|^|10|^|2012-09-04 14:03:58.0|^|TM100001777 V 3.0 30 May 2012|^|NB 73096 p 27|^|CRO-017-02|^|09-AUG-2012|^|17652591|^|0|^|A|^|T|^|Peak 3 (% Area)|^|LMMS|^|LMMS|^|0.3|^|0.3|^|%|^|0.3|^||^|T|^|T|^||^|DEEGAO01|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769676|^|A|^|REGISTERED|^|TURBIDITY|^|Appearance (Clarity)|^|TM100002052|^|1|^|2|^|2012-08-14 13:01:16.0|^|TM100002052 v3 13 Apr 2012|^|NB74373 p4-10|^|CRO-017-02|^|10-AUG-2012|^|17652603|^|0|^|A|^|T|^|Turbidity - Rep|^|Turbidity - Rep|^|Turbidity - Rep|^|4|^|4|^|NTU|^|4|^||^|T|^|T|^||^|BYRNEJ18|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206721|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2013-02-18 12:41:20.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769676|^|A|^|REGISTERED|^|TURBIDITY|^|Appearance (Clarity)|^|TM100002052|^|1|^|2|^|2012-08-14 13:01:16.0|^|TM100002052 v3 13 Apr 2012|^|NB74373 p4-10|^|CRO-017-02|^|10-AUG-2012|^|17652604|^|0|^|A|^|T|^|Turbidity|^|Turbidity|^|Turbidity|^|4|^|4|^|NTU|^|4|^||^|T|^|T|^|<= 18 NTU|^|BYRNEJ18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206722|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2012-09-06 15:45:39.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769675|^|A|^|REGISTERED|^|SPECIFIC_ACTIVITY|^|Potency Assay (Cell Based)|^|TM100001721|^|1|^|10|^|2012-09-06 15:45:39.0|^|TM100001721 V4.0/07Jun2012|^|75293p1|^|CRO-017-01|^|22-AUG-2012|^|17652596|^|0|^|A|^|T|^|Relative Potency|^|Relative Potency|^|Relative Potency|^|75|^|75|^|%|^|75|^||^|T|^|T|^|55 - 158% potency relative to reference material|^|BACHM02|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|206722|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2012-09-06 15:45:39.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769675|^|A|^|REGISTERED|^|SPECIFIC_ACTIVITY|^|Potency Assay (Cell Based)|^|TM100001721|^|1|^|10|^|2012-09-06 15:45:39.0|^|TM100001721 V4.0/07Jun2012|^|75293p1|^|CRO-017-01|^|22-AUG-2012|^|17652597|^|0|^|A|^|T|^|Specific Activity|^|Specific Activity|^|Specific Activity|^|752|^|752|^|U/mg|^|752|^||^|T|^|T|^|550 - 1580 U/mg|^|BACHM02|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806770|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052|^|1|^|1|^|2012-11-08 14:21:37.0|^|TM100002052 V3.0 Effective Date 13Apr2012|^|NB75441 P.1|^|CRO-017-02|^|05-NOV-2012|^|18355494|^|0|^|A|^|T|^|Appearance|^|Visual appearance|^|Visual appearance|^|White cake essentially free from visible particulates|^|White cake essentially free from visible particulates|^||^||^||^|T|^|T|^|White cake essentially free from visible particulates|^|TSENKB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806771|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reduced)|^|TM100001851|^|1|^|10|^|2012-11-13 19:03:12.0|^|TM100001851 Version 3.0 Effective 30 May 2012|^|NB74378 p32|^|CRO-017-02|^|13-NOV-2012|^|20006520|^|0|^|A|^|T|^|LOQ|^|LOQ|^|LOQ|^|0.3|^|0.3|^||^|0.3|^||^|T|^|T|^||^|DEEGAO01|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806771|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reduced)|^|TM100001851|^|1|^|10|^|2012-11-13 19:03:12.0|^|TM100001851 Version 3.0 Effective 30 May 2012|^|NB74378 p32|^|CRO-017-02|^|13-NOV-2012|^|18355499|^|0|^|A|^|T|^|Sum HC and LC|^|Heavy Chain + Light Chain|^|Heavy Chain + Light Chain|^|100.0|^|100.0|^|%|^|100|^||^|T|^|T|^|>= 95.0% IgG as heavy + light chain|^|DEEGAO01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806771|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reduced)|^|TM100001851|^|1|^|10|^|2012-11-13 19:03:12.0|^|TM100001851 Version 3.0 Effective 30 May 2012|^|NB74378 p32|^|CRO-017-02|^|13-NOV-2012|^|18355500|^|0|^|A|^|T|^|Percent Fragment|^|Fragments|^|Fragments|^|0.0|^|NMT 0.3|^|%|^||^||^|T|^|T|^|Report Results|^|DEEGAO01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806772|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|7|^|2012-11-15 16:14:21.0|^|TM100002052 Version 3.0 Effective 13 Apr 2012|^|NB76609 p14|^|CRO-017-02|^|13-NOV-2012|^|18355505|^|0|^|A|^|T|^|Color Hue|^|Color Hue|^|Color Hue|^|B|^|B|^||^||^||^|T|^|T|^||^|DEEGAO01|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806772|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|7|^|2012-11-15 16:14:21.0|^|TM100002052 Version 3.0 Effective 13 Apr 2012|^|NB76609 p14|^|CRO-017-02|^|13-NOV-2012|^|18355506|^|0|^|A|^|T|^|Color Intensity|^|Color Intensity|^|Color Intensity|^|9|^|9|^||^|9|^||^|T|^|T|^||^|DEEGAO01|^|F|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806772|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|7|^|2012-11-15 16:14:21.0|^|TM100002052 Version 3.0 Effective 13 Apr 2012|^|NB76609 p14|^|CRO-017-02|^|13-NOV-2012|^|18355507|^|0|^|A|^|T|^|Color|^|Coloration|^|Coloration|^|<=B9|^|<=B9|^||^||^||^|T|^|T|^|Not more intensely colored than level 5 of the color standard|^|DEEGAO01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806773|^|A|^|REGISTERED|^|CONCENTRATION_UV|^|Protein Concentration (UV)|^|TM100001683, TMC0085|^|1|^|9|^|2012-11-08 10:06:44.0|^|TM100001683 Version 6.0 Effective Date 07 Aug 2012|^|NB75517 p7|^|CRO-017-02|^|05-NOV-2012|^|18355512|^|0|^|A|^|T|^|Protein Concentration|^|Protein Concentration - rep|^|Protein Concentration - rep|^|21.5|^|21.5|^|mg/mL|^|21.5|^||^|T|^|T|^||^|DEEGAO01|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806773|^|A|^|REGISTERED|^|CONCENTRATION_UV|^|Protein Concentration (UV)|^|TM100001683, TMC0085|^|1|^|9|^|2012-11-08 10:06:44.0|^|TM100001683 Version 6.0 Effective Date 07 Aug 2012|^|NB75517 p7|^|CRO-017-02|^|05-NOV-2012|^|18355513|^|0|^|A|^|T|^|Protein Concentration - Average|^|Protein Concentration|^|Protein Concentration|^|21.5|^|21.5|^|mg/mL|^|21.5|^||^|T|^|T|^|Report Results|^|DEEGAO01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806774|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2012-11-08 16:30:54.0|^|TM100001681 V3.0 Effective Date 30May2012|^|NB74375 P.13|^|CRO-017-02|^|07-NOV-2012|^|18355518|^|0|^|A|^|T|^|Peak 1 (% Area)|^|% Acidic Peaks - rep|^|% Acidic Peaks - rep|^|22.2|^|22.2|^|%|^|22.2|^||^|T|^|T|^||^|TSENKB|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806774|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2012-11-08 16:30:54.0|^|TM100001681 V3.0 Effective Date 30May2012|^|NB74375 P.13|^|CRO-017-02|^|07-NOV-2012|^|18355519|^|0|^|A|^|T|^|Peak 1 (% Area) - Average|^|% Acidic Peaks|^|% Acidic Peaks|^|22.2|^|22.2|^|%|^|22.2|^||^|T|^|T|^|17.0 - 33.0%|^|TSENKB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806774|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2012-11-08 16:30:54.0|^|TM100001681 V3.0 Effective Date 30May2012|^|NB74375 P.13|^|CRO-017-02|^|07-NOV-2012|^|18355520|^|0|^|A|^|T|^|Peak 2 (% Area)|^|% Main Peak - rep|^|% Main Peak - rep|^|57.9|^|57.9|^|%|^|57.9|^||^|T|^|T|^||^|TSENKB|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806774|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2012-11-08 16:30:54.0|^|TM100001681 V3.0 Effective Date 30May2012|^|NB74375 P.13|^|CRO-017-02|^|07-NOV-2012|^|18355521|^|0|^|A|^|T|^|Peak 2 (% Area) - Average|^|% Main Peak|^|% Main Peak|^|57.9|^|57.9|^|%|^|57.9|^||^|T|^|T|^|>= 50.0%|^|TSENKB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806774|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2012-11-08 16:30:54.0|^|TM100001681 V3.0 Effective Date 30May2012|^|NB74375 P.13|^|CRO-017-02|^|07-NOV-2012|^|18355522|^|0|^|A|^|T|^|Peak 3 (% Area)|^|% Basic Peaks - rep|^|% Basic Peaks - rep|^|19.9|^|19.9|^|%|^|19.9|^||^|T|^|T|^||^|TSENKB|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806774|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2012-11-08 16:30:54.0|^|TM100001681 V3.0 Effective Date 30May2012|^|NB74375 P.13|^|CRO-017-02|^|07-NOV-2012|^|18355523|^|0|^|A|^|T|^|Peak 3 (% Area) - Average|^|% Basic Peaks|^|% Basic Peaks|^|19.9|^|19.9|^|%|^|19.9|^||^|T|^|T|^|7.0 - 24.0%|^|TSENKB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806775|^|A|^|ADDITIONAL|^|MAB_OXIDATION|^|Lys-C Digest|^|TM100001849|^|1|^|9|^|2012-11-15 14:14:47.0|^|TM100001849 Version 2.0 Effective 30 May 2012|^|NB77598 p10|^|CRO-017-02|^|08-NOV-2012|^|18355528|^|0|^|A|^|T|^|Peak 1 (Relative Area %)|^|Oxidation at Fc-Met-1|^|Oxidation at Fc-Met-1|^|1.3|^|1.3|^|%|^|1.3|^||^|T|^|T|^||^|DEEGAO01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806777|^|A|^|REGISTERED|^|PARTICULATE_BIO|^|Appearance (Visible Particulates)|^|TM100002052|^|1|^|4|^|2012-11-15 17:25:45.0|^|TM100002052 V3.0 Effective Date 13Apr2012|^|NB76609 p.8|^|CRO-017-02|^|13-NOV-2012|^|18355539|^|0|^|A|^|T|^|Particles|^|Visible particulates|^|Visible particulates|^|FREE|^|Essentially Free of Visible Particles|^||^||^||^|T|^|T|^|Essentially Free of Visible Particles|^|TSENKB|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806778|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2012-11-26 14:43:27.0|^|TM100002055 Version 1.0/06May2011|^|75518 P24|^|CRO-017-02|^|19-NOV-2012|^|18581350|^|1|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|15748|^|15748|^|Particles/container|^|15748|^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806778|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2012-11-26 14:43:27.0|^|TM100002055 Version 1.0/06May2011|^|75518 P24|^|CRO-017-02|^|19-NOV-2012|^|18581351|^|2|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|15460|^|15460|^|Particles/container|^|15460|^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806778|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2012-11-26 14:43:27.0|^|TM100002055 Version 1.0/06May2011|^|75518 P24|^|CRO-017-02|^|19-NOV-2012|^|18581352|^|3|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|15348|^|15348|^|Particles/container|^|15348|^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806778|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2012-11-26 14:43:27.0|^|TM100002055 Version 1.0/06May2011|^|75518 P24|^|CRO-017-02|^|19-NOV-2012|^|18355544|^|0|^|A|^|T|^|Light Obscuration: >= 2µm|^|Light Obscuration: >= 2µm|^|Light Obscuration: >= 2µm|^|15518.666667|^|15519|^|Particles/container|^|15519|^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806778|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2012-11-26 14:43:27.0|^|TM100002055 Version 1.0/06May2011|^|75518 P24|^|CRO-017-02|^|19-NOV-2012|^|18581353|^|1|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|4608|^|4608|^|Particles/container|^|4608|^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806778|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2012-11-26 14:43:27.0|^|TM100002055 Version 1.0/06May2011|^|75518 P24|^|CRO-017-02|^|19-NOV-2012|^|18581354|^|2|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|4360|^|4360|^|Particles/container|^|4360|^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806778|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2012-11-26 14:43:27.0|^|TM100002055 Version 1.0/06May2011|^|75518 P24|^|CRO-017-02|^|19-NOV-2012|^|18581355|^|3|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|4300|^|4300|^|Particles/container|^|4300|^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806778|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2012-11-26 14:43:27.0|^|TM100002055 Version 1.0/06May2011|^|75518 P24|^|CRO-017-02|^|19-NOV-2012|^|18355545|^|0|^|A|^|T|^|Light Obscuration: >= 5µm|^|Light Obscuration: >= 5µm|^|Light Obscuration: >= 5µm|^|4422.6666667|^|4423|^|Particles/container|^|4423|^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806778|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2012-11-26 14:43:27.0|^|TM100002055 Version 1.0/06May2011|^|75518 P24|^|CRO-017-02|^|19-NOV-2012|^|18581356|^|1|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|616|^|616|^|Particles/container|^|616|^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806778|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2012-11-26 14:43:27.0|^|TM100002055 Version 1.0/06May2011|^|75518 P24|^|CRO-017-02|^|19-NOV-2012|^|18581357|^|2|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|620|^|620|^|Particles/container|^|620|^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806778|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2012-11-26 14:43:27.0|^|TM100002055 Version 1.0/06May2011|^|75518 P24|^|CRO-017-02|^|19-NOV-2012|^|18581358|^|3|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|612|^|612|^|Particles/container|^|612|^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806778|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2012-11-26 14:43:27.0|^|TM100002055 Version 1.0/06May2011|^|75518 P24|^|CRO-017-02|^|19-NOV-2012|^|18355546|^|0|^|A|^|T|^|Light Obscuration: >= 8µm|^|Light Obscuration: >= 8µm|^|Light Obscuration: >= 8µm|^|616|^|616|^|Particles/container|^|616|^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806778|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2012-11-26 14:43:27.0|^|TM100002055 Version 1.0/06May2011|^|75518 P24|^|CRO-017-02|^|19-NOV-2012|^|18581359|^|1|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|252|^|252|^|Particles/container|^|252|^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806778|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2012-11-26 14:43:27.0|^|TM100002055 Version 1.0/06May2011|^|75518 P24|^|CRO-017-02|^|19-NOV-2012|^|18581360|^|2|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|252|^|252|^|Particles/container|^|252|^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806778|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2012-11-26 14:43:27.0|^|TM100002055 Version 1.0/06May2011|^|75518 P24|^|CRO-017-02|^|19-NOV-2012|^|18581361|^|3|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|224|^|224|^|Particles/container|^|224|^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806778|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2012-11-26 14:43:27.0|^|TM100002055 Version 1.0/06May2011|^|75518 P24|^|CRO-017-02|^|19-NOV-2012|^|18355547|^|0|^|A|^|T|^|Light Obscuration: >= 10µm|^|Light Obscuration: >= 10µm|^|Light Obscuration: >= 10µm|^|242.66666667|^|243|^|Particles/container|^|243|^||^|T|^|T|^|Report Results|^|ROCHEP02|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806778|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2012-11-26 14:43:27.0|^|TM100002055 Version 1.0/06May2011|^|75518 P24|^|CRO-017-02|^|19-NOV-2012|^|18581362|^|1|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|4|^|4|^|Particles/container|^|4|^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806778|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2012-11-26 14:43:27.0|^|TM100002055 Version 1.0/06May2011|^|75518 P24|^|CRO-017-02|^|19-NOV-2012|^|18581363|^|2|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|0|^|0|^|Particles/container|^|0|^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806778|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2012-11-26 14:43:27.0|^|TM100002055 Version 1.0/06May2011|^|75518 P24|^|CRO-017-02|^|19-NOV-2012|^|18581364|^|3|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|0|^|0|^|Particles/container|^|0|^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806778|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2012-11-26 14:43:27.0|^|TM100002055 Version 1.0/06May2011|^|75518 P24|^|CRO-017-02|^|19-NOV-2012|^|18355548|^|0|^|A|^|T|^|Light Obscuration: >= 25µm|^|Light Obscuration: >= 25µm|^|Light Obscuration: >= 25µm|^|1.3333333333|^|1|^|Particles/container|^|1|^||^|T|^|T|^|Report Results|^|ROCHEP02|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806778|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2012-11-26 14:43:27.0|^|TM100002055 Version 1.0/06May2011|^|75518 P24|^|CRO-017-02|^|19-NOV-2012|^|18355549|^|0|^|A|^|T|^|Particulate Matter|^|Particulate Matter|^|Particulate Matter|^|Meets compendial requirements|^|Meets compendial requirements|^||^||^||^|T|^|T|^|Meets compendial requirements|^|ROCHEP02|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806779|^|A|^|REGISTERED|^|PH|^|pH|^|M00125|^|1|^|4|^|2012-11-15 09:32:59.0|^|M00125 V2.0 Effective Date 07May2012|^|NB76606 P. 6|^|CRO-017-02|^|14-NOV-2012|^|18355554|^|0|^|A|^|T|^|pH|^|pH - rep|^|pH - rep|^|5.88|^|5.9|^||^|5.9|^||^|T|^|T|^||^|TSENKB|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806779|^|A|^|REGISTERED|^|PH|^|pH|^|M00125|^|1|^|4|^|2012-11-15 09:32:59.0|^|M00125 V2.0 Effective Date 07May2012|^|NB76606 P. 6|^|CRO-017-02|^|14-NOV-2012|^|18355555|^|0|^|A|^|T|^|pH - Average|^|pH|^|pH|^|5.9|^|5.9|^||^|5.9|^||^|T|^|T|^|6.0 +/- 0.5|^|TSENKB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806780|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2012-11-08 14:28:41.0|^|TM100001683 V6.0 Effective Date 07Aug2012|^|NB75441 P.1|^|CRO-017-02|^|05-NOV-2012|^|18355560|^|0|^|A|^|T|^|Minutes|^|Minutes|^|Minutes|^|3|^|3|^|min|^|3|^||^|T|^|T|^||^|TSENKB|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806780|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2012-11-08 14:28:41.0|^|TM100001683 V6.0 Effective Date 07Aug2012|^|NB75441 P.1|^|CRO-017-02|^|05-NOV-2012|^|18355561|^|0|^|A|^|T|^|Seconds|^|Seconds|^|Seconds|^|18|^|18|^|s|^|18|^||^|T|^|T|^||^|TSENKB|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806780|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2012-11-08 14:28:41.0|^|TM100001683 V6.0 Effective Date 07Aug2012|^|NB75441 P.1|^|CRO-017-02|^|05-NOV-2012|^|18355562|^|0|^|A|^|T|^|Rounding Interval|^|Rounding Interval|^|Rounding Interval|^|NA|^|Not available|^||^||^||^|T|^|T|^||^|TSENKB|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806780|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2012-11-08 14:28:41.0|^|TM100001683 V6.0 Effective Date 07Aug2012|^|NB75441 P.1|^|CRO-017-02|^|05-NOV-2012|^|18355563|^|0|^|A|^|T|^|Total Time|^|Total Time|^|Total Time|^|198|^|198|^|s|^|198|^||^|T|^|T|^||^|TSENKB|^|F|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806780|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2012-11-08 14:28:41.0|^|TM100001683 V6.0 Effective Date 07Aug2012|^|NB75441 P.1|^|CRO-017-02|^|05-NOV-2012|^|18355564|^|0|^|A|^|T|^|Reconstitution Time|^|Reconstitution Time|^|Reconstitution Time|^|3 min 18 sec|^|3 min 18 sec|^||^||^||^|T|^|T|^|Report Results|^|TSENKB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806781|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777|^|1|^|10|^|2012-11-15 14:48:01.0|^|TM100001777 Version 3.0 Effective 30 May 2012|^|NB73096 p45|^|CRO-017-02|^|07-NOV-2012|^|18355569|^|0|^|A|^|T|^|Peak 1 (% Area)|^|Monomer|^|Monomer|^|98.7|^|98.7|^|%|^|98.7|^||^|T|^|T|^|>= 95.0%|^|DEEGAO01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806781|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777|^|1|^|10|^|2012-11-15 14:48:01.0|^|TM100001777 Version 3.0 Effective 30 May 2012|^|NB73096 p45|^|CRO-017-02|^|07-NOV-2012|^|18355570|^|0|^|A|^|T|^|Peak 2 (% Area)|^|HMMS|^|HMMS|^|1.1|^|1.1|^|%|^|1.1|^||^|T|^|T|^|<= 5.0%|^|DEEGAO01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806781|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777|^|1|^|10|^|2012-11-15 14:48:01.0|^|TM100001777 Version 3.0 Effective 30 May 2012|^|NB73096 p45|^|CRO-017-02|^|07-NOV-2012|^|18355571|^|0|^|A|^|T|^|Peak 3 (% Area)|^|LMMS|^|LMMS|^|0.3|^|0.3|^|%|^|0.3|^||^|T|^|T|^||^|DEEGAO01|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806783|^|A|^|REGISTERED|^|TURBIDITY|^|Appearance (Clarity)|^|TM100002052|^|1|^|2|^|2012-11-15 16:16:46.0|^|TM100002052 Version 3.0 Effective 13 Apr 2012|^|NB76609 p14|^|CRO-017-02|^|13-NOV-2012|^|18355583|^|0|^|A|^|T|^|Turbidity - Rep|^|Turbidity - Rep|^|Turbidity - Rep|^|4|^|4|^|NTU|^|4|^||^|T|^|T|^||^|DEEGAO01|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218092|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-18 16:58:51.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 15:40:12.0|^|806783|^|A|^|REGISTERED|^|TURBIDITY|^|Appearance (Clarity)|^|TM100002052|^|1|^|2|^|2012-11-15 16:16:46.0|^|TM100002052 Version 3.0 Effective 13 Apr 2012|^|NB76609 p14|^|CRO-017-02|^|13-NOV-2012|^|18355584|^|0|^|A|^|T|^|Turbidity|^|Turbidity|^|Turbidity|^|4|^|4|^|NTU|^|4|^||^|T|^|T|^|<= 18 NTU|^|DEEGAO01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218093|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-03 18:34:53.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 17:08:07.0|^|806782|^|A|^|REGISTERED|^|SPECIFIC_ACTIVITY|^|Potency Assay (Cell Based)|^|TM100001721|^|1|^|10|^|2013-01-03 18:34:53.0|^|TM100001721V4.0?07JUN2012|^|NB77840p1|^|CRO-017-01|^|21-NOV-2012|^|18355576|^|0|^|A|^|T|^|Relative Potency|^|Relative Potency|^|Relative Potency|^|86|^|86|^|%|^|86|^||^|T|^|T|^|55 - 158% potency relative to reference material|^|BUTZD|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|218093|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2013-01-03 18:34:53.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 17:08:07.0|^|806782|^|A|^|REGISTERED|^|SPECIFIC_ACTIVITY|^|Potency Assay (Cell Based)|^|TM100001721|^|1|^|10|^|2013-01-03 18:34:53.0|^|TM100001721V4.0?07JUN2012|^|NB77840p1|^|CRO-017-01|^|21-NOV-2012|^|18355577|^|0|^|A|^|T|^|Specific Activity|^|Specific Activity|^|Specific Activity|^|860|^|860|^|U/mg|^|860|^||^|T|^|T|^|550 - 1580 U/mg|^|BUTZD|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|218122|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2012-11-08 22:09:11.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769665|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2012-11-08 22:09:11.0|^|TM000001405, Version 2.0|^|126457-71|^|Pfizer, QC, St. Louis, MO, US|^|06-NOV-2012|^|18452912|^|0|^|A|^|T|^|LOQ|^|LOQ|^|LOQ|^|0.2|^|0.2|^||^|0.2|^||^|T|^|T|^||^|MAREAS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|218122|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2012-11-08 22:09:11.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769665|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2012-11-08 22:09:11.0|^|TM000001405, Version 2.0|^|126457-71|^|Pfizer, QC, St. Louis, MO, US|^|06-NOV-2012|^|18452913|^|0|^|A|^|T|^|Manual Entry - Moisture - Replicate|^|Manual Entry - Moisture - Replicate|^|Manual Entry - Moisture - Replicate|^|0.2|^|0.2|^|%|^|0.2|^||^|T|^|T|^||^|MAREAS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|218122|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2012-11-08 22:09:11.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769665|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2012-11-08 22:09:11.0|^|TM000001405, Version 2.0|^|126457-71|^|Pfizer, QC, St. Louis, MO, US|^|06-NOV-2012|^|17652529|^|0|^|A|^|T|^|Moisture - Rep|^|Moisture - Rep|^|Moisture - Rep|^|0.2|^|NMT 0.2|^|%|^||^||^|T|^|T|^||^|MAREAS|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|3|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_03|^|3 Months|^|3|^||^|2012-05-04 00:00:00.0|^|2012-08-04 00:00:00.0|^||^|206720|^|A|^|218122|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-07-31 00:56:51.0|^|2012-11-05 18:48:28.0|^|2012-11-05 18:48:28.0|^|2012-11-08 22:09:11.0|^|2013-10-22 11:53:43.0|^|T|^|T|^|2013-10-22 11:53:50.0|^|769665|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2012-11-08 22:09:11.0|^|TM000001405, Version 2.0|^|126457-71|^|Pfizer, QC, St. Louis, MO, US|^|06-NOV-2012|^|17652530|^|0|^|A|^|T|^|Moisture|^|Moisture|^|Moisture|^|0.2|^|NMT 0.2|^|%|^||^||^|T|^|T|^|<= 2%|^|MAREAS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|222100|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2012-12-11 21:54:07.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 17:07:11.0|^|806776|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2012-12-11 21:54:07.0|^|TM000001405, Version 2.0|^|126457-87|^|Pfizer, QC, St. Louis, MO, US|^|11-DEC-2012|^|18690924|^|0|^|A|^|T|^|LOQ|^|LOQ|^|LOQ|^|0.2|^|0.2|^||^|0.2|^||^|T|^|T|^||^|MAREAS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|222100|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2012-12-11 21:54:07.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 17:07:11.0|^|806776|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2012-12-11 21:54:07.0|^|TM000001405, Version 2.0|^|126457-87|^|Pfizer, QC, St. Louis, MO, US|^|11-DEC-2012|^|18690925|^|0|^|A|^|T|^|Manual Entry - Moisture - Replicate|^|Manual Entry - Moisture - Replicate|^|Manual Entry - Moisture - Replicate|^|0.3|^|0.3|^|%|^|0.3|^||^|T|^|T|^||^|MAREAS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|222100|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2012-12-11 21:54:07.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 17:07:11.0|^|806776|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2012-12-11 21:54:07.0|^|TM000001405, Version 2.0|^|126457-87|^|Pfizer, QC, St. Louis, MO, US|^|11-DEC-2012|^|18355533|^|0|^|A|^|T|^|Moisture - Rep|^|Moisture - Rep|^|Moisture - Rep|^|0.3|^|0.3|^|%|^|0.3|^||^|T|^|T|^||^|MAREAS|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_06|^|6 Months|^|6|^||^|2012-05-04 00:00:00.0|^|2012-11-04 00:00:00.0|^||^|218091|^|A|^|222100|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2012-10-29 06:06:24.0|^|2012-11-26 22:23:15.0|^|2012-11-26 22:23:15.0|^|2012-12-11 21:54:07.0|^|2013-01-18 17:03:14.0|^|T|^|T|^|2015-09-24 17:07:11.0|^|806776|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2012-12-11 21:54:07.0|^|TM000001405, Version 2.0|^|126457-87|^|Pfizer, QC, St. Louis, MO, US|^|11-DEC-2012|^|18355534|^|0|^|A|^|T|^|Moisture|^|Moisture|^|Moisture|^|0.3|^|0.3|^|%|^|0.3|^||^|T|^|T|^|<= 2%|^|MAREAS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230601|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-03-14 20:50:04.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843785|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2013-03-14 20:50:04.0|^|TM000001405, Version 2.0|^|130299-8|^|Pfizer, QC, St. Louis, MO, US|^|14-MAR-2013|^|19448981|^|0|^|A|^|T|^|LOQ|^|LOQ|^|LOQ|^|0.2|^|0.2|^||^|0.2|^||^|T|^|T|^||^|MAREAS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230601|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-03-14 20:50:04.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843785|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2013-03-14 20:50:04.0|^|TM000001405, Version 2.0|^|130299-8|^|Pfizer, QC, St. Louis, MO, US|^|14-MAR-2013|^|19448982|^|0|^|A|^|T|^|Manual Entry - Moisture - Replicate|^|Manual Entry - Moisture - Replicate|^|Manual Entry - Moisture - Replicate|^|0.4|^|0.4|^|%|^|0.4|^||^|T|^|T|^||^|MAREAS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230601|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-03-14 20:50:04.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843785|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2013-03-14 20:50:04.0|^|TM000001405, Version 2.0|^|130299-8|^|Pfizer, QC, St. Louis, MO, US|^|14-MAR-2013|^|18958543|^|0|^|A|^|T|^|Moisture - Rep|^|Moisture - Rep|^|Moisture - Rep|^|0.4|^|0.4|^|%|^|0.4|^||^|T|^|T|^||^|MAREAS|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230601|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-03-14 20:50:04.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843785|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2013-03-14 20:50:04.0|^|TM000001405, Version 2.0|^|130299-8|^|Pfizer, QC, St. Louis, MO, US|^|14-MAR-2013|^|18958544|^|0|^|A|^|T|^|Moisture|^|Moisture|^|Moisture|^|0.4|^|0.4|^|%|^|0.4|^||^|T|^|T|^|<= 2%|^|MAREAS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843779|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052|^|1|^|1|^|2013-01-30 16:53:31.0|^|TM100002052 version 3.0/Effective 13 Apr 2012|^|NB75441 P13|^|CRO-017-02|^|28-JAN-2013|^|18958504|^|0|^|A|^|T|^|Appearance|^|Visual appearance|^|Visual appearance|^|White cake essentially free from visible particulates|^|White cake essentially free from visible particulates|^||^||^||^|T|^|T|^|White cake essentially free from visible particulates|^|DEEGAO01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843780|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reduced)|^|TM100001851|^|1|^|10|^|2013-02-06 12:52:55.0|^|TM100001851 Version 3.0/Effective 30 May 2012|^|NB79372 P. 4|^|CRO-017-02|^|31-JAN-2013|^|20006536|^|0|^|A|^|T|^|LOQ|^|LOQ|^|LOQ|^|0.3|^|0.3|^||^|0.3|^||^|T|^|T|^||^|DEEGAO01|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843780|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reduced)|^|TM100001851|^|1|^|10|^|2013-02-06 12:52:55.0|^|TM100001851 Version 3.0/Effective 30 May 2012|^|NB79372 P. 4|^|CRO-017-02|^|31-JAN-2013|^|18958509|^|0|^|A|^|T|^|Sum HC and LC|^|Heavy Chain + Light Chain|^|Heavy Chain + Light Chain|^|100.0|^|100.0|^|%|^|100|^||^|T|^|T|^|>= 95.0% IgG as heavy + light chain|^|DEEGAO01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843780|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reduced)|^|TM100001851|^|1|^|10|^|2013-02-06 12:52:55.0|^|TM100001851 Version 3.0/Effective 30 May 2012|^|NB79372 P. 4|^|CRO-017-02|^|31-JAN-2013|^|18958510|^|0|^|A|^|T|^|Percent Fragment|^|Fragments|^|Fragments|^|0.0|^|NMT 0.3|^|%|^||^||^|T|^|T|^|Report Results|^|DEEGAO01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843781|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|7|^|2013-01-30 15:25:57.0|^|TM100002052 V3 Effective Date 13Apr2012|^|NB76609 P.28|^|CRO-017-02|^|29-JAN-2013|^|18958515|^|0|^|A|^|T|^|Color Hue|^|Color Hue|^|Color Hue|^|B|^|B|^||^||^||^|T|^|T|^||^|TSENKB|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843781|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|7|^|2013-01-30 15:25:57.0|^|TM100002052 V3 Effective Date 13Apr2012|^|NB76609 P.28|^|CRO-017-02|^|29-JAN-2013|^|18958516|^|0|^|A|^|T|^|Color Intensity|^|Color Intensity|^|Color Intensity|^|9|^|9|^||^|9|^||^|T|^|T|^||^|TSENKB|^|F|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843781|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|7|^|2013-01-30 15:25:57.0|^|TM100002052 V3 Effective Date 13Apr2012|^|NB76609 P.28|^|CRO-017-02|^|29-JAN-2013|^|18958517|^|0|^|A|^|T|^|Color|^|Coloration|^|Coloration|^|<=B9|^|<=B9|^||^||^||^|T|^|T|^|Not more intensely colored than level 5 of the color standard|^|TSENKB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843782|^|A|^|REGISTERED|^|CONCENTRATION_UV|^|Protein Concentration (UV)|^|TM100001683, TMC0085|^|1|^|9|^|2013-01-30 14:32:18.0|^|TM100001683 V6/ 07Aug2012|^|NB75517 P33|^|CRO-017-02|^|28-JAN-2013|^|18958522|^|0|^|A|^|T|^|Protein Concentration|^|Protein Concentration - rep|^|Protein Concentration - rep|^|21.3|^|21.3|^|mg/mL|^|21.3|^||^|T|^|T|^||^|JEFFEL02|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843782|^|A|^|REGISTERED|^|CONCENTRATION_UV|^|Protein Concentration (UV)|^|TM100001683, TMC0085|^|1|^|9|^|2013-01-30 14:32:18.0|^|TM100001683 V6/ 07Aug2012|^|NB75517 P33|^|CRO-017-02|^|28-JAN-2013|^|18958523|^|0|^|A|^|T|^|Protein Concentration - Average|^|Protein Concentration|^|Protein Concentration|^|21.3|^|21.3|^|mg/mL|^|21.3|^||^|T|^|T|^|Report Results|^|JEFFEL02|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843783|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2013-01-29 14:11:16.0|^|TM100001681 V3.0 Effective Date 30May2012|^|NB78128 P.14|^|CRO-017-02|^|28-JAN-2013|^|18958528|^|0|^|A|^|T|^|Peak 1 (% Area)|^|% Acidic Peaks - rep|^|% Acidic Peaks - rep|^|21.9|^|21.9|^|%|^|21.9|^||^|T|^|T|^||^|TSENKB|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843783|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2013-01-29 14:11:16.0|^|TM100001681 V3.0 Effective Date 30May2012|^|NB78128 P.14|^|CRO-017-02|^|28-JAN-2013|^|18958529|^|0|^|A|^|T|^|Peak 1 (% Area) - Average|^|% Acidic Peaks|^|% Acidic Peaks|^|21.9|^|21.9|^|%|^|21.9|^||^|T|^|T|^|17.0 - 33.0%|^|TSENKB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843783|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2013-01-29 14:11:16.0|^|TM100001681 V3.0 Effective Date 30May2012|^|NB78128 P.14|^|CRO-017-02|^|28-JAN-2013|^|18958530|^|0|^|A|^|T|^|Peak 2 (% Area)|^|% Main Peak - rep|^|% Main Peak - rep|^|56.4|^|56.4|^|%|^|56.4|^||^|T|^|T|^||^|TSENKB|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843783|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2013-01-29 14:11:16.0|^|TM100001681 V3.0 Effective Date 30May2012|^|NB78128 P.14|^|CRO-017-02|^|28-JAN-2013|^|18958531|^|0|^|A|^|T|^|Peak 2 (% Area) - Average|^|% Main Peak|^|% Main Peak|^|56.4|^|56.4|^|%|^|56.4|^||^|T|^|T|^|>= 50.0%|^|TSENKB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843783|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2013-01-29 14:11:16.0|^|TM100001681 V3.0 Effective Date 30May2012|^|NB78128 P.14|^|CRO-017-02|^|28-JAN-2013|^|18958532|^|0|^|A|^|T|^|Peak 3 (% Area)|^|% Basic Peaks - rep|^|% Basic Peaks - rep|^|21.7|^|21.7|^|%|^|21.7|^||^|T|^|T|^||^|TSENKB|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843783|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2013-01-29 14:11:16.0|^|TM100001681 V3.0 Effective Date 30May2012|^|NB78128 P.14|^|CRO-017-02|^|28-JAN-2013|^|18958533|^|0|^|A|^|T|^|Peak 3 (% Area) - Average|^|% Basic Peaks|^|% Basic Peaks|^|21.7|^|21.7|^|%|^|21.7|^||^|F|^|F|^|7.0 - 24.0%|^|TSENKB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843784|^|A|^|ADDITIONAL|^|MAB_OXIDATION|^|Lys-C Digest|^|TM100001849|^|1|^|9|^|2013-01-31 12:53:04.0|^|TM100001849 V3 Effective Date 28Nov2012|^|NB78125 P.20|^|CRO-017-02|^|30-JAN-2013|^|18958538|^|0|^|A|^|T|^|Peak 1 (Relative Area %)|^|Oxidation at Fc-Met-1|^|Oxidation at Fc-Met-1|^|1.3|^|1.3|^|%|^|1.3|^||^|T|^|T|^||^|TSENKB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843786|^|A|^|REGISTERED|^|PARTICULATE_BIO|^|Appearance (Visible Particulates)|^|TM100002052|^|1|^|4|^|2013-01-30 15:25:58.0|^|TM100002052 V3 Effective Date 13Apr2012|^|NB76609 P.28|^|CRO-017-02|^|29-JAN-2013|^|18958549|^|0|^|A|^|T|^|Particles|^|Visible particulates|^|Visible particulates|^|FREE|^|Essentially Free of Visible Particles|^||^||^||^|T|^|T|^|Essentially Free of Visible Particles|^|TSENKB|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843787|^|A|^|REGISTERED|^|PH|^|pH|^|M00125|^|1|^|4|^|2013-01-30 15:37:11.0|^|M00125 V2 Effective Date 07May2012|^|NB76606 P.20|^|CRO-017-02|^|30-JAN-2013|^|18958554|^|0|^|A|^|T|^|pH|^|pH - rep|^|pH - rep|^|5.7|^|5.7|^||^|5.7|^||^|T|^|T|^||^|TSENKB|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843787|^|A|^|REGISTERED|^|PH|^|pH|^|M00125|^|1|^|4|^|2013-01-30 15:37:11.0|^|M00125 V2 Effective Date 07May2012|^|NB76606 P.20|^|CRO-017-02|^|30-JAN-2013|^|18958555|^|0|^|A|^|T|^|pH - Average|^|pH|^|pH|^|5.7|^|5.7|^||^|5.7|^||^|T|^|T|^|6.0 +/- 0.5|^|TSENKB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843788|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2013-01-30 16:53:31.0|^|TM100001683 version 6.0/Effective 07 Aug 2012|^|NB75441 P17|^|CRO-017-02|^|28-JAN-2013|^|18958560|^|0|^|A|^|T|^|Minutes|^|Minutes|^|Minutes|^|4|^|4|^|min|^|4|^||^|T|^|T|^||^|DEEGAO01|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843788|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2013-01-30 16:53:31.0|^|TM100001683 version 6.0/Effective 07 Aug 2012|^|NB75441 P17|^|CRO-017-02|^|28-JAN-2013|^|18958561|^|0|^|A|^|T|^|Seconds|^|Seconds|^|Seconds|^|5|^|5|^|s|^|5|^||^|T|^|T|^||^|DEEGAO01|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843788|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2013-01-30 16:53:31.0|^|TM100001683 version 6.0/Effective 07 Aug 2012|^|NB75441 P17|^|CRO-017-02|^|28-JAN-2013|^|18958562|^|0|^|A|^|T|^|Rounding Interval|^|Rounding Interval|^|Rounding Interval|^|NA|^|Not available|^||^||^||^|T|^|T|^||^|DEEGAO01|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843788|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2013-01-30 16:53:31.0|^|TM100001683 version 6.0/Effective 07 Aug 2012|^|NB75441 P17|^|CRO-017-02|^|28-JAN-2013|^|18958563|^|0|^|A|^|T|^|Total Time|^|Total Time|^|Total Time|^|245|^|245|^|s|^|245|^||^|T|^|T|^||^|DEEGAO01|^|F|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843788|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2013-01-30 16:53:31.0|^|TM100001683 version 6.0/Effective 07 Aug 2012|^|NB75441 P17|^|CRO-017-02|^|28-JAN-2013|^|18958564|^|0|^|A|^|T|^|Reconstitution Time|^|Reconstitution Time|^|Reconstitution Time|^|4 min 5 sec|^|4 min 5 sec|^||^||^||^|T|^|T|^|Report Results|^|DEEGAO01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843789|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777|^|1|^|10|^|2013-02-04 09:05:01.0|^|TM100001777 V3.0 Effective Date 30May2012|^|NB78127 P.13|^|CRO-017-02|^|01-FEB-2013|^|18958569|^|0|^|A|^|T|^|Peak 1 (% Area)|^|Monomer|^|Monomer|^|98.4|^|98.4|^|%|^|98.4|^||^|T|^|T|^|>= 95.0%|^|TSENKB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843789|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777|^|1|^|10|^|2013-02-04 09:05:01.0|^|TM100001777 V3.0 Effective Date 30May2012|^|NB78127 P.13|^|CRO-017-02|^|01-FEB-2013|^|18958570|^|0|^|A|^|T|^|Peak 2 (% Area)|^|HMMS|^|HMMS|^|1.3|^|1.3|^|%|^|1.3|^||^|T|^|T|^|<= 5.0%|^|TSENKB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843789|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777|^|1|^|10|^|2013-02-04 09:05:01.0|^|TM100001777 V3.0 Effective Date 30May2012|^|NB78127 P.13|^|CRO-017-02|^|01-FEB-2013|^|18958571|^|0|^|A|^|T|^|Peak 3 (% Area)|^|LMMS|^|LMMS|^|0.3|^|0.3|^|%|^|0.3|^||^|T|^|T|^||^|TSENKB|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843791|^|A|^|REGISTERED|^|TURBIDITY|^|Appearance (Clarity)|^|TM100002052|^|1|^|2|^|2013-01-30 15:25:58.0|^|TM100002052 V3 Effective Date 13Apr2012|^|NB76609 P.28|^|CRO-017-02|^|29-JAN-2013|^|18958583|^|0|^|A|^|T|^|Turbidity - Rep|^|Turbidity - Rep|^|Turbidity - Rep|^|4|^|4|^|NTU|^|4|^||^|T|^|T|^||^|TSENKB|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230602|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-06 12:52:55.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843791|^|A|^|REGISTERED|^|TURBIDITY|^|Appearance (Clarity)|^|TM100002052|^|1|^|2|^|2013-01-30 15:25:58.0|^|TM100002052 V3 Effective Date 13Apr2012|^|NB76609 P.28|^|CRO-017-02|^|29-JAN-2013|^|18958584|^|0|^|A|^|T|^|Turbidity|^|Turbidity|^|Turbidity|^|4|^|4|^|NTU|^|4|^||^|T|^|T|^|<= 18 NTU|^|TSENKB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230603|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-18 19:27:11.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843790|^|A|^|REGISTERED|^|SPECIFIC_ACTIVITY|^|Potency Assay (Cell Based)|^|TM100001721|^|1|^|10|^|2013-02-18 19:27:11.0|^|TM100001721 V4.0|^|00707190-0101|^|Pfizer, BIT, Andover, MA, US|^|12-FEB-2013|^|18958576|^|0|^|A|^|T|^|Relative Potency|^|Relative Potency|^|Relative Potency|^|122|^|122|^|%|^|122|^||^|T|^|T|^|55 - 158% potency relative to reference material|^|TVELASCO|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_09|^|9 Months|^|9|^||^|2012-05-04 00:00:00.0|^|2013-02-04 00:00:00.0|^||^|230601|^|A|^|230603|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-01-28 00:09:06.0|^|2013-02-18 16:08:35.0|^|2013-02-18 16:08:35.0|^|2013-02-18 19:27:11.0|^|2013-10-22 11:57:14.0|^|F|^|F|^|2013-10-22 11:57:21.0|^|843790|^|A|^|REGISTERED|^|SPECIFIC_ACTIVITY|^|Potency Assay (Cell Based)|^|TM100001721|^|1|^|10|^|2013-02-18 19:27:11.0|^|TM100001721 V4.0|^|00707190-0101|^|Pfizer, BIT, Andover, MA, US|^|12-FEB-2013|^|18958577|^|0|^|A|^|T|^|Specific Activity|^|Specific Activity|^|Specific Activity|^|1220|^|1220|^|U/mg|^|1220|^||^|T|^|T|^|550 - 1580 U/mg|^|TVELASCO|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888332|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052|^|1|^|1|^|2013-05-10 09:07:21.0|^|TM100002052 Version 3.0/ 13 Apr 2012|^|73112 p37|^|CRO-017-02|^|07-MAY-2013|^|19794079|^|0|^|A|^|T|^|Appearance|^|Visual appearance|^|Visual appearance|^|White cake essentially free from visible particulates|^|White cake essentially free from visible particulates|^||^||^||^|T|^|T|^|White cake essentially free from visible particulates|^|MCGAHK01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888333|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reduced)|^|TM100001851|^|1|^|10|^|2013-05-15 08:49:56.0|^|TM100001851 version 3.0/30 May 2012|^|81631 P17|^|CRO-017-02|^|10-MAY-2013|^|19972786|^|0|^|A|^|T|^|LOQ|^|LOQ|^|LOQ|^|0.3|^|0.3|^||^|0.3|^||^|T|^|T|^||^|ROCHEP02|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888333|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reduced)|^|TM100001851|^|1|^|10|^|2013-05-15 08:49:56.0|^|TM100001851 version 3.0/30 May 2012|^|81631 P17|^|CRO-017-02|^|10-MAY-2013|^|19794084|^|0|^|A|^|T|^|Sum HC and LC|^|Heavy Chain + Light Chain|^|Heavy Chain + Light Chain|^|99.5|^|99.5|^|%|^|99.5|^||^|T|^|T|^|>= 95.0% IgG as heavy + light chain|^|ROCHEP02|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888333|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reduced)|^|TM100001851|^|1|^|10|^|2013-05-15 08:49:56.0|^|TM100001851 version 3.0/30 May 2012|^|81631 P17|^|CRO-017-02|^|10-MAY-2013|^|19794085|^|0|^|A|^|T|^|Percent Fragment|^|Fragments|^|Fragments|^|0.0|^|NMT 0.3|^|%|^||^||^|T|^|T|^|Report Results|^|ROCHEP02|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888334|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|7|^|2013-05-10 11:11:01.0|^|TM100002052 Version 3.0/ 13 Apr 2012|^|74373 p37|^|CRO-017-02|^|09-MAY-2013|^|19794090|^|0|^|A|^|T|^|Color Hue|^|Color Hue|^|Color Hue|^|B|^|B|^||^||^||^|T|^|T|^||^|MCGAHK01|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888334|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|7|^|2013-05-10 11:11:01.0|^|TM100002052 Version 3.0/ 13 Apr 2012|^|74373 p37|^|CRO-017-02|^|09-MAY-2013|^|19794091|^|0|^|A|^|T|^|Color Intensity|^|Color Intensity|^|Color Intensity|^|9|^|9|^||^|9|^||^|T|^|T|^||^|MCGAHK01|^|F|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888334|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|7|^|2013-05-10 11:11:01.0|^|TM100002052 Version 3.0/ 13 Apr 2012|^|74373 p37|^|CRO-017-02|^|09-MAY-2013|^|19794092|^|0|^|A|^|T|^|Color|^|Coloration|^|Coloration|^|<=B9|^|<=B9|^||^||^||^|T|^|T|^|Not more intensely colored than level 5 of the color standard|^|MCGAHK01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888335|^|A|^|REGISTERED|^|CONCENTRATION_UV|^|Protein Concentration (UV)|^|TM100001683, TMC0085|^|1|^|9|^|2013-05-09 08:05:54.0|^|TM100001683 Version 6.0 07Aug 2012|^|83210 P6|^|CRO-017-02|^|07-MAY-2013|^|19794097|^|0|^|A|^|T|^|Protein Concentration|^|Protein Concentration - rep|^|Protein Concentration - rep|^|21.4|^|21.4|^|mg/mL|^|21.4|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888335|^|A|^|REGISTERED|^|CONCENTRATION_UV|^|Protein Concentration (UV)|^|TM100001683, TMC0085|^|1|^|9|^|2013-05-09 08:05:54.0|^|TM100001683 Version 6.0 07Aug 2012|^|83210 P6|^|CRO-017-02|^|07-MAY-2013|^|19794098|^|0|^|A|^|T|^|Protein Concentration - Average|^|Protein Concentration|^|Protein Concentration|^|21.4|^|21.4|^|mg/mL|^|21.4|^||^|T|^|T|^|Report Results|^|BARREN06|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888336|^|A|^|REGISTERED|^|DYE_INGRESS|^|Container Closure|^|TM100001254|^|1|^|1|^|2013-05-17 07:31:08.0|^|M8721.03/22 Apr 2013|^|79370 p48-49|^|CRO-017-02|^|16-MAY-2013|^|19794103|^|0|^|A|^|T|^|Dye Ingress|^|Dye Ingress|^|Dye Ingress|^|PASS|^|Pass|^||^||^||^|T|^|T|^|Pass|^|MCGAHK01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888337|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2013-05-20 11:17:02.0|^|TM100001681 Version 3.0 Effective Date 30May2012|^|NB78128 P.32|^|CRO-017-02|^|13-MAY-2013|^|19794108|^|0|^|A|^|T|^|Peak 1 (% Area)|^|% Acidic Peaks - rep|^|% Acidic Peaks - rep|^|21.6|^|21.6|^|%|^|21.6|^||^|T|^|T|^||^|TSENKB|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888337|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2013-05-20 11:17:02.0|^|TM100001681 Version 3.0 Effective Date 30May2012|^|NB78128 P.32|^|CRO-017-02|^|13-MAY-2013|^|19794109|^|0|^|A|^|T|^|Peak 1 (% Area) - Average|^|% Acidic Peaks|^|% Acidic Peaks|^|21.6|^|21.6|^|%|^|21.6|^||^|T|^|T|^|17.0 - 33.0%|^|TSENKB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888337|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2013-05-20 11:17:02.0|^|TM100001681 Version 3.0 Effective Date 30May2012|^|NB78128 P.32|^|CRO-017-02|^|13-MAY-2013|^|19794110|^|0|^|A|^|T|^|Peak 2 (% Area)|^|% Main Peak - rep|^|% Main Peak - rep|^|56.1|^|56.1|^|%|^|56.1|^||^|T|^|T|^||^|TSENKB|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888337|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2013-05-20 11:17:02.0|^|TM100001681 Version 3.0 Effective Date 30May2012|^|NB78128 P.32|^|CRO-017-02|^|13-MAY-2013|^|19794111|^|0|^|A|^|T|^|Peak 2 (% Area) - Average|^|% Main Peak|^|% Main Peak|^|56.1|^|56.1|^|%|^|56.1|^||^|T|^|T|^|>= 50.0%|^|TSENKB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888337|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2013-05-20 11:17:02.0|^|TM100001681 Version 3.0 Effective Date 30May2012|^|NB78128 P.32|^|CRO-017-02|^|13-MAY-2013|^|19794112|^|0|^|A|^|T|^|Peak 3 (% Area)|^|% Basic Peaks - rep|^|% Basic Peaks - rep|^|22.3|^|22.3|^|%|^|22.3|^||^|T|^|T|^||^|TSENKB|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888337|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2013-05-20 11:17:02.0|^|TM100001681 Version 3.0 Effective Date 30May2012|^|NB78128 P.32|^|CRO-017-02|^|13-MAY-2013|^|19794113|^|0|^|A|^|T|^|Peak 3 (% Area) - Average|^|% Basic Peaks|^|% Basic Peaks|^|22.3|^|22.3|^|%|^|22.3|^||^|F|^|F|^|7.0 - 24.0%|^|TSENKB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888323|^|A|^|ADDITIONAL|^|MAB_OXIDATION|^|Lys-C Digest|^|TM100001849|^|1|^|9|^|2013-05-13 12:51:41.0|^|TM100001849 Version 3.0/ Effective 28 Nov 2012|^|NB81632 P.20|^|CRO-017-02|^|10-MAY-2013|^|19794018|^|0|^|A|^|T|^|Peak 1 (Relative Area %)|^|Oxidation at Fc-Met-1|^|Oxidation at Fc-Met-1|^|1.4|^|1.4|^|%|^|1.4|^||^|T|^|T|^||^|DEEGAO01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888325|^|A|^|REGISTERED|^|PARTICULATE_BIO|^|Appearance (Visible Particulates)|^|TM100002052|^|1|^|4|^|2013-05-10 11:11:01.0|^|TM100002052 Version 3.0/ 13 Apr 2012|^|74373 p29|^|CRO-017-02|^|09-MAY-2013|^|19794029|^|0|^|A|^|T|^|Particles|^|Visible particulates|^|Visible particulates|^|FREE|^|Essentially Free of Visible Particles|^||^||^||^|T|^|T|^|Essentially Free of Visible Particles|^|MCGAHK01|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888325|^|A|^|REGISTERED|^|PARTICULATE_BIO|^|Appearance (Visible Particulates)|^|TM100002052|^|1|^|4|^|2013-05-10 11:11:01.0|^|TM100002052 Version 3.0/ 13 Apr 2012|^|74373 p29|^|CRO-017-02|^|09-MAY-2013|^|19916746|^|0|^|A|^|T|^|Visible Particulates|^|Visible Particulates|^|Visible Particulates|^|FREE|^|Essentially free from visible particulates|^||^||^||^|T|^|T|^||^|MCGAHK01|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888326|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-05-17 08:00:53.0|^|TM100002055 version 1.0 \ 06 May2011|^|73097 P 28|^|CRO-017-02|^|13-MAY-2013|^|20001990|^|1|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|5500|^|5500|^|Particles/container|^|5500|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888326|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-05-17 08:00:53.0|^|TM100002055 version 1.0 \ 06 May2011|^|73097 P 28|^|CRO-017-02|^|13-MAY-2013|^|20001991|^|2|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|5072|^|5072|^|Particles/container|^|5072|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888326|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-05-17 08:00:53.0|^|TM100002055 version 1.0 \ 06 May2011|^|73097 P 28|^|CRO-017-02|^|13-MAY-2013|^|20001992|^|3|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|5052|^|5052|^|Particles/container|^|5052|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888326|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-05-17 08:00:53.0|^|TM100002055 version 1.0 \ 06 May2011|^|73097 P 28|^|CRO-017-02|^|13-MAY-2013|^|19794034|^|0|^|A|^|T|^|Light Obscuration: >= 2µm|^|Light Obscuration: >= 2µm|^|Light Obscuration: >= 2µm|^|5208|^|5208|^|Particles/container|^|5208|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888326|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-05-17 08:00:53.0|^|TM100002055 version 1.0 \ 06 May2011|^|73097 P 28|^|CRO-017-02|^|13-MAY-2013|^|20001993|^|1|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|1064|^|1064|^|Particles/container|^|1064|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888326|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-05-17 08:00:53.0|^|TM100002055 version 1.0 \ 06 May2011|^|73097 P 28|^|CRO-017-02|^|13-MAY-2013|^|20001994|^|2|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|996|^|996|^|Particles/container|^|996|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888326|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-05-17 08:00:53.0|^|TM100002055 version 1.0 \ 06 May2011|^|73097 P 28|^|CRO-017-02|^|13-MAY-2013|^|20001995|^|3|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|812|^|812|^|Particles/container|^|812|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888326|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-05-17 08:00:53.0|^|TM100002055 version 1.0 \ 06 May2011|^|73097 P 28|^|CRO-017-02|^|13-MAY-2013|^|19794035|^|0|^|A|^|T|^|Light Obscuration: >= 5µm|^|Light Obscuration: >= 5µm|^|Light Obscuration: >= 5µm|^|957.33333333|^|957|^|Particles/container|^|957|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888326|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-05-17 08:00:53.0|^|TM100002055 version 1.0 \ 06 May2011|^|73097 P 28|^|CRO-017-02|^|13-MAY-2013|^|20001996|^|1|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|268|^|268|^|Particles/container|^|268|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888326|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-05-17 08:00:53.0|^|TM100002055 version 1.0 \ 06 May2011|^|73097 P 28|^|CRO-017-02|^|13-MAY-2013|^|20001997|^|2|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|184|^|184|^|Particles/container|^|184|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888326|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-05-17 08:00:53.0|^|TM100002055 version 1.0 \ 06 May2011|^|73097 P 28|^|CRO-017-02|^|13-MAY-2013|^|20001998|^|3|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|132|^|132|^|Particles/container|^|132|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888326|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-05-17 08:00:53.0|^|TM100002055 version 1.0 \ 06 May2011|^|73097 P 28|^|CRO-017-02|^|13-MAY-2013|^|19794036|^|0|^|A|^|T|^|Light Obscuration: >= 8µm|^|Light Obscuration: >= 8µm|^|Light Obscuration: >= 8µm|^|194.66666667|^|195|^|Particles/container|^|195|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888326|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-05-17 08:00:53.0|^|TM100002055 version 1.0 \ 06 May2011|^|73097 P 28|^|CRO-017-02|^|13-MAY-2013|^|20001999|^|1|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|160|^|160|^|Particles/container|^|160|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888326|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-05-17 08:00:53.0|^|TM100002055 version 1.0 \ 06 May2011|^|73097 P 28|^|CRO-017-02|^|13-MAY-2013|^|20002000|^|2|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|96|^|96|^|Particles/container|^|96|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888326|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-05-17 08:00:53.0|^|TM100002055 version 1.0 \ 06 May2011|^|73097 P 28|^|CRO-017-02|^|13-MAY-2013|^|20002001|^|3|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|68|^|68|^|Particles/container|^|68|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888326|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-05-17 08:00:53.0|^|TM100002055 version 1.0 \ 06 May2011|^|73097 P 28|^|CRO-017-02|^|13-MAY-2013|^|19794037|^|0|^|A|^|T|^|Light Obscuration: >= 10µm|^|Light Obscuration: >= 10µm|^|Light Obscuration: >= 10µm|^|108|^|108|^|Particles/container|^|108|^||^|T|^|T|^|Report Results|^|BARREN06|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888326|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-05-17 08:00:53.0|^|TM100002055 version 1.0 \ 06 May2011|^|73097 P 28|^|CRO-017-02|^|13-MAY-2013|^|20002002|^|1|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|44|^|44|^|Particles/container|^|44|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888326|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-05-17 08:00:53.0|^|TM100002055 version 1.0 \ 06 May2011|^|73097 P 28|^|CRO-017-02|^|13-MAY-2013|^|20002003|^|2|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|28|^|28|^|Particles/container|^|28|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888326|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-05-17 08:00:53.0|^|TM100002055 version 1.0 \ 06 May2011|^|73097 P 28|^|CRO-017-02|^|13-MAY-2013|^|20002004|^|3|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|24|^|24|^|Particles/container|^|24|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888326|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-05-17 08:00:53.0|^|TM100002055 version 1.0 \ 06 May2011|^|73097 P 28|^|CRO-017-02|^|13-MAY-2013|^|19794038|^|0|^|A|^|T|^|Light Obscuration: >= 25µm|^|Light Obscuration: >= 25µm|^|Light Obscuration: >= 25µm|^|32|^|32|^|Particles/container|^|32|^||^|T|^|T|^|Report Results|^|BARREN06|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888326|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-05-17 08:00:53.0|^|TM100002055 version 1.0 \ 06 May2011|^|73097 P 28|^|CRO-017-02|^|13-MAY-2013|^|19794039|^|0|^|A|^|T|^|Particulate Matter|^|Particulate Matter|^|Particulate Matter|^|Meets compendial requirements|^|Meets compendial requirements|^||^||^||^|T|^|T|^|Meets compendial requirements|^|BARREN06|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888327|^|A|^|REGISTERED|^|PH|^|pH|^|M00125|^|1|^|4|^|2013-05-11 14:50:10.0|^|M00125 Version 2.0/07 May 2012|^|78560 p10|^|CRO-017-02|^|11-MAY-2013|^|19794044|^|0|^|A|^|T|^|pH|^|pH - rep|^|pH - rep|^|6.00|^|6.0|^||^|6|^||^|T|^|T|^||^|MCGAHK01|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888327|^|A|^|REGISTERED|^|PH|^|pH|^|M00125|^|1|^|4|^|2013-05-11 14:50:10.0|^|M00125 Version 2.0/07 May 2012|^|78560 p10|^|CRO-017-02|^|11-MAY-2013|^|19794045|^|0|^|A|^|T|^|pH - Average|^|pH|^|pH|^|6.0|^|6.0|^||^|6|^||^|T|^|T|^|6.0 +/- 0.5|^|MCGAHK01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888328|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2013-05-10 09:05:22.0|^|TM100001683 Version: 6.0/07 Aug 2012|^|73112 p40|^|CRO-017-02|^|07-MAY-2013|^|19794050|^|0|^|A|^|T|^|Minutes|^|Minutes|^|Minutes|^|1|^|1|^|min|^|1|^||^|T|^|T|^||^|MCGAHK01|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888328|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2013-05-10 09:05:22.0|^|TM100001683 Version: 6.0/07 Aug 2012|^|73112 p40|^|CRO-017-02|^|07-MAY-2013|^|19794051|^|0|^|A|^|T|^|Seconds|^|Seconds|^|Seconds|^|58|^|58|^|s|^|58|^||^|T|^|T|^||^|MCGAHK01|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888328|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2013-05-10 09:05:22.0|^|TM100001683 Version: 6.0/07 Aug 2012|^|73112 p40|^|CRO-017-02|^|07-MAY-2013|^|19794052|^|0|^|A|^|T|^|Rounding Interval|^|Rounding Interval|^|Rounding Interval|^|NA|^|Not available|^||^||^||^|T|^|T|^||^|MCGAHK01|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888328|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2013-05-10 09:05:22.0|^|TM100001683 Version: 6.0/07 Aug 2012|^|73112 p40|^|CRO-017-02|^|07-MAY-2013|^|19794053|^|0|^|A|^|T|^|Total Time|^|Total Time|^|Total Time|^|118|^|118|^|s|^|118|^||^|T|^|T|^||^|MCGAHK01|^|F|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888328|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2013-05-10 09:05:22.0|^|TM100001683 Version: 6.0/07 Aug 2012|^|73112 p40|^|CRO-017-02|^|07-MAY-2013|^|19794054|^|0|^|A|^|T|^|Reconstitution Time|^|Reconstitution Time|^|Reconstitution Time|^|1 min 58 sec|^|1 min 58 sec|^||^||^||^|T|^|T|^|Report Results|^|MCGAHK01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888329|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777|^|1|^|10|^|2013-05-15 15:06:16.0|^|TM100001777 version 3.0/30May2012|^|78127 P27|^|CRO-017-02|^|14-MAY-2013|^|19794059|^|0|^|A|^|T|^|Peak 1 (% Area)|^|Monomer|^|Monomer|^|98.3|^|98.3|^|%|^|98.3|^||^|T|^|T|^|>= 95.0%|^|ROCHEP02|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888329|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777|^|1|^|10|^|2013-05-15 15:06:16.0|^|TM100001777 version 3.0/30May2012|^|78127 P27|^|CRO-017-02|^|14-MAY-2013|^|19794060|^|0|^|A|^|T|^|Peak 2 (% Area)|^|HMMS|^|HMMS|^|1.5|^|1.5|^|%|^|1.5|^||^|T|^|T|^|<= 5.0%|^|ROCHEP02|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888329|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777|^|1|^|10|^|2013-05-15 15:06:16.0|^|TM100001777 version 3.0/30May2012|^|78127 P27|^|CRO-017-02|^|14-MAY-2013|^|19794061|^|0|^|A|^|T|^|Peak 3 (% Area)|^|LMMS|^|LMMS|^|0.2|^|0.2|^|%|^|0.2|^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888331|^|A|^|REGISTERED|^|TURBIDITY|^|Appearance (Clarity)|^|TM100002052|^|1|^|2|^|2013-05-10 11:11:01.0|^|TM100002052 Version 3.0/ 13 Apr 2012|^|74373 p35|^|CRO-017-02|^|09-MAY-2013|^|19794073|^|0|^|A|^|T|^|Turbidity - Rep|^|Turbidity - Rep|^|Turbidity - Rep|^|2.94|^|3|^|NTU|^|3|^||^|T|^|T|^||^|MCGAHK01|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241323|^|A|^||^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:44.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888331|^|A|^|REGISTERED|^|TURBIDITY|^|Appearance (Clarity)|^|TM100002052|^|1|^|2|^|2013-05-10 11:11:01.0|^|TM100002052 Version 3.0/ 13 Apr 2012|^|74373 p35|^|CRO-017-02|^|09-MAY-2013|^|19794074|^|0|^|A|^|T|^|Turbidity|^|Turbidity|^|Turbidity|^|2.94|^|3|^|NTU|^|3|^||^|T|^|T|^|<= 18 NTU|^|MCGAHK01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241324|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-05-31 17:13:29.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888324|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2013-05-31 17:13:29.0|^|TM000001405, Version 2.0|^|130299-20|^|Pfizer, QC, St. Louis, MO, US|^|31-MAY-2013|^|20122335|^|0|^|A|^|T|^|LOQ|^|LOQ|^|LOQ|^|0.2|^|0.2|^||^|0.2|^||^|T|^|T|^||^|MAREAS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241324|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-05-31 17:13:29.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888324|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2013-05-31 17:13:29.0|^|TM000001405, Version 2.0|^|130299-20|^|Pfizer, QC, St. Louis, MO, US|^|31-MAY-2013|^|20122336|^|0|^|A|^|T|^|Manual Entry - Moisture - Replicate|^|Manual Entry - Moisture - Replicate|^|Manual Entry - Moisture - Replicate|^|0.4|^|0.4|^|%|^|0.4|^||^|T|^|T|^||^|MAREAS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241324|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-05-31 17:13:29.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888324|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2013-05-31 17:13:29.0|^|TM000001405, Version 2.0|^|130299-20|^|Pfizer, QC, St. Louis, MO, US|^|31-MAY-2013|^|19794023|^|0|^|A|^|T|^|Moisture - Rep|^|Moisture - Rep|^|Moisture - Rep|^|0.4|^|0.4|^|%|^|0.4|^||^|T|^|T|^||^|MAREAS|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241324|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-05-31 17:13:29.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888324|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2013-05-31 17:13:29.0|^|TM000001405, Version 2.0|^|130299-20|^|Pfizer, QC, St. Louis, MO, US|^|31-MAY-2013|^|19794024|^|0|^|A|^|T|^|Moisture|^|Moisture|^|Moisture|^|0.4|^|0.4|^|%|^|0.4|^||^|T|^|T|^|<= 2%|^|MAREAS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241325|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:42.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888330|^|A|^|REGISTERED|^|SPECIFIC_ACTIVITY|^|Potency Assay (Cell Based)|^|TM100001721|^|1|^|10|^|2013-06-12 19:34:42.0|^|TM100001721 V5.0|^|00707666-0099-1, 00707666-0095-2,3|^|Pfizer, BIT, Andover, MA, US|^|06-JUN-2013|^|19794066|^|0|^|A|^|T|^|Relative Potency|^|Relative Potency|^|Relative Potency|^|102|^|102|^|%|^|102|^||^|T|^|T|^|55 - 158% potency relative to reference material|^|MALIKB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|5|^|PF-05280014 21 mg/mL (440mg/vial), Injection|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^||^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_12|^|12 Months|^|12|^||^|2012-05-04 00:00:00.0|^|2013-05-04 00:00:00.0|^||^|241323|^|A|^|241325|^|A|^||^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-04-27 01:10:45.0|^|2013-05-09 07:43:22.0|^|2013-05-09 08:05:54.0|^|2013-06-12 19:34:42.0|^|2013-10-22 12:26:26.0|^|F|^|F|^|2013-10-22 12:26:31.0|^|888330|^|A|^|REGISTERED|^|SPECIFIC_ACTIVITY|^|Potency Assay (Cell Based)|^|TM100001721|^|1|^|10|^|2013-06-12 19:34:42.0|^|TM100001721 V5.0|^|00707666-0099-1, 00707666-0095-2,3|^|Pfizer, BIT, Andover, MA, US|^|06-JUN-2013|^|19794067|^|0|^|A|^|T|^|Specific Activity|^|Specific Activity|^|Specific Activity|^|1015|^|1015|^|U/mg|^|1015|^||^|T|^|T|^|550 - 1580 U/mg|^|MALIKB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2014-01-02 19:12:26.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2014-01-28 17:32:28.0|^|974952|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2013-12-09 18:39:45.0|^|TM000001405, Version 3.0|^|00708123-0022|^|Pfizer, QC, St. Louis, MO, US|^|09-DEC-2013|^|22096710|^|0|^|A|^|T|^|LOQ|^|LOQ|^|LOQ|^|0.2|^|0.2|^||^|0.2|^||^|T|^|T|^||^|MAREAS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2014-01-02 19:12:26.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2014-01-28 17:32:28.0|^|974952|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2013-12-09 18:39:45.0|^|TM000001405, Version 3.0|^|00708123-0022|^|Pfizer, QC, St. Louis, MO, US|^|09-DEC-2013|^|22096714|^|0|^|A|^|T|^|Diluent Weight|^|Diluent Weight|^|Diluent Weight|^|24.7306|^|24.7306|^|g|^|24.7306|^||^|T|^|T|^||^|MAREAS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2014-01-02 19:12:26.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2014-01-28 17:32:28.0|^|974952|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2013-12-09 18:39:45.0|^|TM000001405, Version 3.0|^|00708123-0022|^|Pfizer, QC, St. Louis, MO, US|^|09-DEC-2013|^|22096733|^|0|^|A|^|T|^|Sample Weight|^|Sample Weight|^|Sample Weight|^|2.0329|^|2.0329|^|g|^|2.0329|^||^|T|^|T|^||^|MAREAS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2014-01-02 19:12:26.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2014-01-28 17:32:28.0|^|974952|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2013-12-09 18:39:45.0|^|TM000001405, Version 3.0|^|00708123-0022|^|Pfizer, QC, St. Louis, MO, US|^|09-DEC-2013|^|22097265|^|0|^|A|^|T|^|Cake Weight|^|Cake Weight|^|Cake Weight|^|0.8827|^|0.8827|^|g|^|0.8827|^||^|T|^|T|^||^|MAREAS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2014-01-02 19:12:26.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2014-01-28 17:32:28.0|^|974952|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2013-12-09 18:39:45.0|^|TM000001405, Version 3.0|^|00708123-0022|^|Pfizer, QC, St. Louis, MO, US|^|09-DEC-2013|^|22096734|^|0|^|A|^|T|^|Instrument Reading|^|Instrument Reading|^|Instrument Reading|^|427.2|^|427.2|^|µg|^|427.2|^||^|T|^|T|^||^|MAREAS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2014-01-02 19:12:26.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2014-01-28 17:32:28.0|^|974952|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2013-12-09 18:39:45.0|^|TM000001405, Version 3.0|^|00708123-0022|^|Pfizer, QC, St. Louis, MO, US|^|09-DEC-2013|^|22097206|^|0|^|A|^|T|^|Average H2O in Blank Injections|^|Average H2O in Blank Injections|^|Average H2O in Blank Injections|^|95.23723902|^|95.23723902|^|ppm|^|95.23723902|^||^|T|^|T|^||^|MAREAS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2014-01-02 19:12:26.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2014-01-28 17:32:28.0|^|974952|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2013-12-09 18:39:45.0|^|TM000001405, Version 3.0|^|00708123-0022|^|Pfizer, QC, St. Louis, MO, US|^|09-DEC-2013|^|21613518|^|0|^|A|^|T|^|Moisture - Rep|^|Moisture - Rep|^|Moisture - Rep|^|0.3334223913|^|0.3|^|%|^|0.3|^||^|T|^|T|^||^|MAREAS|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2014-01-02 19:12:26.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2014-01-28 17:32:28.0|^|974952|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2013-12-09 18:39:45.0|^|TM000001405, Version 3.0|^|00708123-0022|^|Pfizer, QC, St. Louis, MO, US|^|09-DEC-2013|^|21613519|^|0|^|A|^|T|^|Moisture|^|Moisture|^|Moisture|^|0.3334223913|^|0.3|^|%|^|0.3|^||^|T|^|T|^|<= 2%|^|MAREAS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974960|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052|^|1|^|2|^|2013-11-12 17:10:56.0|^|TM100002052 V4.0 19 Sep 2013|^|NB89575 P2|^|CRO-017-02|^|11-NOV-2013|^|21613574|^|0|^|A|^|T|^|Appearance|^|Visual appearance|^|Visual appearance|^|White cake essentially free from visible particulates|^|White cake essentially free from visible particulates|^||^||^||^|T|^|T|^|White cake essentially free from visible particulates|^|MOHANC03|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974961|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reduced)|^|TM100001851|^|1|^|10|^|2013-11-19 10:05:00.0|^|TM100001851 Version 4.0 Effective Date 19Aug2013|^|NB83212 P.19|^|CRO-017-02|^|18-NOV-2013|^|21900611|^|0|^|A|^|T|^|LOQ|^|LOQ|^|LOQ|^|0.3|^|0.3|^||^|0.3|^||^|T|^|T|^||^|TSENKB|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974961|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reduced)|^|TM100001851|^|1|^|10|^|2013-11-19 10:05:00.0|^|TM100001851 Version 4.0 Effective Date 19Aug2013|^|NB83212 P.19|^|CRO-017-02|^|18-NOV-2013|^|21613580|^|0|^|A|^|T|^|Sum HC and LC|^|Heavy Chain + Light Chain|^|Heavy Chain + Light Chain|^|99.6|^|99.6|^|%|^|99.6|^||^|T|^|T|^|>= 95.0% IgG as heavy + light chain|^|BARREN06|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974961|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reduced)|^|TM100001851|^|1|^|10|^|2013-11-19 10:05:00.0|^|TM100001851 Version 4.0 Effective Date 19Aug2013|^|NB83212 P.19|^|CRO-017-02|^|18-NOV-2013|^|21613581|^|0|^|A|^|T|^|Percent Fragment|^|Fragments|^|Fragments|^|0.4|^|0.4|^|%|^|0.4|^||^|T|^|T|^|Report Results|^|BARREN06|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974961|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reduced)|^|TM100001851|^|1|^|10|^|2013-11-19 10:05:00.0|^|TM100001851 Version 4.0 Effective Date 19Aug2013|^|NB83212 P.19|^|CRO-017-02|^|18-NOV-2013|^|27509056|^|0|^|A|^|T|^|Percent Other|^|Percent Other|^|Other|^|0.0|^|NMT 0.3|^|%|^||^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974948|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|9|^|2013-11-18 15:45:07.0|^|TM100002052 V4.0 19 Sep 2013|^|NB84736 P14|^|CRO-017-02|^|13-NOV-2013|^|21613490|^|0|^|A|^|T|^|Color Hue|^|Color Hue|^|Color Hue|^|B|^|B|^||^||^||^|T|^|T|^||^|MOHANC03|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974948|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|9|^|2013-11-18 15:45:07.0|^|TM100002052 V4.0 19 Sep 2013|^|NB84736 P14|^|CRO-017-02|^|13-NOV-2013|^|21613491|^|0|^|A|^|T|^|Color Intensity|^|Color Intensity|^|Color Intensity|^|8|^|8|^||^|8|^||^|T|^|T|^||^|MOHANC03|^|F|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974948|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|9|^|2013-11-18 15:45:07.0|^|TM100002052 V4.0 19 Sep 2013|^|NB84736 P14|^|CRO-017-02|^|13-NOV-2013|^|21894909|^|0|^|A|^|T|^|Color Result|^|Color Result|^|Color Result|^|Not more intensely colored than level 8 of the color standard|^|Not more intensely colored than level 8 of the color standard|^||^||^||^|T|^|T|^||^|MOHANC03|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974948|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|9|^|2013-11-18 15:45:07.0|^|TM100002052 V4.0 19 Sep 2013|^|NB84736 P14|^|CRO-017-02|^|13-NOV-2013|^|21894910|^|0|^|A|^|T|^|Color Description|^|Color Description|^|Color Description|^|Very Very Slightly Brown|^|Very Very Slightly Brown|^||^||^||^|T|^|T|^||^|MOHANC03|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974948|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|9|^|2013-11-18 15:45:07.0|^|TM100002052 V4.0 19 Sep 2013|^|NB84736 P14|^|CRO-017-02|^|13-NOV-2013|^|21613492|^|0|^|A|^|T|^|Color|^|Coloration|^|Coloration|^|<=B8|^|<=B8|^||^||^||^|T|^|T|^|Not more intensely colored than level 5 of the color standard|^|MOHANC03|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974949|^|A|^|REGISTERED|^|CONCENTRATION_UV|^|Protein Concentration (UV)|^|TM100001683, TMC0085|^|1|^|9|^|2013-11-14 11:45:30.0|^|TM100001683 Version 6.0 Effective Date 07Aug2012|^|NB83214 P.28|^|CRO-017-02|^|11-NOV-2013|^|21613497|^|0|^|A|^|T|^|Protein Concentration|^|Protein Concentration - rep|^|Protein Concentration - rep|^|21.5|^|21.5|^|mg/mL|^|21.5|^||^|T|^|T|^||^|TSENKB|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974949|^|A|^|REGISTERED|^|CONCENTRATION_UV|^|Protein Concentration (UV)|^|TM100001683, TMC0085|^|1|^|9|^|2013-11-14 11:45:30.0|^|TM100001683 Version 6.0 Effective Date 07Aug2012|^|NB83214 P.28|^|CRO-017-02|^|11-NOV-2013|^|21613498|^|0|^|A|^|T|^|Protein Concentration - Average|^|Protein Concentration|^|Protein Concentration|^|21.5|^|21.5|^|mg/mL|^|21.5|^||^|T|^|T|^|Report Results|^|TSENKB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974950|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2013-12-04 16:02:32.0|^|TM100001681 V3.0 30 May 2012|^|NB89634 P13|^|CRO-017-02|^|28-NOV-2013|^|21613503|^|0|^|A|^|T|^|Peak 1 (% Area)|^|% Acidic Peaks - rep|^|% Acidic Peaks - rep|^|21.1|^|21.1|^|%|^|21.1|^||^|T|^|T|^||^|MOHANC03|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974950|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2013-12-04 16:02:32.0|^|TM100001681 V3.0 30 May 2012|^|NB89634 P13|^|CRO-017-02|^|28-NOV-2013|^|21613504|^|0|^|A|^|T|^|Peak 1 (% Area) - Average|^|% Acidic Peaks|^|% Acidic Peaks|^|21.1|^|21.1|^|%|^|21.1|^||^|T|^|T|^|17.0 - 33.0%|^|MOHANC03|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974950|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2013-12-04 16:02:32.0|^|TM100001681 V3.0 30 May 2012|^|NB89634 P13|^|CRO-017-02|^|28-NOV-2013|^|21613505|^|0|^|A|^|T|^|Peak 2 (% Area)|^|% Main Peak - rep|^|% Main Peak - rep|^|54.7|^|54.7|^|%|^|54.7|^||^|T|^|T|^||^|MOHANC03|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974950|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2013-12-04 16:02:32.0|^|TM100001681 V3.0 30 May 2012|^|NB89634 P13|^|CRO-017-02|^|28-NOV-2013|^|21613506|^|0|^|A|^|T|^|Peak 2 (% Area) - Average|^|% Main Peak|^|% Main Peak|^|54.7|^|54.7|^|%|^|54.7|^||^|F|^|F|^|>= 50.0%|^|MOHANC03|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974950|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2013-12-04 16:02:32.0|^|TM100001681 V3.0 30 May 2012|^|NB89634 P13|^|CRO-017-02|^|28-NOV-2013|^|21613507|^|0|^|A|^|T|^|Peak 3 (% Area)|^|% Basic Peaks - rep|^|% Basic Peaks - rep|^|24.3|^|24.3|^|%|^|24.3|^||^|T|^|T|^||^|MOHANC03|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974950|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2013-12-04 16:02:32.0|^|TM100001681 V3.0 30 May 2012|^|NB89634 P13|^|CRO-017-02|^|28-NOV-2013|^|21613508|^|0|^|A|^|T|^|Peak 3 (% Area) - Average|^|% Basic Peaks|^|% Basic Peaks|^|24.3|^|24.3|^|%|^|24.3|^||^|F|^|F|^|7.0 - 24.0%|^|MOHANC03|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974951|^|A|^|ADDITIONAL|^|MAB_OXIDATION|^|Lys-C Digest|^|TM100001849|^|1|^|9|^|2013-12-06 13:59:42.0|^|TM100001849 V3.0 28 Nov 2012|^|NB78125 P47|^|CRO-017-02|^|04-DEC-2013|^|21613513|^|0|^|A|^|T|^|Peak 1 (Relative Area %)|^|Oxidation at Fc-Met-1|^|Oxidation at Fc-Met-1|^|0.6|^|0.6|^|%|^|0.6|^||^|T|^|T|^||^|MOHANC03|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974953|^|A|^|REGISTERED|^|PARTICULATE_BIO|^|Appearance (Visible Particulates)|^|TM100002052|^|1|^|4|^|2013-11-12 17:21:29.0|^|TM100002052 V4.0 19 Sep 2013|^|NB84736 P14|^|CRO-017-02|^|13-NOV-2013|^|21613524|^|0|^|A|^|T|^|Particles|^|Visible particulates|^|Visible particulates|^|FREE|^|Essentially Free of Visible Particles|^||^||^||^|T|^|T|^|Essentially Free of Visible Particles|^|MOHANC03|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974953|^|A|^|REGISTERED|^|PARTICULATE_BIO|^|Appearance (Visible Particulates)|^|TM100002052|^|1|^|4|^|2013-11-12 17:21:29.0|^|TM100002052 V4.0 19 Sep 2013|^|NB84736 P14|^|CRO-017-02|^|13-NOV-2013|^|21829428|^|0|^|A|^|T|^|Visible Particulates|^|Visible Particulates|^|Visible Particulates|^|FREE|^|Essentially free from visible particulates|^||^||^||^|T|^|T|^||^|MOHANC03|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974954|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-12-02 15:07:58.0|^|TM100002055 Version 1.0 06 May 2011|^|87268 P18|^|CRO-017-02|^|20-NOV-2013|^|22013490|^|1|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|8392|^|8392|^|Particles/container|^|8392|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974954|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-12-02 15:07:58.0|^|TM100002055 Version 1.0 06 May 2011|^|87268 P18|^|CRO-017-02|^|20-NOV-2013|^|22013491|^|2|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|8604|^|8604|^|Particles/container|^|8604|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974954|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-12-02 15:07:58.0|^|TM100002055 Version 1.0 06 May 2011|^|87268 P18|^|CRO-017-02|^|20-NOV-2013|^|22013492|^|3|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|8644|^|8644|^|Particles/container|^|8644|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974954|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-12-02 15:07:58.0|^|TM100002055 Version 1.0 06 May 2011|^|87268 P18|^|CRO-017-02|^|20-NOV-2013|^|21613529|^|0|^|A|^|T|^|Light Obscuration: >= 2µm|^|Light Obscuration: >= 2µm|^|Light Obscuration: >= 2µm|^|8546.6666667|^|8547|^|Particles/container|^|8547|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974954|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-12-02 15:07:58.0|^|TM100002055 Version 1.0 06 May 2011|^|87268 P18|^|CRO-017-02|^|20-NOV-2013|^|22013493|^|1|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|1592|^|1592|^|Particles/container|^|1592|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974954|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-12-02 15:07:58.0|^|TM100002055 Version 1.0 06 May 2011|^|87268 P18|^|CRO-017-02|^|20-NOV-2013|^|22013494|^|2|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|1776|^|1776|^|Particles/container|^|1776|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974954|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-12-02 15:07:58.0|^|TM100002055 Version 1.0 06 May 2011|^|87268 P18|^|CRO-017-02|^|20-NOV-2013|^|22013495|^|3|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|1728|^|1728|^|Particles/container|^|1728|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974954|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-12-02 15:07:58.0|^|TM100002055 Version 1.0 06 May 2011|^|87268 P18|^|CRO-017-02|^|20-NOV-2013|^|21613530|^|0|^|A|^|T|^|Light Obscuration: >= 5µm|^|Light Obscuration: >= 5µm|^|Light Obscuration: >= 5µm|^|1698.6666667|^|1699|^|Particles/container|^|1699|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974954|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-12-02 15:07:58.0|^|TM100002055 Version 1.0 06 May 2011|^|87268 P18|^|CRO-017-02|^|20-NOV-2013|^|22013496|^|1|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|220|^|220|^|Particles/container|^|220|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974954|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-12-02 15:07:58.0|^|TM100002055 Version 1.0 06 May 2011|^|87268 P18|^|CRO-017-02|^|20-NOV-2013|^|22013497|^|2|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|228|^|228|^|Particles/container|^|228|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974954|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-12-02 15:07:58.0|^|TM100002055 Version 1.0 06 May 2011|^|87268 P18|^|CRO-017-02|^|20-NOV-2013|^|22013498|^|3|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|260|^|260|^|Particles/container|^|260|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974954|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-12-02 15:07:58.0|^|TM100002055 Version 1.0 06 May 2011|^|87268 P18|^|CRO-017-02|^|20-NOV-2013|^|21613531|^|0|^|A|^|T|^|Light Obscuration: >= 8µm|^|Light Obscuration: >= 8µm|^|Light Obscuration: >= 8µm|^|236|^|236|^|Particles/container|^|236|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974954|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-12-02 15:07:58.0|^|TM100002055 Version 1.0 06 May 2011|^|87268 P18|^|CRO-017-02|^|20-NOV-2013|^|22013499|^|1|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|96|^|96|^|Particles/container|^|96|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974954|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-12-02 15:07:58.0|^|TM100002055 Version 1.0 06 May 2011|^|87268 P18|^|CRO-017-02|^|20-NOV-2013|^|22013500|^|2|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|76|^|76|^|Particles/container|^|76|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974954|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-12-02 15:07:58.0|^|TM100002055 Version 1.0 06 May 2011|^|87268 P18|^|CRO-017-02|^|20-NOV-2013|^|22013501|^|3|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|100|^|100|^|Particles/container|^|100|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974954|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-12-02 15:07:58.0|^|TM100002055 Version 1.0 06 May 2011|^|87268 P18|^|CRO-017-02|^|20-NOV-2013|^|21613532|^|0|^|A|^|T|^|Light Obscuration: >= 10µm|^|Light Obscuration: >= 10µm|^|Light Obscuration: >= 10µm|^|90.666666667|^|91|^|Particles/container|^|91|^||^|T|^|T|^|Report Results|^|BARREN06|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974954|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-12-02 15:07:58.0|^|TM100002055 Version 1.0 06 May 2011|^|87268 P18|^|CRO-017-02|^|20-NOV-2013|^|22013502|^|1|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|8|^|8|^|Particles/container|^|8|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974954|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-12-02 15:07:58.0|^|TM100002055 Version 1.0 06 May 2011|^|87268 P18|^|CRO-017-02|^|20-NOV-2013|^|22013503|^|2|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|0|^|0|^|Particles/container|^|0|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974954|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-12-02 15:07:58.0|^|TM100002055 Version 1.0 06 May 2011|^|87268 P18|^|CRO-017-02|^|20-NOV-2013|^|22013504|^|3|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|0|^|0|^|Particles/container|^|0|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974954|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-12-02 15:07:58.0|^|TM100002055 Version 1.0 06 May 2011|^|87268 P18|^|CRO-017-02|^|20-NOV-2013|^|21613533|^|0|^|A|^|T|^|Light Obscuration: >= 25µm|^|Light Obscuration: >= 25µm|^|Light Obscuration: >= 25µm|^|2.6666666667|^|3|^|Particles/container|^|3|^||^|T|^|T|^|Report Results|^|BARREN06|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974954|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2013-12-02 15:07:58.0|^|TM100002055 Version 1.0 06 May 2011|^|87268 P18|^|CRO-017-02|^|20-NOV-2013|^|21613534|^|0|^|A|^|T|^|Particulate Matter|^|Particulate Matter|^|Particulate Matter|^|Meets compendial requirements|^|Meets compendial requirements|^||^||^||^|T|^|T|^|Meets compendial requirements|^|BARREN06|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974955|^|A|^|REGISTERED|^|PH|^|pH|^|M00125|^|1|^|4|^|2013-11-14 12:32:35.0|^|M00125 Version 2.0 Effective Date 07May2012 |^|NB83839 P.10|^|CRO-017-02|^|13-NOV-2013|^|21613539|^|0|^|A|^|T|^|pH|^|pH - rep|^|pH - rep|^|6.0|^|6.0|^||^|6|^||^|T|^|T|^||^|TSENKB|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974955|^|A|^|REGISTERED|^|PH|^|pH|^|M00125|^|1|^|4|^|2013-11-14 12:32:35.0|^|M00125 Version 2.0 Effective Date 07May2012 |^|NB83839 P.10|^|CRO-017-02|^|13-NOV-2013|^|21613540|^|0|^|A|^|T|^|pH - Average|^|pH|^|pH|^|6.0|^|6.0|^||^|6|^||^|T|^|T|^|6.0 +/- 0.5|^|TSENKB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974956|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2013-11-12 17:14:57.0|^|TM100001683 V6.0 07 Aug 2012|^|NB89575 P4|^|CRO-017-02|^|11-NOV-2013|^|21613545|^|0|^|A|^|T|^|Minutes|^|Minutes|^|Minutes|^|2|^|2|^|min|^|2|^||^|T|^|T|^||^|MOHANC03|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974956|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2013-11-12 17:14:57.0|^|TM100001683 V6.0 07 Aug 2012|^|NB89575 P4|^|CRO-017-02|^|11-NOV-2013|^|21613546|^|0|^|A|^|T|^|Seconds|^|Seconds|^|Seconds|^|56|^|56|^|s|^|56|^||^|T|^|T|^||^|MOHANC03|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974956|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2013-11-12 17:14:57.0|^|TM100001683 V6.0 07 Aug 2012|^|NB89575 P4|^|CRO-017-02|^|11-NOV-2013|^|21613547|^|0|^|A|^|T|^|Rounding Interval|^|Rounding Interval|^|Rounding Interval|^|NA|^|Not available|^||^||^||^|T|^|T|^||^|MOHANC03|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974956|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2013-11-12 17:14:57.0|^|TM100001683 V6.0 07 Aug 2012|^|NB89575 P4|^|CRO-017-02|^|11-NOV-2013|^|21613548|^|0|^|A|^|T|^|Total Time|^|Total Time|^|Total Time|^|176|^|176|^|s|^|176|^||^|T|^|T|^||^|MOHANC03|^|F|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974956|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2013-11-12 17:14:57.0|^|TM100001683 V6.0 07 Aug 2012|^|NB89575 P4|^|CRO-017-02|^|11-NOV-2013|^|21613549|^|0|^|A|^|T|^|Reconstitution Time|^|Reconstitution Time|^|Reconstitution Time|^|2 min 56 sec|^|2 min 56 sec|^||^||^||^|T|^|T|^|Report Results|^|MOHANC03|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974957|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777|^|1|^|10|^|2013-11-20 09:25:13.0|^|TM100001777 V3.0 30 May 2012|^|NB83213 P43|^|CRO-017-02|^|14-NOV-2013|^|21613554|^|0|^|A|^|T|^|Peak 1 (% Area)|^|Monomer|^|Monomer|^|98.1|^|98.1|^|%|^|98.1|^||^|T|^|T|^|>= 95.0%|^|MOHANC03|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974957|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777|^|1|^|10|^|2013-11-20 09:25:13.0|^|TM100001777 V3.0 30 May 2012|^|NB83213 P43|^|CRO-017-02|^|14-NOV-2013|^|21613555|^|0|^|A|^|T|^|Peak 2 (% Area)|^|HMMS|^|HMMS|^|1.7|^|1.7|^|%|^|1.7|^||^|T|^|T|^|<= 5.0%|^|MOHANC03|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974957|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777|^|1|^|10|^|2013-11-20 09:25:13.0|^|TM100001777 V3.0 30 May 2012|^|NB83213 P43|^|CRO-017-02|^|14-NOV-2013|^|21613556|^|0|^|A|^|T|^|Peak 3 (% Area)|^|LMMS|^|LMMS|^|0.2|^|0.2|^|%|^|0.2|^||^|T|^|T|^||^|MOHANC03|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974959|^|A|^|REGISTERED|^|TURBIDITY|^|Appearance (Clarity)|^|TM100002052|^|1|^|2|^|2013-11-18 15:49:12.0|^|TM100002052 V4.0 19 Sep 2013|^|NB84736 P14|^|CRO-017-02|^|13-NOV-2013|^|21613568|^|0|^|A|^|T|^|Turbidity - Rep|^|Turbidity - Rep|^|Turbidity - Rep|^|4|^|4|^|NTU|^|4|^||^|T|^|T|^||^|MOHANC03|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2013-12-06 13:59:42.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2015-09-24 18:15:11.0|^|974959|^|A|^|REGISTERED|^|TURBIDITY|^|Appearance (Clarity)|^|TM100002052|^|1|^|2|^|2013-11-18 15:49:12.0|^|TM100002052 V4.0 19 Sep 2013|^|NB84736 P14|^|CRO-017-02|^|13-NOV-2013|^|21613569|^|0|^|A|^|T|^|Turbidity|^|Turbidity|^|Turbidity|^|4|^|4|^|NTU|^|4|^||^|T|^|T|^|<= 18 NTU|^|MOHANC03|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266976|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2014-01-02 19:12:23.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2014-01-28 17:32:28.0|^|974958|^|A|^|REGISTERED|^|SPECIFIC_ACTIVITY|^|Potency Assay (Cell Based)|^|TM100001721|^|1|^|10|^|2014-01-02 19:12:23.0|^|TM100001721ver6.0/09JuL2013|^|NB90293 p1|^|CRO-017-01|^|13-DEC-2013|^|21613561|^|0|^|A|^|T|^|Relative Potency|^|Relative Potency|^|Relative Potency|^|93|^|93|^|%|^|93|^||^|T|^|T|^|55 - 158% potency relative to reference material|^|ZANY|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_18|^|18 Months|^|18|^||^|2012-05-04 00:00:00.0|^|2013-11-04 00:00:00.0|^||^|266974|^|A|^|266976|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_18|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2013-10-28 00:07:26.0|^|2013-12-05 16:41:42.0|^|2013-12-05 16:41:42.0|^|2014-01-02 19:12:23.0|^|2014-01-28 17:32:23.0|^|F|^|F|^|2014-01-28 17:32:28.0|^|974958|^|A|^|REGISTERED|^|SPECIFIC_ACTIVITY|^|Potency Assay (Cell Based)|^|TM100001721|^|1|^|10|^|2014-01-02 19:12:23.0|^|TM100001721ver6.0/09JuL2013|^|NB90293 p1|^|CRO-017-01|^|13-DEC-2013|^|21613562|^|0|^|A|^|T|^|Specific Activity|^|Specific Activity|^|Specific Activity|^|930|^|930|^|U/mg|^|930|^||^|T|^|T|^|550 - 1580 U/mg|^|ZANY|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067768|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052|^|1|^|2|^|2014-05-06 16:32:36.0|^|TM100002052 Version 5.0 / 20Mar2014|^|74374 P41-46|^|CRO-017-02|^|06-MAY-2014|^|23473748|^|0|^|A|^|T|^|Appearance|^|Visual appearance|^|Visual appearance|^|White cake essentially free from visible particulates|^|White cake essentially free from visible particulates|^||^||^||^|T|^|T|^|White cake essentially free from visible particulates|^|HAROOR|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067769|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reduced)|^|TM100001851|^|1|^|11|^|2014-06-12 12:46:32.0|^|TM100001851 Version 4.0/19 Aug 2013|^|83212 P31|^|CRO-017-02|^|11-JUN-2014|^|23921719|^|0|^|A|^|T|^|LOQ (% Area)|^|LOQ (% Area)|^|LOQ (% Area)|^|0.3|^|0.3|^||^|0.3|^||^|T|^|T|^||^|ROCHEP02|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067769|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reduced)|^|TM100001851|^|1|^|11|^|2014-06-12 12:46:32.0|^|TM100001851 Version 4.0/19 Aug 2013|^|83212 P31|^|CRO-017-02|^|11-JUN-2014|^|23473754|^|0|^|A|^|T|^|Sum HC and LC|^|Heavy Chain + Light Chain|^|Heavy Chain + Light Chain|^|99.7|^|99.7|^|%|^|99.7|^||^|T|^|T|^|>= 95.0% IgG as heavy + light chain|^|ROCHEP02|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067769|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reduced)|^|TM100001851|^|1|^|11|^|2014-06-12 12:46:32.0|^|TM100001851 Version 4.0/19 Aug 2013|^|83212 P31|^|CRO-017-02|^|11-JUN-2014|^|23473755|^|0|^|A|^|T|^|Percent Fragment|^|Fragments|^|Fragments|^|0.0|^|NMT 0.3|^|%|^||^||^|T|^|T|^|Report Results|^|ROCHEP02|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067769|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reduced)|^|TM100001851|^|1|^|11|^|2014-06-12 12:46:32.0|^|TM100001851 Version 4.0/19 Aug 2013|^|83212 P31|^|CRO-017-02|^|11-JUN-2014|^|23921720|^|0|^|A|^|T|^|Percent Other|^|Percent Other|^|Other|^|0.0|^|NMT 0.3|^|%|^||^||^|T|^|T|^||^|ROCHEP02|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067770|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|9|^|2014-05-13 08:27:54.0|^|TM100002052 Version 5.0/ 20Mar2014|^|94868 p7|^|CRO-017-02|^|12-MAY-2014|^|23473760|^|0|^|A|^|T|^|Color Hue|^|Color Hue|^|Color Hue|^|B|^|B|^||^||^||^|T|^|T|^||^|HAROOR|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067770|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|9|^|2014-05-13 08:27:54.0|^|TM100002052 Version 5.0/ 20Mar2014|^|94868 p7|^|CRO-017-02|^|12-MAY-2014|^|23473761|^|0|^|A|^|T|^|Color Intensity|^|Color Intensity|^|Color Intensity|^|9|^|9|^||^|9|^||^|T|^|T|^||^|HAROOR|^|F|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067770|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|9|^|2014-05-13 08:27:54.0|^|TM100002052 Version 5.0/ 20Mar2014|^|94868 p7|^|CRO-017-02|^|12-MAY-2014|^|23625474|^|0|^|A|^|T|^|Color Result|^|Color Result|^|Color Result|^|Not more intensely colored than level 9 of the color standard|^|Not more intensely colored than level 9 of the color standard|^||^||^||^|T|^|T|^||^|HAROOR|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067770|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|9|^|2014-05-13 08:27:54.0|^|TM100002052 Version 5.0/ 20Mar2014|^|94868 p7|^|CRO-017-02|^|12-MAY-2014|^|23625475|^|0|^|A|^|T|^|Color Description|^|Color Description|^|Color Description|^|Colorless|^|Colorless|^||^||^||^|T|^|T|^||^|HAROOR|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067770|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052|^|1|^|9|^|2014-05-13 08:27:54.0|^|TM100002052 Version 5.0/ 20Mar2014|^|94868 p7|^|CRO-017-02|^|12-MAY-2014|^|23473762|^|0|^|A|^|T|^|Color|^|Coloration|^|Coloration|^|<=B9|^|<=B9|^||^||^||^|T|^|T|^|Not more intensely colored than level 5 of the color standard|^|HAROOR|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067771|^|A|^|REGISTERED|^|CONCENTRATION_UV|^|Protein Concentration (UV)|^|TM100001683, TMC0085|^|1|^|9|^|2014-05-08 09:58:38.0|^|TM100001683 Version:6.0/ 07Aug2012|^|89570 p11|^|CRO-017-02|^|07-MAY-2014|^|23473767|^|0|^|A|^|T|^|Protein Concentration|^|Protein Concentration - rep|^|Protein Concentration - rep|^|21.1|^|21.1|^|mg/mL|^|21.1|^||^|T|^|T|^||^|HAROOR|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067771|^|A|^|REGISTERED|^|CONCENTRATION_UV|^|Protein Concentration (UV)|^|TM100001683, TMC0085|^|1|^|9|^|2014-05-08 09:58:38.0|^|TM100001683 Version:6.0/ 07Aug2012|^|89570 p11|^|CRO-017-02|^|07-MAY-2014|^|23473768|^|0|^|A|^|T|^|Protein Concentration - Average|^|Protein Concentration|^|Protein Concentration|^|21.1|^|21.1|^|mg/mL|^|21.1|^||^|T|^|T|^|Report Results|^|HAROOR|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067772|^|A|^|REGISTERED|^|DYE_INGRESS|^|Container Closure|^|TM100001254|^|1|^|1|^|2014-05-27 08:38:05.0|^|M8721.03 22APR2013|^|NB92114p8|^|CRO-017-02|^|26-MAY-2014|^|23473773|^|0|^|A|^|T|^|Dye Ingress|^|Dye Ingress|^|Dye Ingress|^|PASS|^|Pass|^||^||^||^|T|^|T|^|Pass|^|TIERCC|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067758|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2014-06-19 09:19:00.0|^|TM100001681 Version 3.0 30 May 2012|^|NB 89636 P1|^|CRO-017-02|^|17-JUN-2014|^|23473677|^|0|^|A|^|T|^|Peak 1 (% Area)|^|% Acidic Peaks - rep|^|% Acidic Peaks - rep|^|21.3|^|21.3|^|%|^|21.3|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067758|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2014-06-19 09:19:00.0|^|TM100001681 Version 3.0 30 May 2012|^|NB 89636 P1|^|CRO-017-02|^|17-JUN-2014|^|23473678|^|0|^|A|^|T|^|Peak 1 (% Area) - Average|^|% Acidic Peaks|^|% Acidic Peaks|^|21.3|^|21.3|^|%|^|21.3|^||^|T|^|T|^|17.0 - 33.0%|^|BARREN06|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067758|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2014-06-19 09:19:00.0|^|TM100001681 Version 3.0 30 May 2012|^|NB 89636 P1|^|CRO-017-02|^|17-JUN-2014|^|23473679|^|0|^|A|^|T|^|Peak 2 (% Area)|^|% Main Peak - rep|^|% Main Peak - rep|^|54.4|^|54.4|^|%|^|54.4|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067758|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2014-06-19 09:19:00.0|^|TM100001681 Version 3.0 30 May 2012|^|NB 89636 P1|^|CRO-017-02|^|17-JUN-2014|^|23473680|^|0|^|A|^|T|^|Peak 2 (% Area) - Average|^|% Main Peak|^|% Main Peak|^|54.4|^|54.4|^|%|^|54.4|^||^|F|^|F|^|>= 50.0%|^|BARREN06|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067758|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2014-06-19 09:19:00.0|^|TM100001681 Version 3.0 30 May 2012|^|NB 89636 P1|^|CRO-017-02|^|17-JUN-2014|^|23473681|^|0|^|A|^|T|^|Peak 3 (% Area)|^|% Basic Peaks - rep|^|% Basic Peaks - rep|^|24.3|^|24.3|^|%|^|24.3|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067758|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681|^|1|^|2|^|2014-06-19 09:19:00.0|^|TM100001681 Version 3.0 30 May 2012|^|NB 89636 P1|^|CRO-017-02|^|17-JUN-2014|^|23473682|^|0|^|A|^|T|^|Peak 3 (% Area) - Average|^|% Basic Peaks|^|% Basic Peaks|^|24.3|^|24.3|^|%|^|24.3|^||^|F|^|F|^|7.0 - 24.0%|^|BARREN06|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067759|^|A|^|ADDITIONAL|^|MAB_OXIDATION|^|Lys-C Digest|^|TM100001849|^|1|^|9|^|2014-06-10 12:52:51.0|^|TM100001849 Version 3.0 28 Nov 2012|^|NB 89571 P32|^|CRO-017-02|^|09-JUN-2014|^|23473687|^|0|^|A|^|T|^|Peak 1 (Relative Area %)|^|Oxidation at Fc-Met-1|^|Oxidation at Fc-Met-1|^|1.5|^|1.5|^|%|^|1.5|^||^|T|^|T|^||^|BARREN06|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067761|^|A|^|REGISTERED|^|PARTICULATE_BIO|^|Appearance (Visible Particulates)|^|TM100002052|^|1|^|4|^|2014-05-13 08:30:44.0|^|TM100002052 Version 5.0/ 20Mar2014|^|94868 p7|^|CRO-017-02|^|12-MAY-2014|^|23473698|^|0|^|A|^|T|^|Particles|^|Visible particulates|^|Visible particulates|^|FREE|^|Essentially Free of Visible Particles|^||^||^||^|T|^|T|^|Essentially Free of Visible Particles|^|HAROOR|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067762|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2014-06-09 07:53:14.0|^|TM100002055 Version 1.0 06 May 2011|^|NB 92231 P8|^|CRO-017-02|^|04-JUN-2014|^|23868670|^|1|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|4984|^|4984|^|Particles/container|^|4984|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067762|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2014-06-09 07:53:14.0|^|TM100002055 Version 1.0 06 May 2011|^|NB 92231 P8|^|CRO-017-02|^|04-JUN-2014|^|23868671|^|2|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|5260|^|5260|^|Particles/container|^|5260|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067762|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2014-06-09 07:53:14.0|^|TM100002055 Version 1.0 06 May 2011|^|NB 92231 P8|^|CRO-017-02|^|04-JUN-2014|^|23868672|^|3|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|4768|^|4768|^|Particles/container|^|4768|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067762|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2014-06-09 07:53:14.0|^|TM100002055 Version 1.0 06 May 2011|^|NB 92231 P8|^|CRO-017-02|^|04-JUN-2014|^|23473703|^|0|^|A|^|T|^|Light Obscuration: >= 2µm|^|Light Obscuration: >= 2µm|^|Light Obscuration: >= 2µm|^|5004|^|5004|^|Particles/container|^|5004|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067762|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2014-06-09 07:53:14.0|^|TM100002055 Version 1.0 06 May 2011|^|NB 92231 P8|^|CRO-017-02|^|04-JUN-2014|^|23868673|^|1|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|1028|^|1028|^|Particles/container|^|1028|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067762|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2014-06-09 07:53:14.0|^|TM100002055 Version 1.0 06 May 2011|^|NB 92231 P8|^|CRO-017-02|^|04-JUN-2014|^|23868674|^|2|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|912|^|912|^|Particles/container|^|912|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067762|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2014-06-09 07:53:14.0|^|TM100002055 Version 1.0 06 May 2011|^|NB 92231 P8|^|CRO-017-02|^|04-JUN-2014|^|23868675|^|3|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|768|^|768|^|Particles/container|^|768|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067762|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2014-06-09 07:53:14.0|^|TM100002055 Version 1.0 06 May 2011|^|NB 92231 P8|^|CRO-017-02|^|04-JUN-2014|^|23473704|^|0|^|A|^|T|^|Light Obscuration: >= 5µm|^|Light Obscuration: >= 5µm|^|Light Obscuration: >= 5µm|^|902.66666667|^|903|^|Particles/container|^|903|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067762|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2014-06-09 07:53:14.0|^|TM100002055 Version 1.0 06 May 2011|^|NB 92231 P8|^|CRO-017-02|^|04-JUN-2014|^|23868676|^|1|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|176|^|176|^|Particles/container|^|176|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067762|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2014-06-09 07:53:14.0|^|TM100002055 Version 1.0 06 May 2011|^|NB 92231 P8|^|CRO-017-02|^|04-JUN-2014|^|23868677|^|2|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|156|^|156|^|Particles/container|^|156|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067762|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2014-06-09 07:53:14.0|^|TM100002055 Version 1.0 06 May 2011|^|NB 92231 P8|^|CRO-017-02|^|04-JUN-2014|^|23868678|^|3|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|140|^|140|^|Particles/container|^|140|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067762|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2014-06-09 07:53:14.0|^|TM100002055 Version 1.0 06 May 2011|^|NB 92231 P8|^|CRO-017-02|^|04-JUN-2014|^|23473705|^|0|^|A|^|T|^|Light Obscuration: >= 8µm|^|Light Obscuration: >= 8µm|^|Light Obscuration: >= 8µm|^|157.33333333|^|157|^|Particles/container|^|157|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067762|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2014-06-09 07:53:14.0|^|TM100002055 Version 1.0 06 May 2011|^|NB 92231 P8|^|CRO-017-02|^|04-JUN-2014|^|23868679|^|1|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|72|^|72|^|Particles/container|^|72|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067762|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2014-06-09 07:53:14.0|^|TM100002055 Version 1.0 06 May 2011|^|NB 92231 P8|^|CRO-017-02|^|04-JUN-2014|^|23868680|^|2|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|72|^|72|^|Particles/container|^|72|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067762|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2014-06-09 07:53:14.0|^|TM100002055 Version 1.0 06 May 2011|^|NB 92231 P8|^|CRO-017-02|^|04-JUN-2014|^|23868681|^|3|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|80|^|80|^|Particles/container|^|80|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067762|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2014-06-09 07:53:14.0|^|TM100002055 Version 1.0 06 May 2011|^|NB 92231 P8|^|CRO-017-02|^|04-JUN-2014|^|23473706|^|0|^|A|^|T|^|Light Obscuration: >= 10µm|^|Light Obscuration: >= 10µm|^|Light Obscuration: >= 10µm|^|74.666666667|^|75|^|Particles/container|^|75|^||^|T|^|T|^|Report Results|^|BARREN06|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067762|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2014-06-09 07:53:14.0|^|TM100002055 Version 1.0 06 May 2011|^|NB 92231 P8|^|CRO-017-02|^|04-JUN-2014|^|23868682|^|1|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|12|^|12|^|Particles/container|^|12|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067762|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2014-06-09 07:53:14.0|^|TM100002055 Version 1.0 06 May 2011|^|NB 92231 P8|^|CRO-017-02|^|04-JUN-2014|^|23868683|^|2|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|20|^|20|^|Particles/container|^|20|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067762|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2014-06-09 07:53:14.0|^|TM100002055 Version 1.0 06 May 2011|^|NB 92231 P8|^|CRO-017-02|^|04-JUN-2014|^|23868684|^|3|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|20|^|20|^|Particles/container|^|20|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067762|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2014-06-09 07:53:14.0|^|TM100002055 Version 1.0 06 May 2011|^|NB 92231 P8|^|CRO-017-02|^|04-JUN-2014|^|23473707|^|0|^|A|^|T|^|Light Obscuration: >= 25µm|^|Light Obscuration: >= 25µm|^|Light Obscuration: >= 25µm|^|17.333333333|^|17|^|Particles/container|^|17|^||^|T|^|T|^|Report Results|^|BARREN06|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067762|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055|^|1|^|7|^|2014-06-09 07:53:14.0|^|TM100002055 Version 1.0 06 May 2011|^|NB 92231 P8|^|CRO-017-02|^|04-JUN-2014|^|23473708|^|0|^|A|^|T|^|Particulate Matter|^|Particulate Matter|^|Particulate Matter|^|Meets compendial requirements|^|Meets compendial requirements|^||^||^||^|T|^|T|^|Meets compendial requirements|^|BARREN06|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067763|^|A|^|REGISTERED|^|PH|^|pH|^|M00125|^|1|^|4|^|2014-05-28 10:13:31.0|^|M00125 Version 2.0|^|83839 p15|^|CRO-017-02|^|27-MAY-2014|^|23473713|^|0|^|A|^|T|^|pH|^|pH - rep|^|pH - rep|^|5.9|^|5.9|^||^|5.9|^||^|T|^|T|^||^|TELFOJ01|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067763|^|A|^|REGISTERED|^|PH|^|pH|^|M00125|^|1|^|4|^|2014-05-28 10:13:31.0|^|M00125 Version 2.0|^|83839 p15|^|CRO-017-02|^|27-MAY-2014|^|23473714|^|0|^|A|^|T|^|pH - Average|^|pH|^|pH|^|5.9|^|5.9|^||^|5.9|^||^|T|^|T|^|6.0 +/- 0.5|^|TELFOJ01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067764|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2014-05-06 16:36:48.0|^|TM100001683 Version:6.0/ 07Aug2012|^|74374 p44|^|CRO-017-02|^|06-MAY-2014|^|23473719|^|0|^|A|^|T|^|Minutes|^|Minutes|^|Minutes|^|9|^|9|^|min|^|9|^||^|T|^|T|^||^|HAROOR|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067764|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2014-05-06 16:36:48.0|^|TM100001683 Version:6.0/ 07Aug2012|^|74374 p44|^|CRO-017-02|^|06-MAY-2014|^|23473720|^|0|^|A|^|T|^|Seconds|^|Seconds|^|Seconds|^|23|^|23|^|s|^|23|^||^|T|^|T|^||^|HAROOR|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067764|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2014-05-06 16:36:48.0|^|TM100001683 Version:6.0/ 07Aug2012|^|74374 p44|^|CRO-017-02|^|06-MAY-2014|^|23473721|^|0|^|A|^|T|^|Rounding Interval|^|Rounding Interval|^|Rounding Interval|^|30|^|30|^||^|30|^||^|T|^|T|^||^|HAROOR|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067764|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2014-05-06 16:36:48.0|^|TM100001683 Version:6.0/ 07Aug2012|^|74374 p44|^|CRO-017-02|^|06-MAY-2014|^|23473722|^|0|^|A|^|T|^|Total Time|^|Total Time|^|Total Time|^|570|^|570|^|s|^|570|^||^|T|^|T|^||^|HAROOR|^|F|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067764|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052|^|1|^|5|^|2014-05-06 16:36:48.0|^|TM100001683 Version:6.0/ 07Aug2012|^|74374 p44|^|CRO-017-02|^|06-MAY-2014|^|23473723|^|0|^|A|^|T|^|Reconstitution Time|^|Reconstitution Time|^|Reconstitution Time|^|9 min 30 sec|^|9 min 30 sec|^||^||^||^|T|^|T|^|Report Results|^|HAROOR|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067765|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777|^|1|^|12|^|2014-05-08 09:39:36.0|^|TM100001777V3.0 30 May 2012|^|NB 92230 P8|^|CRO-017-02|^|07-MAY-2014|^|23588484|^|0|^|A|^|T|^|Peak 1 (% Area) - rep|^|Peak 1 (% Area) - rep|^|Peak 1 (% Area) - rep|^|97.71|^|97.7|^|%|^|97.7|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067765|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777|^|1|^|12|^|2014-05-08 09:39:36.0|^|TM100001777V3.0 30 May 2012|^|NB 92230 P8|^|CRO-017-02|^|07-MAY-2014|^|23473728|^|0|^|A|^|T|^|Peak 1 (% Area)|^|Monomer|^|Monomer|^|97.71|^|97.7|^|%|^|97.7|^||^|T|^|T|^|>= 95.0%|^|BARREN06|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067765|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777|^|1|^|12|^|2014-05-08 09:39:36.0|^|TM100001777V3.0 30 May 2012|^|NB 92230 P8|^|CRO-017-02|^|07-MAY-2014|^|23588485|^|0|^|A|^|T|^|Peak 2 (% Area) - rep|^|Peak 2 (% Area) - rep|^|Peak 2 (% Area) - rep|^|2.07|^|2.1|^|%|^|2.1|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067765|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777|^|1|^|12|^|2014-05-08 09:39:36.0|^|TM100001777V3.0 30 May 2012|^|NB 92230 P8|^|CRO-017-02|^|07-MAY-2014|^|23473729|^|0|^|A|^|T|^|Peak 2 (% Area)|^|HMMS|^|HMMS|^|2.07|^|2.1|^|%|^|2.1|^||^|T|^|T|^|<= 5.0%|^|BARREN06|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067765|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777|^|1|^|12|^|2014-05-08 09:39:36.0|^|TM100001777V3.0 30 May 2012|^|NB 92230 P8|^|CRO-017-02|^|07-MAY-2014|^|23588486|^|0|^|A|^|T|^|Peak 3 (% Area) - rep|^|Peak 3 (% Area) - rep|^|Peak 3 (% Area) - rep|^|0.22|^|0.2|^|%|^|0.2|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067765|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777|^|1|^|12|^|2014-05-08 09:39:36.0|^|TM100001777V3.0 30 May 2012|^|NB 92230 P8|^|CRO-017-02|^|07-MAY-2014|^|23473730|^|0|^|A|^|T|^|Peak 3 (% Area)|^|LMMS|^|LMMS|^|0.22|^|0.2|^|%|^|0.2|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067767|^|A|^|REGISTERED|^|TURBIDITY|^|Appearance (Clarity)|^|TM100002052|^|1|^|2|^|2014-05-13 08:32:48.0|^|TM100002052 Version 5.0/ 20Mar2014|^|94868 p7|^|CRO-017-02|^|12-MAY-2014|^|23473742|^|0|^|A|^|T|^|Turbidity - Rep|^|Turbidity - Rep|^|Turbidity - Rep|^|3|^|3|^|NTU|^|3|^||^|T|^|T|^||^|HAROOR|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299192|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-06-19 09:19:00.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067767|^|A|^|REGISTERED|^|TURBIDITY|^|Appearance (Clarity)|^|TM100002052|^|1|^|2|^|2014-05-13 08:32:48.0|^|TM100002052 Version 5.0/ 20Mar2014|^|94868 p7|^|CRO-017-02|^|12-MAY-2014|^|23473743|^|0|^|A|^|T|^|Turbidity|^|Turbidity|^|Turbidity|^|3|^|3|^|NTU|^|3|^||^|T|^|T|^|<= 18 NTU|^|HAROOR|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299193|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-05-28 22:06:51.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067760|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2014-05-28 19:10:59.0|^|TM000001405 v3.0|^|00708343-0044|^|Pfizer, QC, St. Louis, MO, US|^|28-MAY-2014|^|23748725|^|0|^|A|^|T|^|LOQ|^|LOQ|^|LOQ|^|0.2|^|0.2|^||^|0.2|^||^|T|^|T|^||^|HOMANB|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299193|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-05-28 22:06:51.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067760|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2014-05-28 19:10:59.0|^|TM000001405 v3.0|^|00708343-0044|^|Pfizer, QC, St. Louis, MO, US|^|28-MAY-2014|^|23748726|^|0|^|A|^|T|^|Diluent Weight|^|Diluent Weight|^|Diluent Weight|^|13.2301|^|13.2301|^|g|^|13.2301|^||^|T|^|T|^||^|HOMANB|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299193|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-05-28 22:06:51.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067760|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2014-05-28 19:10:59.0|^|TM000001405 v3.0|^|00708343-0044|^|Pfizer, QC, St. Louis, MO, US|^|28-MAY-2014|^|23749557|^|0|^|A|^|T|^|Sample Weight|^|Sample Weight|^|Sample Weight|^|2.2124|^|2.2124|^|g|^|2.2124|^||^|T|^|T|^||^|HOMANB|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299193|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-05-28 22:06:51.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067760|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2014-05-28 19:10:59.0|^|TM000001405 v3.0|^|00708343-0044|^|Pfizer, QC, St. Louis, MO, US|^|28-MAY-2014|^|23749564|^|0|^|A|^|T|^|Cake Weight|^|Cake Weight|^|Cake Weight|^|0.8845|^|0.8845|^|g|^|0.8845|^||^|T|^|T|^||^|HOMANB|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299193|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-05-28 22:06:51.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067760|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2014-05-28 19:10:59.0|^|TM000001405 v3.0|^|00708343-0044|^|Pfizer, QC, St. Louis, MO, US|^|28-MAY-2014|^|23749558|^|0|^|A|^|T|^|Instrument Reading|^|Instrument Reading|^|Instrument Reading|^|985.2|^|985.2|^|µg|^|985.2|^||^|T|^|T|^||^|HOMANB|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299193|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-05-28 22:06:51.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067760|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2014-05-28 19:10:59.0|^|TM000001405 v3.0|^|00708343-0044|^|Pfizer, QC, St. Louis, MO, US|^|28-MAY-2014|^|23749568|^|0|^|A|^|T|^|Average H2O in Blank Injections|^|Average H2O in Blank Injections|^|Average H2O in Blank Injections|^|29.41615498|^|29.41615498|^|ppm|^|29.41615498|^||^|T|^|T|^||^|HOMANB|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299193|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-05-28 22:06:51.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067760|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2014-05-28 19:10:59.0|^|TM000001405 v3.0|^|00708343-0044|^|Pfizer, QC, St. Louis, MO, US|^|28-MAY-2014|^|23473692|^|0|^|A|^|T|^|Moisture - Rep|^|Moisture - Rep|^|Moisture - Rep|^|0.6636688232|^|0.7|^|%|^|0.7|^||^|T|^|T|^||^|HOMANB|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299193|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-05-28 22:06:51.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067760|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405|^|1|^|4|^|2014-05-28 19:10:59.0|^|TM000001405 v3.0|^|00708343-0044|^|Pfizer, QC, St. Louis, MO, US|^|28-MAY-2014|^|23473693|^|0|^|A|^|T|^|Moisture|^|Moisture|^|Moisture|^|0.6636688232|^|0.7|^|%|^|0.7|^||^|T|^|T|^|<= 2%|^|HOMANB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299194|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-05-21 16:34:10.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067766|^|A|^|REGISTERED|^|SPECIFIC_ACTIVITY|^|Potency Assay (Cell Based)|^|TM100001721|^|1|^|11|^|2014-05-21 16:34:10.0|^|TM100001721V7.0/24Apr2014|^|92046p1-12|^|CRO-017-01|^|16-MAY-2014|^|23473735|^|0|^|A|^|T|^|Relative Potency|^|Relative Potency|^|Relative Potency|^|131|^|131|^|%|^|131|^||^|T|^|T|^|55 - 158% potency relative to reference material|^|ALBRIC04|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|6|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_24|^|24 Months|^|24|^||^|2012-05-04 00:00:00.0|^|2014-05-04 00:00:00.0|^||^|299191|^|A|^|299194|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_24|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-04-27 00:02:18.0|^|2014-08-25 20:23:18.0|^|2014-08-25 20:23:18.0|^|2014-05-21 16:34:10.0|^|2014-09-29 19:26:59.0|^|F|^|F|^|2014-09-29 19:27:05.0|^|1067766|^|A|^|REGISTERED|^|SPECIFIC_ACTIVITY|^|Potency Assay (Cell Based)|^|TM100001721|^|1|^|11|^|2014-05-21 16:34:10.0|^|TM100001721V7.0/24Apr2014|^|92046p1-12|^|CRO-017-01|^|16-MAY-2014|^|23473736|^|0|^|A|^|T|^|Specific Activity|^|Specific Activity|^|Specific Activity|^|1306|^|1306|^|U/mg|^|1306|^||^|T|^|T|^|550 - 1580 U/mg|^|ALBRIC04|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169720|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052, SOP-67108|^|1|^|2|^|2014-11-13 17:47:25.0|^|TM100002052 Version 5.0|^|NB98651 p 7|^|CRO-017-02|^|11-NOV-2014|^|25288425|^|0|^|A|^|T|^|Appearance|^|Visual appearance|^|Visual appearance|^|White cake essentially free from visible particulates|^|White cake essentially free from visible particulates|^||^||^||^|T|^|T|^|White cake essentially free from visible particulates|^|OBYRNS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169721|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reducing)|^|TM100001851, SOP-68795|^|1|^|11|^|2014-12-12 13:59:26.0|^|TM100001851 version 4.0 19 Aug 2013|^|79372 P23|^|CRO-017-02|^|30-NOV-2014|^|27296643|^|0|^|A|^|T|^|LOQ (% Area)|^|LOQ (% Area)|^|LOQ (% Area)|^|0.3|^|0.3|^||^|0.3|^||^|T|^|T|^||^|BARREN06|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169721|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reducing)|^|TM100001851, SOP-68795|^|1|^|11|^|2014-12-12 13:59:26.0|^|TM100001851 version 4.0 19 Aug 2013|^|79372 P23|^|CRO-017-02|^|30-NOV-2014|^|25288431|^|0|^|A|^|T|^|Sum HC and LC|^|Heavy Chain + Light Chain|^|Heavy Chain + Light Chain|^|99.2|^|99.2|^|%|^|99.2|^||^|T|^|T|^|>= 95.0% IgG as heavy + light chain|^|BARREN06|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169721|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reducing)|^|TM100001851, SOP-68795|^|1|^|11|^|2014-12-12 13:59:26.0|^|TM100001851 version 4.0 19 Aug 2013|^|79372 P23|^|CRO-017-02|^|30-NOV-2014|^|25288432|^|0|^|A|^|T|^|Percent Fragment|^|Fragments|^|Fragments|^|0.0|^|NMT 0.3|^|%|^||^||^|T|^|T|^|Report Results|^|BARREN06|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169721|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reducing)|^|TM100001851, SOP-68795|^|1|^|11|^|2014-12-12 13:59:26.0|^|TM100001851 version 4.0 19 Aug 2013|^|79372 P23|^|CRO-017-02|^|30-NOV-2014|^|25288433|^|0|^|A|^|T|^|Percent Other|^|Other|^|Other|^|0.8|^|0.8|^|%|^|0.8|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169722|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|10|^|2014-11-17 10:54:53.0|^|TM100002052 Version 5.0|^|NB 99973 p8|^|CRO-017-02|^|14-NOV-2014|^|25288438|^|0|^|A|^|T|^|Color Hue|^|Color Hue|^|Color Hue|^|B|^|B|^||^||^||^|T|^|T|^||^|OBYRNS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169722|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|10|^|2014-11-17 10:54:53.0|^|TM100002052 Version 5.0|^|NB 99973 p8|^|CRO-017-02|^|14-NOV-2014|^|25288439|^|0|^|A|^|T|^|Color Intensity|^|Color Intensity|^|Color Intensity|^|8|^|8|^||^|8|^||^|T|^|T|^||^|OBYRNS|^|F|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169722|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|10|^|2014-11-17 10:54:53.0|^|TM100002052 Version 5.0|^|NB 99973 p8|^|CRO-017-02|^|14-NOV-2014|^|25487170|^|0|^|A|^|T|^|Color Result|^|Color Result|^|Color Result|^|Not more intensely colored than level 8 of the color standard|^|Not more intensely colored than level 8 of the color standard|^||^||^||^|T|^|T|^||^|OBYRNS|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169722|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|10|^|2014-11-17 10:54:53.0|^|TM100002052 Version 5.0|^|NB 99973 p8|^|CRO-017-02|^|14-NOV-2014|^|25487171|^|0|^|A|^|T|^|Color Description|^|Color Description|^|Color Description|^|Very Very Slightly Brown|^|Very Very Slightly Brown|^||^||^||^|T|^|T|^||^|OBYRNS|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169722|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|10|^|2014-11-17 10:54:53.0|^|TM100002052 Version 5.0|^|NB 99973 p8|^|CRO-017-02|^|14-NOV-2014|^|25288440|^|0|^|A|^|T|^|Color|^|Coloration|^|Coloration|^|<=B8|^|<=B8|^||^||^||^|T|^|T|^|Not more intensely colored than level 5 of the color standard|^|OBYRNS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169723|^|A|^|REGISTERED|^|CONCENTRATION_UV|^|Protein Concentration (UV)|^|TM100001683, TMC0085, SOP-68797|^|1|^|9|^|2014-11-21 10:30:45.0|^|TM100001683 Version 6.0, Effective date 07AUG2012|^|NB 83210 p 37|^|CRO-017-02|^|20-NOV-2014|^|25288445|^|0|^|A|^|T|^|Protein Concentration|^|Protein Concentration - rep|^|Protein Concentration - rep|^|20.5|^|20.5|^|mg/mL|^|20.5|^||^|T|^|T|^||^|CONMYS|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169723|^|A|^|REGISTERED|^|CONCENTRATION_UV|^|Protein Concentration (UV)|^|TM100001683, TMC0085, SOP-68797|^|1|^|9|^|2014-11-21 10:30:45.0|^|TM100001683 Version 6.0, Effective date 07AUG2012|^|NB 83210 p 37|^|CRO-017-02|^|20-NOV-2014|^|25288446|^|0|^|A|^|T|^|Protein Concentration - Average|^|Protein Concentration|^|Protein Concentration|^|20.5|^|20.5|^|mg/mL|^|20.5|^||^|T|^|T|^|Report Results|^|CONMYS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169724|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2014-11-25 09:16:23.0|^|TM100001681 Version 3.0|^|NB 89638 P8|^|CRO-017-02|^|23-NOV-2014|^|25288451|^|0|^|A|^|T|^|Peak 1 (% Area)|^|% Acidic Peaks - rep|^|% Acidic Peaks - rep|^|20.6|^|20.6|^|%|^|20.6|^||^|T|^|T|^||^|RYANP18|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169724|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2014-11-25 09:16:23.0|^|TM100001681 Version 3.0|^|NB 89638 P8|^|CRO-017-02|^|23-NOV-2014|^|25288452|^|0|^|A|^|T|^|Peak 1 (% Area) - Average|^|% Acidic Peaks|^|% Acidic Peaks|^|20.6|^|20.6|^|%|^|20.6|^||^|T|^|T|^|17.0 - 33.0%|^|RYANP18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169724|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2014-11-25 09:16:23.0|^|TM100001681 Version 3.0|^|NB 89638 P8|^|CRO-017-02|^|23-NOV-2014|^|25288453|^|0|^|A|^|T|^|Peak 2 (% Area)|^|% Main Peak - rep|^|% Main Peak - rep|^|54.8|^|54.8|^|%|^|54.8|^||^|T|^|T|^||^|RYANP18|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169724|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2014-11-25 09:16:23.0|^|TM100001681 Version 3.0|^|NB 89638 P8|^|CRO-017-02|^|23-NOV-2014|^|25288454|^|0|^|A|^|T|^|Peak 2 (% Area) - Average|^|% Main Peak|^|% Main Peak|^|54.8|^|54.8|^|%|^|54.8|^||^|F|^|F|^|>= 50.0%|^|RYANP18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169724|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2014-11-25 09:16:23.0|^|TM100001681 Version 3.0|^|NB 89638 P8|^|CRO-017-02|^|23-NOV-2014|^|25288455|^|0|^|A|^|T|^|Peak 3 (% Area)|^|% Basic Peaks - rep|^|% Basic Peaks - rep|^|24.6|^|24.6|^|%|^|24.6|^||^|T|^|T|^||^|RYANP18|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169724|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2014-11-25 09:16:23.0|^|TM100001681 Version 3.0|^|NB 89638 P8|^|CRO-017-02|^|23-NOV-2014|^|25288456|^|0|^|A|^|T|^|Peak 3 (% Area) - Average|^|% Basic Peaks|^|% Basic Peaks|^|24.6|^|24.6|^|%|^|24.6|^||^|F|^|F|^|7.0 - 24.0%|^|RYANP18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169725|^|A|^|ADDITIONAL|^|MAB_OXIDATION|^|Lys-C Digest|^|TM100001849, SOP-68792|^|1|^|10|^|2014-11-30 18:00:56.0|^|TM100001849 version 3.0 28 Nov 2012|^|89571 P41|^|CRO-017-02|^|27-NOV-2014|^|25288461|^|0|^|A|^|T|^|Peak 1 (Relative Area %)|^|Oxidation at Fc-Met-1|^|Oxidation at Fc-Met-1|^|1.27|^|1.3|^|%|^|1.3|^||^|T|^|T|^||^|BARREN06|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169727|^|A|^|REGISTERED|^|PARTICULATE_BIO|^|Appearance (Visible Particulates)|^|TM100002052, SOP-67108|^|1|^|4|^|2014-11-17 11:01:37.0|^|TM100002052 Version 5.0|^|NB99973 p 8|^|CRO-017-02|^|14-NOV-2014|^|25288472|^|0|^|A|^|T|^|Particles|^|Visible particulates|^|Visible particulates|^|FREE|^|Essentially Free of Visible Particles|^||^||^||^|T|^|T|^|Essentially Free of Visible Particles|^|OBYRNS|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169728|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2014-12-12 15:08:57.0|^|TM100002055 version 1.0 06 May 2011|^|92231 P11|^|CRO-017-02|^|11-DEC-2014|^|25797210|^|1|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|5652|^|5652|^|Particles/container|^|5652|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169728|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2014-12-12 15:08:57.0|^|TM100002055 version 1.0 06 May 2011|^|92231 P11|^|CRO-017-02|^|11-DEC-2014|^|25797211|^|2|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|5232|^|5232|^|Particles/container|^|5232|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169728|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2014-12-12 15:08:57.0|^|TM100002055 version 1.0 06 May 2011|^|92231 P11|^|CRO-017-02|^|11-DEC-2014|^|25797212|^|3|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|5340|^|5340|^|Particles/container|^|5340|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169728|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2014-12-12 15:08:57.0|^|TM100002055 version 1.0 06 May 2011|^|92231 P11|^|CRO-017-02|^|11-DEC-2014|^|25288477|^|0|^|A|^|T|^|Light Obscuration: >= 2µm|^|Light Obscuration: >= 2µm|^|Light Obscuration: >= 2µm|^|5408|^|5408|^|Particles/container|^|5408|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169728|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2014-12-12 15:08:57.0|^|TM100002055 version 1.0 06 May 2011|^|92231 P11|^|CRO-017-02|^|11-DEC-2014|^|25797213|^|1|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|916|^|916|^|Particles/container|^|916|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169728|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2014-12-12 15:08:57.0|^|TM100002055 version 1.0 06 May 2011|^|92231 P11|^|CRO-017-02|^|11-DEC-2014|^|25797214|^|2|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|792|^|792|^|Particles/container|^|792|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169728|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2014-12-12 15:08:57.0|^|TM100002055 version 1.0 06 May 2011|^|92231 P11|^|CRO-017-02|^|11-DEC-2014|^|25797215|^|3|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|748|^|748|^|Particles/container|^|748|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169728|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2014-12-12 15:08:57.0|^|TM100002055 version 1.0 06 May 2011|^|92231 P11|^|CRO-017-02|^|11-DEC-2014|^|25288478|^|0|^|A|^|T|^|Light Obscuration: >= 5µm|^|Light Obscuration: >= 5µm|^|Light Obscuration: >= 5µm|^|818.66666667|^|819|^|Particles/container|^|819|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169728|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2014-12-12 15:08:57.0|^|TM100002055 version 1.0 06 May 2011|^|92231 P11|^|CRO-017-02|^|11-DEC-2014|^|25797216|^|1|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|272|^|272|^|Particles/container|^|272|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169728|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2014-12-12 15:08:57.0|^|TM100002055 version 1.0 06 May 2011|^|92231 P11|^|CRO-017-02|^|11-DEC-2014|^|25797217|^|2|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|232|^|232|^|Particles/container|^|232|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169728|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2014-12-12 15:08:57.0|^|TM100002055 version 1.0 06 May 2011|^|92231 P11|^|CRO-017-02|^|11-DEC-2014|^|25797218|^|3|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|236|^|236|^|Particles/container|^|236|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169728|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2014-12-12 15:08:57.0|^|TM100002055 version 1.0 06 May 2011|^|92231 P11|^|CRO-017-02|^|11-DEC-2014|^|25288479|^|0|^|A|^|T|^|Light Obscuration: >= 8µm|^|Light Obscuration: >= 8µm|^|Light Obscuration: >= 8µm|^|246.66666667|^|247|^|Particles/container|^|247|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169728|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2014-12-12 15:08:57.0|^|TM100002055 version 1.0 06 May 2011|^|92231 P11|^|CRO-017-02|^|11-DEC-2014|^|25797219|^|1|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|128|^|128|^|Particles/container|^|128|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169728|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2014-12-12 15:08:57.0|^|TM100002055 version 1.0 06 May 2011|^|92231 P11|^|CRO-017-02|^|11-DEC-2014|^|25797220|^|2|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|104|^|104|^|Particles/container|^|104|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169728|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2014-12-12 15:08:57.0|^|TM100002055 version 1.0 06 May 2011|^|92231 P11|^|CRO-017-02|^|11-DEC-2014|^|25797221|^|3|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|124|^|124|^|Particles/container|^|124|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169728|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2014-12-12 15:08:57.0|^|TM100002055 version 1.0 06 May 2011|^|92231 P11|^|CRO-017-02|^|11-DEC-2014|^|25288480|^|0|^|A|^|T|^|Light Obscuration: >= 10µm|^|Light Obscuration: >= 10µm|^|Light Obscuration: >= 10µm|^|118.66666667|^|119|^|Particles/container|^|119|^||^|T|^|T|^|Report Results|^|BARREN06|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169728|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2014-12-12 15:08:57.0|^|TM100002055 version 1.0 06 May 2011|^|92231 P11|^|CRO-017-02|^|11-DEC-2014|^|25797222|^|1|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|8|^|8|^|Particles/container|^|8|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169728|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2014-12-12 15:08:57.0|^|TM100002055 version 1.0 06 May 2011|^|92231 P11|^|CRO-017-02|^|11-DEC-2014|^|25797223|^|2|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|16|^|16|^|Particles/container|^|16|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169728|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2014-12-12 15:08:57.0|^|TM100002055 version 1.0 06 May 2011|^|92231 P11|^|CRO-017-02|^|11-DEC-2014|^|25797224|^|3|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|40|^|40|^|Particles/container|^|40|^||^|T|^|T|^||^|BARREN06|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169728|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2014-12-12 15:08:57.0|^|TM100002055 version 1.0 06 May 2011|^|92231 P11|^|CRO-017-02|^|11-DEC-2014|^|25288481|^|0|^|A|^|T|^|Light Obscuration: >= 25µm|^|Light Obscuration: >= 25µm|^|Light Obscuration: >= 25µm|^|21.333333333|^|21|^|Particles/container|^|21|^||^|T|^|T|^|Report Results|^|BARREN06|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169728|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2014-12-12 15:08:57.0|^|TM100002055 version 1.0 06 May 2011|^|92231 P11|^|CRO-017-02|^|11-DEC-2014|^|25288482|^|0|^|A|^|T|^|Particulate Matter|^|Particulate Matter|^|Particulate Matter|^|Meets compendial requirements|^|Meets compendial requirements|^||^||^||^|T|^|T|^|Meets compendial requirements|^|BARREN06|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169729|^|A|^|REGISTERED|^|PH|^|pH|^|M00125, TMS-000000862, SOP-67110|^|1|^|4|^|2014-11-20 18:28:44.0|^|M00125 Version 2.0, 07-May2012|^|NB83835 p31-35|^|CRO-017-02|^|19-NOV-2014|^|25288487|^|0|^|A|^|T|^|pH|^|pH - rep|^|pH - rep|^|5.9|^|5.9|^||^|5.9|^||^|T|^|T|^||^|OBYRNS|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169729|^|A|^|REGISTERED|^|PH|^|pH|^|M00125, TMS-000000862, SOP-67110|^|1|^|4|^|2014-11-20 18:28:44.0|^|M00125 Version 2.0, 07-May2012|^|NB83835 p31-35|^|CRO-017-02|^|19-NOV-2014|^|25288488|^|0|^|A|^|T|^|pH - Average|^|pH|^|pH|^|5.9|^|5.9|^||^|5.9|^||^|T|^|T|^|6.0 +/- 0.5|^|OBYRNS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169730|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2014-11-13 17:55:04.0|^|TM100001683 Version 6.0, TM100002052 Version 5.0|^|NB98651 p7|^|CRO-017-02|^|11-NOV-2014|^|25288493|^|0|^|A|^|T|^|Minutes|^|Minutes|^|Minutes|^|3|^|3|^|min|^|3|^||^|T|^|T|^||^|OBYRNS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169730|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2014-11-13 17:55:04.0|^|TM100001683 Version 6.0, TM100002052 Version 5.0|^|NB98651 p7|^|CRO-017-02|^|11-NOV-2014|^|25288494|^|0|^|A|^|T|^|Seconds|^|Seconds|^|Seconds|^|0|^|0|^|s|^|0|^||^|T|^|T|^||^|OBYRNS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169730|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2014-11-13 17:55:04.0|^|TM100001683 Version 6.0, TM100002052 Version 5.0|^|NB98651 p7|^|CRO-017-02|^|11-NOV-2014|^|25288495|^|0|^|A|^|T|^|Rounding Interval|^|Rounding Interval|^|Rounding Interval|^|30|^|30|^||^|30|^||^|T|^|T|^||^|OBYRNS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169730|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2014-11-13 17:55:04.0|^|TM100001683 Version 6.0, TM100002052 Version 5.0|^|NB98651 p7|^|CRO-017-02|^|11-NOV-2014|^|25288496|^|0|^|A|^|T|^|Total Time|^|Total Time|^|Total Time|^|180|^|180|^|s|^|180|^||^|T|^|T|^||^|OBYRNS|^|F|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169730|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2014-11-13 17:55:04.0|^|TM100001683 Version 6.0, TM100002052 Version 5.0|^|NB98651 p7|^|CRO-017-02|^|11-NOV-2014|^|25288497|^|0|^|A|^|T|^|Reconstitution Time|^|Reconstitution Time|^|Reconstitution Time|^|3 min |^|3 min |^||^||^||^|T|^|T|^|Report Results|^|OBYRNS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169731|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777, 018-QA54699, SOP-68796|^|1|^|14|^|2014-11-19 13:55:34.0|^|TM100001777 Version 3.0|^|NB103717 P1|^|CRO-017-02|^|16-NOV-2014|^|25288502|^|0|^|A|^|T|^|Peak 1 (% Area)|^|Monomer|^|Monomer|^|97.4|^|97.4|^|%|^|97.4|^||^|T|^|T|^|>= 95.0%|^|LINEHC01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169731|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777, 018-QA54699, SOP-68796|^|1|^|14|^|2014-11-19 13:55:34.0|^|TM100001777 Version 3.0|^|NB103717 P1|^|CRO-017-02|^|16-NOV-2014|^|25288503|^|0|^|A|^|T|^|Peak 2 (% Area)|^|HMMS|^|HMMS|^|2.4|^|2.4|^|%|^|2.4|^||^|T|^|T|^|<= 5.0%|^|LINEHC01|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169731|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777, 018-QA54699, SOP-68796|^|1|^|14|^|2014-11-19 13:55:34.0|^|TM100001777 Version 3.0|^|NB103717 P1|^|CRO-017-02|^|16-NOV-2014|^|25288504|^|0|^|A|^|T|^|Peak 3 (% Area)|^|LMMS|^|LMMS|^|0.2|^|0.2|^|%|^|0.2|^||^|T|^|T|^||^|LINEHC01|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169733|^|A|^|REGISTERED|^|TURBIDITY|^|Appearance (Clarity)|^|TM100002052, SOP-67108|^|1|^|2|^|2014-11-17 10:59:43.0|^|TM100002052 Version 5.0|^|NB99973 p 8|^|CRO-017-02|^|14-NOV-2014|^|25288516|^|0|^|A|^|T|^|Turbidity - Rep|^|Turbidity - Rep|^|Turbidity - Rep|^|5|^|5|^|NTU|^|5|^||^|T|^|T|^||^|OBYRNS|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336607|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-12 15:08:57.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-07-28 14:25:16.0|^|1169733|^|A|^|REGISTERED|^|TURBIDITY|^|Appearance (Clarity)|^|TM100002052, SOP-67108|^|1|^|2|^|2014-11-17 10:59:43.0|^|TM100002052 Version 5.0|^|NB99973 p 8|^|CRO-017-02|^|14-NOV-2014|^|25288517|^|0|^|A|^|T|^|Turbidity|^|Turbidity|^|Turbidity|^|5|^|5|^|NTU|^|5|^||^|T|^|T|^|<= 18 NTU|^|OBYRNS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336608|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-11 20:47:33.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-03-18 16:08:57.0|^|1169726|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405, SOP-68798|^|1|^|4|^|2014-12-11 18:52:28.0|^|TM000001405, Version 4.0|^|00708123-0117|^|Pfizer, QC, St. Louis, MO, US|^|11-DEC-2014|^|25787697|^|0|^|A|^|T|^|LOQ|^|LOQ|^|LOQ|^|0.2|^|0.2|^||^|0.2|^||^|T|^|T|^||^|MAREAS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336608|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-11 20:47:33.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-03-18 16:08:57.0|^|1169726|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405, SOP-68798|^|1|^|4|^|2014-12-11 18:52:28.0|^|TM000001405, Version 4.0|^|00708123-0117|^|Pfizer, QC, St. Louis, MO, US|^|11-DEC-2014|^|25787698|^|0|^|A|^|T|^|Diluent Weight|^|Diluent Weight|^|Diluent Weight|^|22.9002|^|22.9002|^|g|^|22.9002|^||^|T|^|T|^||^|MAREAS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336608|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-11 20:47:33.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-03-18 16:08:57.0|^|1169726|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405, SOP-68798|^|1|^|4|^|2014-12-11 18:52:28.0|^|TM000001405, Version 4.0|^|00708123-0117|^|Pfizer, QC, St. Louis, MO, US|^|11-DEC-2014|^|25787703|^|0|^|A|^|T|^|Sample Weight|^|Sample Weight|^|Sample Weight|^|2.0522|^|2.0522|^|g|^|2.0522|^||^|T|^|T|^||^|MAREAS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336608|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-11 20:47:33.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-03-18 16:08:57.0|^|1169726|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405, SOP-68798|^|1|^|4|^|2014-12-11 18:52:28.0|^|TM000001405, Version 4.0|^|00708123-0117|^|Pfizer, QC, St. Louis, MO, US|^|11-DEC-2014|^|25787841|^|0|^|A|^|T|^|Cake Weight|^|Cake Weight|^|Cake Weight|^|0.8826|^|0.8826|^|g|^|0.8826|^||^|T|^|T|^||^|MAREAS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336608|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-11 20:47:33.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-03-18 16:08:57.0|^|1169726|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405, SOP-68798|^|1|^|4|^|2014-12-11 18:52:28.0|^|TM000001405, Version 4.0|^|00708123-0117|^|Pfizer, QC, St. Louis, MO, US|^|11-DEC-2014|^|25787704|^|0|^|A|^|T|^|Instrument Reading|^|Instrument Reading|^|Instrument Reading|^|584.1|^|584.1|^|µg|^|584.1|^||^|T|^|T|^||^|MAREAS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336608|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-11 20:47:33.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-03-18 16:08:57.0|^|1169726|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405, SOP-68798|^|1|^|4|^|2014-12-11 18:52:28.0|^|TM000001405, Version 4.0|^|00708123-0117|^|Pfizer, QC, St. Louis, MO, US|^|11-DEC-2014|^|25787758|^|0|^|A|^|T|^|Average H2O in Blank Injections|^|Average H2O in Blank Injections|^|Average H2O in Blank Injections|^|84.0091343|^|84.0091343|^|ppm|^|84.0091343|^||^|T|^|T|^||^|MAREAS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336608|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-11 20:47:33.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-03-18 16:08:57.0|^|1169726|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405, SOP-68798|^|1|^|4|^|2014-12-11 18:52:28.0|^|TM000001405, Version 4.0|^|00708123-0117|^|Pfizer, QC, St. Louis, MO, US|^|11-DEC-2014|^|25288466|^|0|^|A|^|T|^|Moisture - Rep|^|Moisture - Rep|^|Moisture - Rep|^|0.5405756813|^|0.5|^|%|^|0.5|^||^|T|^|T|^||^|MAREAS|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336608|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-11 20:47:33.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-03-18 16:08:57.0|^|1169726|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405, SOP-68798|^|1|^|4|^|2014-12-11 18:52:28.0|^|TM000001405, Version 4.0|^|00708123-0117|^|Pfizer, QC, St. Louis, MO, US|^|11-DEC-2014|^|25288467|^|0|^|A|^|T|^|Moisture|^|Moisture|^|Moisture|^|0.5405756813|^|0.5|^|%|^|0.5|^||^|T|^|T|^|<= 2%|^|MAREAS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336609|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-29 15:42:37.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-03-18 16:08:57.0|^|1169732|^|A|^|REGISTERED|^|SPECIFIC_ACTIVITY|^|Potency Assay (Cell Based)|^|TM100001721, SOP-68246|^|1|^|11|^|2014-12-29 15:42:37.0|^|TM100001721v8.0 18SEP2014|^|104911 p4|^|CRO-017-01|^|23-DEC-2014|^|25288509|^|0|^|A|^|T|^|Relative Potency|^|Relative Potency|^|Relative Potency|^|107|^|107|^|%|^|107|^||^|T|^|T|^|55 - 158% potency relative to reference material|^|RAGLAE|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|Trastuzumab (Biosimilar 2, PF8) / PF-05280014:1-0*|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_30|^|30 Months|^|30|^||^|2012-05-04 00:00:00.0|^|2014-11-04 00:00:00.0|^||^|336606|^|A|^|336609|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_30|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2014-10-28 00:01:07.0|^|2015-02-17 20:44:15.0|^|2015-02-17 20:44:15.0|^|2014-12-29 15:42:37.0|^|2015-03-18 16:08:51.0|^|F|^|F|^|2015-03-18 16:08:57.0|^|1169732|^|A|^|REGISTERED|^|SPECIFIC_ACTIVITY|^|Potency Assay (Cell Based)|^|TM100001721, SOP-68246|^|1|^|11|^|2014-12-29 15:42:37.0|^|TM100001721v8.0 18SEP2014|^|104911 p4|^|CRO-017-01|^|23-DEC-2014|^|25288510|^|0|^|A|^|T|^|Specific Activity|^|Specific Activity|^|Specific Activity|^|1067|^|1067|^|U/mg|^|1067|^||^|T|^|T|^|550 - 1580 U/mg|^|RAGLAE|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301958|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052, SOP-67108|^|1|^|2|^|2015-05-11 17:10:10.0|^|TM100002052 Version 5.0/20MAR2014|^|NB 109696 p1|^|CRO-017-02|^|08-MAY-2015|^|27342867|^|0|^|A|^|T|^|Appearance|^|Visual appearance|^|Visual appearance|^|White cake essentially free from visible particulates|^|White cake essentially free from visible particulates|^||^||^||^|T|^|T|^|White cake essentially free from visible particulates|^|CONMYS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301959|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reducing)|^|TM100001851, SOP-68795|^|1|^|11|^|2015-05-15 10:05:48.0|^|TM100001851 Version 4.0 Effective Date 19 Aug 2013|^|NB87265 P22|^|CRO-017-02|^|14-MAY-2015|^|27548997|^|0|^|A|^|T|^|LOQ (% Area)|^|LOQ (% Area)|^|LOQ (% Area)|^|0.3|^|0.3|^||^|0.3|^||^|T|^|T|^||^|RYANP18|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301959|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reducing)|^|TM100001851, SOP-68795|^|1|^|11|^|2015-05-15 10:05:48.0|^|TM100001851 Version 4.0 Effective Date 19 Aug 2013|^|NB87265 P22|^|CRO-017-02|^|14-MAY-2015|^|27342873|^|0|^|A|^|T|^|Sum HC and LC|^|Heavy Chain + Light Chain|^|Heavy Chain + Light Chain|^|99.6|^|99.6|^|%|^|99.6|^||^|T|^|T|^|>= 95.0% IgG as heavy + light chain|^|RYANP18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301959|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reducing)|^|TM100001851, SOP-68795|^|1|^|11|^|2015-05-15 10:05:48.0|^|TM100001851 Version 4.0 Effective Date 19 Aug 2013|^|NB87265 P22|^|CRO-017-02|^|14-MAY-2015|^|27342874|^|0|^|A|^|T|^|Percent Fragment|^|Fragments|^|Fragments|^|0.4|^|0.4|^|%|^|0.4|^||^|T|^|T|^|Report Results|^|RYANP18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301959|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reducing)|^|TM100001851, SOP-68795|^|1|^|11|^|2015-05-15 10:05:48.0|^|TM100001851 Version 4.0 Effective Date 19 Aug 2013|^|NB87265 P22|^|CRO-017-02|^|14-MAY-2015|^|27342875|^|0|^|A|^|T|^|Percent Other|^|Other|^|Other|^|0.0|^|NMT 0.3|^|%|^||^||^|T|^|T|^||^|RYANP18|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301960|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|10|^|2015-05-15 13:30:29.0|^|TM100002052 Version 5.0/20MAR2014|^|NB 104952 p8|^|CRO-017-02|^|11-MAY-2015|^|27342880|^|0|^|A|^|T|^|Color Hue|^|Color Hue|^|Color Hue|^|B|^|B|^||^||^||^|T|^|T|^||^|CABRII|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301960|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|10|^|2015-05-15 13:30:29.0|^|TM100002052 Version 5.0/20MAR2014|^|NB 104952 p8|^|CRO-017-02|^|11-MAY-2015|^|27342881|^|0|^|A|^|T|^|Color Intensity|^|Color Intensity|^|Color Intensity|^|9|^|9|^||^|9|^||^|T|^|T|^||^|CABRII|^|F|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301960|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|10|^|2015-05-15 13:30:29.0|^|TM100002052 Version 5.0/20MAR2014|^|NB 104952 p8|^|CRO-017-02|^|11-MAY-2015|^|27551577|^|0|^|A|^|T|^|Color Result|^|Color Result|^|Color Result|^|Not more intensely colored than level 9 of the color standard|^|Not more intensely colored than level 9 of the color standard|^||^||^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301960|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|10|^|2015-05-15 13:30:29.0|^|TM100002052 Version 5.0/20MAR2014|^|NB 104952 p8|^|CRO-017-02|^|11-MAY-2015|^|27551578|^|0|^|A|^|T|^|Color Description|^|Color Description|^|Color Description|^|Colorless|^|Colorless|^||^||^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301960|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|10|^|2015-05-15 13:30:29.0|^|TM100002052 Version 5.0/20MAR2014|^|NB 104952 p8|^|CRO-017-02|^|11-MAY-2015|^|27342882|^|0|^|A|^|T|^|Color|^|Coloration|^|Coloration|^|<=B9|^|<=B9|^||^||^||^|T|^|T|^|Not more intensely colored than level 5 of the color standard|^|CABRII|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301961|^|A|^|REGISTERED|^|CONCENTRATION_UV|^|Protein Concentration (UV)|^|TM100001683, TMC0085, SOP-68797|^|1|^|10|^|2015-05-19 07:24:14.0|^|TM100001683 Version 6.0 Effective date 07AUG2012|^|NB 103718 p 32|^|CRO-017-02|^|13-MAY-2015|^|27342887|^|0|^|A|^|T|^|Protein Concentration|^|Protein Concentration - rep|^|Protein Concentration - rep|^|21.5|^|21.5|^|mg/mL|^|21.5|^||^|T|^|T|^||^|CONMYS|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301961|^|A|^|REGISTERED|^|CONCENTRATION_UV|^|Protein Concentration (UV)|^|TM100001683, TMC0085, SOP-68797|^|1|^|10|^|2015-05-19 07:24:14.0|^|TM100001683 Version 6.0 Effective date 07AUG2012|^|NB 103718 p 32|^|CRO-017-02|^|13-MAY-2015|^|27342888|^|0|^|A|^|T|^|Protein Concentration - Average|^|Protein Concentration|^|Protein Concentration|^|21.5|^|21.5|^|mg/mL|^|21.5|^||^|T|^|T|^|Report Results|^|CONMYS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301962|^|A|^|REGISTERED|^|DYE_INGRESS|^|Container Closure|^|TM100002636, SOP-12349|^|1|^|1|^|2015-05-15 16:22:18.0|^|M8721.03 Effective date 22APR2013|^|NB 92234 p22|^|CRO-017-02|^|14-MAY-2015|^|27342896|^|0|^|A|^|T|^|Dye Ingress|^|Dye Ingress|^|Dye Ingress|^|PASS|^|Pass|^||^||^||^|T|^|T|^|Pass|^|CONMYS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301963|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2015-05-21 11:21:02.0|^|TM100001681 Version 3.0 Effective date 20 May 2012|^|NB89637 P15|^|CRO-017-02|^|20-MAY-2015|^|27342901|^|0|^|A|^|T|^|Peak 1 (% Area)|^|% Acidic Peaks - rep|^|% Acidic Peaks - rep|^|21.0|^|21.0|^|%|^|21|^||^|T|^|T|^||^|RYANP18|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301963|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2015-05-21 11:21:02.0|^|TM100001681 Version 3.0 Effective date 20 May 2012|^|NB89637 P15|^|CRO-017-02|^|20-MAY-2015|^|27342902|^|0|^|A|^|T|^|Peak 1 (% Area) - Average|^|% Acidic Peaks|^|% Acidic Peaks|^|21.0|^|21.0|^|%|^|21|^||^|T|^|T|^|17.0 - 33.0%|^|RYANP18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301963|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2015-05-21 11:21:02.0|^|TM100001681 Version 3.0 Effective date 20 May 2012|^|NB89637 P15|^|CRO-017-02|^|20-MAY-2015|^|27342903|^|0|^|A|^|T|^|Peak 2 (% Area)|^|% Main Peak - rep|^|% Main Peak - rep|^|53.4|^|53.4|^|%|^|53.4|^||^|T|^|T|^||^|RYANP18|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301963|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2015-05-21 11:21:02.0|^|TM100001681 Version 3.0 Effective date 20 May 2012|^|NB89637 P15|^|CRO-017-02|^|20-MAY-2015|^|27342904|^|0|^|A|^|T|^|Peak 2 (% Area) - Average|^|% Main Peak|^|% Main Peak|^|53.4|^|53.4|^|%|^|53.4|^||^|F|^|F|^|>= 50.0%|^|RYANP18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301963|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2015-05-21 11:21:02.0|^|TM100001681 Version 3.0 Effective date 20 May 2012|^|NB89637 P15|^|CRO-017-02|^|20-MAY-2015|^|27342905|^|0|^|A|^|T|^|Peak 3 (% Area)|^|% Basic Peaks - rep|^|% Basic Peaks - rep|^|25.5|^|25.5|^|%|^|25.5|^||^|T|^|T|^||^|RYANP18|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301963|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2015-05-21 11:21:02.0|^|TM100001681 Version 3.0 Effective date 20 May 2012|^|NB89637 P15|^|CRO-017-02|^|20-MAY-2015|^|27342906|^|0|^|A|^|T|^|Peak 3 (% Area) - Average|^|% Basic Peaks|^|% Basic Peaks|^|25.5|^|25.5|^|%|^|25.5|^||^|F|^|F|^|7.0 - 24.0%|^|RYANP18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301964|^|A|^|ADDITIONAL|^|MAB_OXIDATION|^|Lys-C Digest|^|TM100001849, SOP-68792|^|1|^|11|^|2015-05-19 13:37:57.0|^|TM100001849 Version 3.0 Effective date 28 Nov 2012|^|NB92233 P41|^|CRO-017-02|^|18-MAY-2015|^|27342911|^|0|^|A|^|T|^|Peak 1 (Relative Area %)|^|Oxidation at Fc-Met-1|^|Oxidation at Fc-Met-1|^|1.5|^|1.5|^|%|^|1.5|^||^|T|^|T|^||^|RYANP18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301966|^|A|^|REGISTERED|^|PARTICULATE_BIO|^|Appearance (Visible Particulates)|^|TM100002052, SOP-67108|^|1|^|4|^|2015-05-11 17:20:14.0|^|TM100002052 Version 5.0/20MAR2014|^|NB 109696 p1|^|CRO-017-02|^|08-MAY-2015|^|27342923|^|0|^|A|^|T|^|Particles|^|Visible particulates|^|Visible particulates|^|FREE|^|Essentially Free of Visible Particles|^||^||^||^|T|^|T|^|Essentially Free of Visible Particles|^|CONMYS|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301967|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-05-15 15:23:49.0|^|TM100002055 v2.0 / 03-MAR-2014|^|110957p1|^|CRO-017-02|^|15-MAY-2015|^|27553878|^|1|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|9416|^|9416|^|Particles/container|^|9416|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301967|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-05-15 15:23:49.0|^|TM100002055 v2.0 / 03-MAR-2014|^|110957p1|^|CRO-017-02|^|15-MAY-2015|^|27553879|^|2|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|8796|^|8796|^|Particles/container|^|8796|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301967|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-05-15 15:23:49.0|^|TM100002055 v2.0 / 03-MAR-2014|^|110957p1|^|CRO-017-02|^|15-MAY-2015|^|27553880|^|3|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|8960|^|8960|^|Particles/container|^|8960|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301967|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-05-15 15:23:49.0|^|TM100002055 v2.0 / 03-MAR-2014|^|110957p1|^|CRO-017-02|^|15-MAY-2015|^|27342928|^|0|^|A|^|T|^|Light Obscuration: >= 2µm|^|Light Obscuration: >= 2µm|^|Light Obscuration: >= 2µm|^|9057.3333333|^|9057|^|Particles/container|^|9057|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301967|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-05-15 15:23:49.0|^|TM100002055 v2.0 / 03-MAR-2014|^|110957p1|^|CRO-017-02|^|15-MAY-2015|^|27553881|^|1|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|1616|^|1616|^|Particles/container|^|1616|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301967|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-05-15 15:23:49.0|^|TM100002055 v2.0 / 03-MAR-2014|^|110957p1|^|CRO-017-02|^|15-MAY-2015|^|27553882|^|2|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|1420|^|1420|^|Particles/container|^|1420|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301967|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-05-15 15:23:49.0|^|TM100002055 v2.0 / 03-MAR-2014|^|110957p1|^|CRO-017-02|^|15-MAY-2015|^|27553883|^|3|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|1348|^|1348|^|Particles/container|^|1348|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301967|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-05-15 15:23:49.0|^|TM100002055 v2.0 / 03-MAR-2014|^|110957p1|^|CRO-017-02|^|15-MAY-2015|^|27342929|^|0|^|A|^|T|^|Light Obscuration: >= 5µm|^|Light Obscuration: >= 5µm|^|Light Obscuration: >= 5µm|^|1461.3333333|^|1461|^|Particles/container|^|1461|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301967|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-05-15 15:23:49.0|^|TM100002055 v2.0 / 03-MAR-2014|^|110957p1|^|CRO-017-02|^|15-MAY-2015|^|27553884|^|1|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|516|^|516|^|Particles/container|^|516|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301967|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-05-15 15:23:49.0|^|TM100002055 v2.0 / 03-MAR-2014|^|110957p1|^|CRO-017-02|^|15-MAY-2015|^|27553885|^|2|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|384|^|384|^|Particles/container|^|384|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301967|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-05-15 15:23:49.0|^|TM100002055 v2.0 / 03-MAR-2014|^|110957p1|^|CRO-017-02|^|15-MAY-2015|^|27553886|^|3|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|420|^|420|^|Particles/container|^|420|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301967|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-05-15 15:23:49.0|^|TM100002055 v2.0 / 03-MAR-2014|^|110957p1|^|CRO-017-02|^|15-MAY-2015|^|27342930|^|0|^|A|^|T|^|Light Obscuration: >= 8µm|^|Light Obscuration: >= 8µm|^|Light Obscuration: >= 8µm|^|440|^|440|^|Particles/container|^|440|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301967|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-05-15 15:23:49.0|^|TM100002055 v2.0 / 03-MAR-2014|^|110957p1|^|CRO-017-02|^|15-MAY-2015|^|27553887|^|1|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|348|^|348|^|Particles/container|^|348|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301967|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-05-15 15:23:49.0|^|TM100002055 v2.0 / 03-MAR-2014|^|110957p1|^|CRO-017-02|^|15-MAY-2015|^|27553888|^|2|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|240|^|240|^|Particles/container|^|240|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301967|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-05-15 15:23:49.0|^|TM100002055 v2.0 / 03-MAR-2014|^|110957p1|^|CRO-017-02|^|15-MAY-2015|^|27553889|^|3|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|260|^|260|^|Particles/container|^|260|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301967|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-05-15 15:23:49.0|^|TM100002055 v2.0 / 03-MAR-2014|^|110957p1|^|CRO-017-02|^|15-MAY-2015|^|27342931|^|0|^|A|^|T|^|Light Obscuration: >= 10µm|^|Light Obscuration: >= 10µm|^|Light Obscuration: >= 10µm|^|282.66666667|^|283|^|Particles/container|^|283|^||^|T|^|T|^|Report Results|^|CABRII|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301967|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-05-15 15:23:49.0|^|TM100002055 v2.0 / 03-MAR-2014|^|110957p1|^|CRO-017-02|^|15-MAY-2015|^|27553890|^|1|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|116|^|116|^|Particles/container|^|116|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301967|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-05-15 15:23:49.0|^|TM100002055 v2.0 / 03-MAR-2014|^|110957p1|^|CRO-017-02|^|15-MAY-2015|^|27553891|^|2|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|40|^|40|^|Particles/container|^|40|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301967|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-05-15 15:23:49.0|^|TM100002055 v2.0 / 03-MAR-2014|^|110957p1|^|CRO-017-02|^|15-MAY-2015|^|27553892|^|3|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|76|^|76|^|Particles/container|^|76|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301967|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-05-15 15:23:49.0|^|TM100002055 v2.0 / 03-MAR-2014|^|110957p1|^|CRO-017-02|^|15-MAY-2015|^|27342932|^|0|^|A|^|T|^|Light Obscuration: >= 25µm|^|Light Obscuration: >= 25µm|^|Light Obscuration: >= 25µm|^|77.333333333|^|77|^|Particles/container|^|77|^||^|T|^|T|^|Report Results|^|CABRII|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301967|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-05-15 15:23:49.0|^|TM100002055 v2.0 / 03-MAR-2014|^|110957p1|^|CRO-017-02|^|15-MAY-2015|^|27342933|^|0|^|A|^|T|^|Particulate Matter|^|Particulate Matter|^|Particulate Matter|^|Meets compendial requirements|^|Meets compendial requirements|^||^||^||^|T|^|T|^|Meets compendial requirements|^|CABRII|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301968|^|A|^|REGISTERED|^|PH|^|pH|^|M00125, TMS-000000862, SOP-67110|^|1|^|4|^|2015-05-13 13:44:56.0|^|M00125 Version 2.0 Effective date 07MAY2012|^|NB 104950 p 6|^|CRO-017-02|^|12-MAY-2015|^|27342938|^|0|^|A|^|T|^|pH|^|pH - rep|^|pH - rep|^|5.9|^|5.9|^||^|5.9|^||^|T|^|T|^||^|CONMYS|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301968|^|A|^|REGISTERED|^|PH|^|pH|^|M00125, TMS-000000862, SOP-67110|^|1|^|4|^|2015-05-13 13:44:56.0|^|M00125 Version 2.0 Effective date 07MAY2012|^|NB 104950 p 6|^|CRO-017-02|^|12-MAY-2015|^|27342939|^|0|^|A|^|T|^|pH - Average|^|pH|^|pH|^|5.9|^|5.9|^||^|5.9|^||^|T|^|T|^|6.0 +/- 0.5|^|CONMYS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301969|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2015-05-11 17:15:56.0|^|TM100001683 Version 6.0/07AUG2012, TM100002052 Version 5.0/20MAR2014|^|NB 109696 p1|^|CRO-017-02|^|08-MAY-2015|^|27342944|^|0|^|A|^|T|^|Minutes|^|Minutes|^|Minutes|^|1|^|1|^|min|^|1|^||^|T|^|T|^||^|CONMYS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301969|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2015-05-11 17:15:56.0|^|TM100001683 Version 6.0/07AUG2012, TM100002052 Version 5.0/20MAR2014|^|NB 109696 p1|^|CRO-017-02|^|08-MAY-2015|^|27342945|^|0|^|A|^|T|^|Seconds|^|Seconds|^|Seconds|^|44|^|44|^|s|^|44|^||^|T|^|T|^||^|CONMYS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301969|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2015-05-11 17:15:56.0|^|TM100001683 Version 6.0/07AUG2012, TM100002052 Version 5.0/20MAR2014|^|NB 109696 p1|^|CRO-017-02|^|08-MAY-2015|^|27342946|^|0|^|A|^|T|^|Rounding Interval|^|Rounding Interval|^|Rounding Interval|^|30|^|30|^||^|30|^||^|T|^|T|^||^|CONMYS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301969|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2015-05-11 17:15:56.0|^|TM100001683 Version 6.0/07AUG2012, TM100002052 Version 5.0/20MAR2014|^|NB 109696 p1|^|CRO-017-02|^|08-MAY-2015|^|27342947|^|0|^|A|^|T|^|Total Time|^|Total Time|^|Total Time|^|120|^|120|^|s|^|120|^||^|T|^|T|^||^|CONMYS|^|F|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301969|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2015-05-11 17:15:56.0|^|TM100001683 Version 6.0/07AUG2012, TM100002052 Version 5.0/20MAR2014|^|NB 109696 p1|^|CRO-017-02|^|08-MAY-2015|^|27342948|^|0|^|A|^|T|^|Reconstitution Time|^|Reconstitution Time|^|Reconstitution Time|^|2 min |^|2 min |^||^||^||^|T|^|T|^|Report Results|^|CONMYS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301970|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777, 018-QA54699, SOP-68796|^|1|^|14|^|2015-05-12 11:42:06.0|^|TM100001777 v3.0 Effective date 30MAY2012|^|NB 103717 p 11|^|CRO-017-02|^|11-MAY-2015|^|27342953|^|0|^|A|^|T|^|Peak 1 (% Area)|^|Monomer|^|Monomer|^|97.2|^|97.2|^|%|^|97.2|^||^|T|^|T|^|>= 95.0%|^|CONMYS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301970|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777, 018-QA54699, SOP-68796|^|1|^|14|^|2015-05-12 11:42:06.0|^|TM100001777 v3.0 Effective date 30MAY2012|^|NB 103717 p 11|^|CRO-017-02|^|11-MAY-2015|^|27342954|^|0|^|A|^|T|^|Peak 2 (% Area)|^|HMMS|^|HMMS|^|2.6|^|2.6|^|%|^|2.6|^||^|T|^|F|^|<= 5.0%|^|CONMYS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301970|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777, 018-QA54699, SOP-68796|^|1|^|14|^|2015-05-12 11:42:06.0|^|TM100001777 v3.0 Effective date 30MAY2012|^|NB 103717 p 11|^|CRO-017-02|^|11-MAY-2015|^|27342955|^|0|^|A|^|T|^|Peak 3 (% Area)|^|LMMS|^|LMMS|^|0.2|^|0.2|^|%|^|0.2|^||^|T|^|T|^||^|CONMYS|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301972|^|A|^|REGISTERED|^|TURBIDITY|^|Appearance (Clarity)|^|TM100002052, SOP-67108|^|1|^|2|^|2015-05-15 13:31:30.0|^|TM100002052 Version 5.0/20MAR2014|^|NB 104952 p8|^|CRO-017-02|^|11-MAY-2015|^|27342967|^|0|^|A|^|T|^|Turbidity - Rep|^|Turbidity - Rep|^|Turbidity - Rep|^|4|^|4|^|NTU|^|4|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380488|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-21 11:21:02.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301972|^|A|^|REGISTERED|^|TURBIDITY|^|Appearance (Clarity)|^|TM100002052, SOP-67108|^|1|^|2|^|2015-05-15 13:31:30.0|^|TM100002052 Version 5.0/20MAR2014|^|NB 104952 p8|^|CRO-017-02|^|11-MAY-2015|^|27342968|^|0|^|A|^|T|^|Turbidity|^|Turbidity|^|Turbidity|^|4|^|4|^|NTU|^|4|^||^|T|^|T|^|<= 18 NTU|^|CABRII|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380489|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-28 20:41:47.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301965|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405, SOP-68798|^|1|^|5|^|2015-05-28 14:12:25.0|^|TM000001405 Ver. 4.0|^|00709821-0169|^|Pfizer, QC, St. Louis, MO, US|^|28-MAY-2015|^|27342916|^|0|^|A|^|T|^|LOQ|^|LOQ|^|LOQ|^|0.2|^|0.2|^||^|0.2|^||^|T|^|T|^||^|BERESB|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380489|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-28 20:41:47.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301965|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405, SOP-68798|^|1|^|5|^|2015-05-28 14:12:25.0|^|TM000001405 Ver. 4.0|^|00709821-0169|^|Pfizer, QC, St. Louis, MO, US|^|28-MAY-2015|^|27342917|^|1|^|A|^|T|^|Moisture - Rep|^|Moisture - Rep|^|Moisture - Rep|^|0.687505|^|0.7|^|%|^|0.7|^||^|T|^|T|^||^|BERESB|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380489|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-05-28 20:41:47.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301965|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405, SOP-68798|^|1|^|5|^|2015-05-28 14:12:25.0|^|TM000001405 Ver. 4.0|^|00709821-0169|^|Pfizer, QC, St. Louis, MO, US|^|28-MAY-2015|^|27342918|^|0|^|A|^|T|^|Moisture|^|Moisture|^|Moisture|^|0.687505|^|0.7|^|%|^|0.7|^||^|T|^|T|^|<= 2%|^|BERESB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380490|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-06-16 15:02:54.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301971|^|A|^|REGISTERED|^|SPECIFIC_ACTIVITY|^|Potency Assay (Cell Based)|^|TM100001721, SOP-68246|^|1|^|11|^|2015-06-16 15:02:54.0|^|TM100001721v8.0/18SEP2014|^|NB104857 p43|^|CRO-017-01|^|10-JUN-2015|^|27342960|^|0|^|A|^|T|^|Relative Potency|^|Relative Potency|^|Relative Potency|^|76|^|76|^|%|^|76|^||^|T|^|T|^|55 - 158% potency relative to reference material|^|HANSOT03|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|7|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_36|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_36|^|36 Months|^|36|^||^|2012-05-04 00:00:00.0|^|2015-05-04 00:00:00.0|^||^|380487|^|A|^|380490|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_36|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-04-27 00:01:16.0|^|2015-05-26 12:54:32.0|^|2015-05-26 12:54:33.0|^|2015-06-16 15:02:54.0|^|2015-07-21 15:06:32.0|^|F|^|F|^|2015-07-21 15:06:40.0|^|1301971|^|A|^|REGISTERED|^|SPECIFIC_ACTIVITY|^|Potency Assay (Cell Based)|^|TM100001721, SOP-68246|^|1|^|11|^|2015-06-16 15:02:54.0|^|TM100001721v8.0/18SEP2014|^|NB104857 p43|^|CRO-017-01|^|10-JUN-2015|^|27342961|^|0|^|A|^|T|^|Specific Activity|^|Specific Activity|^|Specific Activity|^|762|^|762|^|U/mg|^|762|^||^|T|^|T|^|550 - 1580 U/mg|^|HANSOT03|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449195|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052, SOP-67108|^|1|^|3|^|2015-11-06 12:04:19.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB117593p1|^|CRO-017-02|^|05-NOV-2015|^|29329362|^|0|^|A|^|T|^|Appearance|^|Visual appearance|^|Visual appearance|^|White cake essentially free from visible particulates|^|White cake essentially free from visible particulates|^||^||^||^|T|^|T|^|White cake essentially free from visible particulates|^|CABRII|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449195|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052, SOP-67108|^|1|^|3|^|2015-11-06 12:04:19.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB117593p1|^|CRO-017-02|^|05-NOV-2015|^|29329364|^|0|^|A|^|T|^|Color|^|Color|^|Color|^|Y|^|Yes|^||^||^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449195|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052, SOP-67108|^|1|^|3|^|2015-11-06 12:04:19.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB117593p1|^|CRO-017-02|^|05-NOV-2015|^|29329365|^|0|^|A|^|T|^|Uniformity|^|Uniformity|^|Uniformity|^|Y|^|Yes|^||^||^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449195|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052, SOP-67108|^|1|^|3|^|2015-11-06 12:04:19.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB117593p1|^|CRO-017-02|^|05-NOV-2015|^|29329366|^|0|^|A|^|T|^|Absence of Foreign Matter|^|Absence of Foreign Matter|^|Absence of Foreign Matter|^|Y|^|Yes|^||^||^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449195|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052, SOP-67108|^|1|^|3|^|2015-11-06 12:04:19.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB117593p1|^|CRO-017-02|^|05-NOV-2015|^|29329367|^|0|^|A|^|T|^|Absence of Moisture|^|Absence of Moisture|^|Absence of Moisture|^|Y|^|Yes|^||^||^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449195|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052, SOP-67108|^|1|^|3|^|2015-11-06 12:04:19.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB117593p1|^|CRO-017-02|^|05-NOV-2015|^|29329368|^|0|^|A|^|T|^|Absence of Other Defects|^|Absence of Other Defects|^|Absence of Other Defects|^|Y|^|Yes|^||^||^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449196|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reducing)|^|TM100001851, SOP-68795|^|1|^|11|^|2015-11-16 14:32:36.0|^|TM100001851 Version 4.0 Effective Date 19 aug 2013|^|NB83212 P43|^|CRO-017-02|^|12-NOV-2015|^|29563270|^|0|^|A|^|T|^|LOQ (% Area)|^|LOQ (% Area)|^|LOQ (% Area)|^|0.3|^|0.3|^||^|0.3|^||^|T|^|T|^||^|RYANP18|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449196|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reducing)|^|TM100001851, SOP-68795|^|1|^|11|^|2015-11-16 14:32:36.0|^|TM100001851 Version 4.0 Effective Date 19 aug 2013|^|NB83212 P43|^|CRO-017-02|^|12-NOV-2015|^|29329373|^|0|^|A|^|T|^|Sum HC and LC|^|Heavy Chain + Light Chain|^|Heavy Chain + Light Chain|^|99.7|^|99.7|^|%|^|99.7|^||^|T|^|T|^|>= 95.0% IgG as heavy + light chain|^|RYANP18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449196|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reducing)|^|TM100001851, SOP-68795|^|1|^|11|^|2015-11-16 14:32:36.0|^|TM100001851 Version 4.0 Effective Date 19 aug 2013|^|NB83212 P43|^|CRO-017-02|^|12-NOV-2015|^|29329374|^|0|^|A|^|T|^|Percent Fragment|^|Fragments|^|Fragments|^|0.3|^|NMT 0.3|^|%|^||^||^|T|^|T|^|Report Results|^|RYANP18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449196|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reducing)|^|TM100001851, SOP-68795|^|1|^|11|^|2015-11-16 14:32:36.0|^|TM100001851 Version 4.0 Effective Date 19 aug 2013|^|NB83212 P43|^|CRO-017-02|^|12-NOV-2015|^|29329375|^|0|^|A|^|T|^|Percent Other|^|Other|^|Other|^|0.0|^|NMT 0.3|^|%|^||^||^|T|^|T|^||^|RYANP18|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449197|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|10|^|2015-11-06 15:27:15.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB117594p1|^|CRO-017-02|^|06-NOV-2015|^|29329380|^|0|^|A|^|T|^|Color Hue|^|Color Hue|^|Color Hue|^|B|^|B|^||^||^||^|T|^|T|^||^|CABRII|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449197|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|10|^|2015-11-06 15:27:15.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB117594p1|^|CRO-017-02|^|06-NOV-2015|^|29329381|^|0|^|A|^|T|^|Color Intensity|^|Color Intensity|^|Color Intensity|^|8|^|8|^||^|8|^||^|T|^|T|^||^|CABRII|^|F|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449197|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|10|^|2015-11-06 15:27:15.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB117594p1|^|CRO-017-02|^|06-NOV-2015|^|29459385|^|0|^|A|^|T|^|Color Result|^|Color Result|^|Color Result|^|Not more intensely colored than level 8 of the color standard|^|Not more intensely colored than level 8 of the color standard|^||^||^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449197|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|10|^|2015-11-06 15:27:15.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB117594p1|^|CRO-017-02|^|06-NOV-2015|^|29459386|^|0|^|A|^|T|^|Color Description|^|Color Description|^|Color Description|^|Very Very Slightly Brown|^|Very Very Slightly Brown|^||^||^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449197|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|10|^|2015-11-06 15:27:15.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB117594p1|^|CRO-017-02|^|06-NOV-2015|^|29329382|^|0|^|A|^|T|^|Color|^|Coloration|^|Coloration|^|<=B8|^|<=B8|^||^||^||^|T|^|T|^|Not more intensely colored than level 5 of the color standard|^|CABRII|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449198|^|A|^|REGISTERED|^|CONCENTRATION_UV|^|Protein Concentration (UV)|^|TM100001683, TMC0085, SOP-68797|^|1|^|10|^|2015-11-27 16:23:46.0|^|TM100001683 Version: 7.0 / 24-JUL-2015|^|NB105517p43|^|CRO-017-02|^|19-NOV-2015|^|29329387|^|0|^|A|^|T|^|Protein Concentration|^|Protein Concentration - rep|^|Protein Concentration - rep|^|21.5|^|21.5|^|mg/mL|^|21.5|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449198|^|A|^|REGISTERED|^|CONCENTRATION_UV|^|Protein Concentration (UV)|^|TM100001683, TMC0085, SOP-68797|^|1|^|10|^|2015-11-27 16:23:46.0|^|TM100001683 Version: 7.0 / 24-JUL-2015|^|NB105517p43|^|CRO-017-02|^|19-NOV-2015|^|29329388|^|0|^|A|^|T|^|Protein Concentration - Average|^|Protein Concentration|^|Protein Concentration|^|21.5|^|21.5|^|mg/mL|^|21.5|^||^|T|^|T|^|Report Results|^|CABRII|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449199|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2015-11-23 16:24:36.0|^|TM100001681 Version 3.0 / 30MAY2012|^|89634 p29|^|CRO-017-02|^|19-NOV-2015|^|29329396|^|0|^|A|^|T|^|Peak 1 (% Area)|^|% Acidic Peaks - rep|^|% Acidic Peaks - rep|^|20.4|^|20.4|^|%|^|20.4|^||^|T|^|T|^||^|CONMYS|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449199|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2015-11-23 16:24:36.0|^|TM100001681 Version 3.0 / 30MAY2012|^|89634 p29|^|CRO-017-02|^|19-NOV-2015|^|29329397|^|0|^|A|^|T|^|Peak 1 (% Area) - Average|^|% Acidic Peaks|^|% Acidic Peaks|^|20.4|^|20.4|^|%|^|20.4|^||^|T|^|T|^|17.0 - 33.0%|^|CONMYS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449199|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2015-11-23 16:24:36.0|^|TM100001681 Version 3.0 / 30MAY2012|^|89634 p29|^|CRO-017-02|^|19-NOV-2015|^|29329398|^|0|^|A|^|T|^|Peak 2 (% Area)|^|% Main Peak - rep|^|% Main Peak - rep|^|54.1|^|54.1|^|%|^|54.1|^||^|T|^|T|^||^|CONMYS|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449199|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2015-11-23 16:24:36.0|^|TM100001681 Version 3.0 / 30MAY2012|^|89634 p29|^|CRO-017-02|^|19-NOV-2015|^|29329399|^|0|^|A|^|T|^|Peak 2 (% Area) - Average|^|% Main Peak|^|% Main Peak|^|54.1|^|54.1|^|%|^|54.1|^||^|T|^|F|^|>= 50.0%|^|CONMYS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449199|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2015-11-23 16:24:36.0|^|TM100001681 Version 3.0 / 30MAY2012|^|89634 p29|^|CRO-017-02|^|19-NOV-2015|^|29329400|^|0|^|A|^|T|^|Peak 3 (% Area)|^|% Basic Peaks - rep|^|% Basic Peaks - rep|^|25.5|^|25.5|^|%|^|25.5|^||^|T|^|T|^||^|CONMYS|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449199|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2015-11-23 16:24:36.0|^|TM100001681 Version 3.0 / 30MAY2012|^|89634 p29|^|CRO-017-02|^|19-NOV-2015|^|29329401|^|0|^|A|^|T|^|Peak 3 (% Area) - Average|^|% Basic Peaks|^|% Basic Peaks|^|25.5|^|25.5|^|%|^|25.5|^||^|F|^|F|^|7.0 - 24.0%|^|CONMYS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449200|^|A|^|ADDITIONAL|^|MAB_OXIDATION|^|Lys-C Digest|^|TM100001849, SOP-68792|^|1|^|11|^|2015-11-26 14:32:02.0|^|TM100001849 Version 3.0 Effective Date28 Nov 2012|^|NB111670 P11|^|CRO-017-02|^|22-NOV-2015|^|29713414|^|0|^|A|^|T|^|LOQ|^|LOQ|^|LOQ|^|0.7|^|0.7|^|%|^|0.7|^||^|T|^|T|^||^|RYANP18|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449200|^|A|^|ADDITIONAL|^|MAB_OXIDATION|^|Lys-C Digest|^|TM100001849, SOP-68792|^|1|^|11|^|2015-11-26 14:32:02.0|^|TM100001849 Version 3.0 Effective Date28 Nov 2012|^|NB111670 P11|^|CRO-017-02|^|22-NOV-2015|^|29713415|^|0|^|A|^|T|^|LOQ (% Area)|^|LOQ (% Area)|^|LOQ (% Area)|^|0.7|^|0.7|^||^|0.7|^||^|T|^|T|^||^|RYANP18|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449200|^|A|^|ADDITIONAL|^|MAB_OXIDATION|^|Lys-C Digest|^|TM100001849, SOP-68792|^|1|^|11|^|2015-11-26 14:32:02.0|^|TM100001849 Version 3.0 Effective Date28 Nov 2012|^|NB111670 P11|^|CRO-017-02|^|22-NOV-2015|^|29329406|^|0|^|A|^|T|^|Peak 1 (Relative Area %)|^|Oxidation at Fc-Met-1|^|Oxidation at Fc-Met-1|^|1.1|^|1.1|^|%|^|1.1|^||^|T|^|T|^||^|RYANP18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449202|^|A|^|REGISTERED|^|PARTICULATE_BIO|^|Appearance (Visible Particulates)|^|TM100002052, SOP-67108|^|1|^|4|^|2015-11-06 12:04:57.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB117594p1|^|CRO-017-02|^|05-NOV-2015|^|29329418|^|0|^|A|^|T|^|Particles|^|Visible particulates|^|Visible particulates|^|FREE|^|Essentially Free of Visible Particles|^||^||^||^|T|^|T|^|Essentially Free of Visible Particles|^|CABRII|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29807308|^|1|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|8652|^|8652|^|Particles/container|^|8652|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29807309|^|2|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|9908|^|9908|^|Particles/container|^|9908|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29807310|^|3|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|8616|^|8616|^|Particles/container|^|8616|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29329423|^|0|^|A|^|T|^|Light Obscuration: >= 2µm|^|Light Obscuration: >= 2µm|^|Light Obscuration: >= 2µm|^|9058.6666667|^|9059|^|Particles/container|^|9059|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29807311|^|1|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|3028|^|3028|^|Particles/container|^|3028|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29807312|^|2|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|4068|^|4068|^|Particles/container|^|4068|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29807313|^|3|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|2856|^|2856|^|Particles/container|^|2856|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29329424|^|0|^|A|^|T|^|Light Obscuration: >= 5µm|^|Light Obscuration: >= 5µm|^|Light Obscuration: >= 5µm|^|3317.3333333|^|3317|^|Particles/container|^|3317|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29807314|^|1|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|2136|^|2136|^|Particles/container|^|2136|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29807315|^|2|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|3128|^|3128|^|Particles/container|^|3128|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29807316|^|3|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|1976|^|1976|^|Particles/container|^|1976|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29329425|^|0|^|A|^|T|^|Light Obscuration: >= 8µm|^|Light Obscuration: >= 8µm|^|Light Obscuration: >= 8µm|^|2413.3333333|^|2413|^|Particles/container|^|2413|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29805940|^|1|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|1880|^|1880|^|Particles/container|^|1880|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29807317|^|2|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|2836|^|2836|^|Particles/container|^|2836|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29807318|^|3|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|1712|^|1712|^|Particles/container|^|1712|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29329426|^|0|^|A|^|T|^|Light Obscuration: >= 10µm|^|Light Obscuration: >= 10µm|^|Light Obscuration: >= 10µm|^|2142.6666667|^|2143|^|Particles/container|^|2143|^||^|T|^|T|^|Report Results|^|CABRII|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29805941|^|1|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|796|^|796|^|Particles/container|^|796|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29807319|^|2|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|1120|^|1120|^|Particles/container|^|1120|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29807320|^|3|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|704|^|704|^|Particles/container|^|704|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29329427|^|0|^|A|^|T|^|Light Obscuration: >= 25µm|^|Light Obscuration: >= 25µm|^|Light Obscuration: >= 25µm|^|873.33333333|^|873|^|Particles/container|^|873|^||^|T|^|T|^|Report Results|^|CABRII|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29807321|^|1|^|A|^|T|^|Microscopic: >= 10µm - rep|^|Microscopic: >= 10µm - rep|^|Microscopic: >= 10µm - rep|^|6|^|6|^|Particles/container|^|6|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29807322|^|0|^|A|^|T|^|Microscopic: >= 10µm|^|Microscopic: >= 10µm|^|Microscopic: >= 10µm|^|6|^|6|^|Particles/container|^|6|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29807323|^|1|^|A|^|T|^|Microscopic: >= 25µm - rep|^|Microscopic: >= 25µm - rep|^|Microscopic: >= 25µm - rep|^|1|^|1|^|Particles/container|^|1|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29807324|^|0|^|A|^|T|^|Microscopic: >= 25µm|^|Microscopic: >= 25µm|^|Microscopic: >= 25µm|^|1|^|1|^|Particles/container|^|1|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449203|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2015-12-02 16:40:49.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|92231p28|^|CRO-017-02|^|19-NOV-2015|^|29329428|^|0|^|A|^|T|^|Particulate Matter|^|Particulate Matter|^|Particulate Matter|^|Meets compendial requirements|^|Meets compendial requirements|^||^||^||^|T|^|T|^|Meets compendial requirements|^|CABRII|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449204|^|A|^|REGISTERED|^|PH|^|pH|^|M00125, TMS-000000862, SOP-67110|^|1|^|6|^|2015-11-12 17:19:43.0|^|M00125-01 / 15-MAR-2005|^|NB111671p5|^|CRO-017-02|^|12-NOV-2015|^|29329433|^|0|^|A|^|T|^|pH|^|pH - rep|^|pH - rep|^|5.9|^|5.9|^||^|5.9|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449204|^|A|^|REGISTERED|^|PH|^|pH|^|M00125, TMS-000000862, SOP-67110|^|1|^|6|^|2015-11-12 17:19:43.0|^|M00125-01 / 15-MAR-2005|^|NB111671p5|^|CRO-017-02|^|12-NOV-2015|^|29329434|^|0|^|A|^|T|^|pH - Average|^|pH|^|pH|^|5.9|^|5.9|^||^|5.9|^||^|T|^|T|^|6.0 +/- 0.5|^|CABRII|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449205|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2015-11-06 12:11:44.0|^|TM100001683 Version: 7.0 / 24-JUL-2015|^|NB117593p1|^|CRO-017-02|^|05-NOV-2015|^|29329439|^|0|^|A|^|T|^|Minutes|^|Minutes|^|Minutes|^|2|^|2|^|min|^|2|^||^|T|^|T|^||^|CABRII|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449205|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2015-11-06 12:11:44.0|^|TM100001683 Version: 7.0 / 24-JUL-2015|^|NB117593p1|^|CRO-017-02|^|05-NOV-2015|^|29329440|^|0|^|A|^|T|^|Seconds|^|Seconds|^|Seconds|^|22|^|22|^|s|^|22|^||^|T|^|T|^||^|CABRII|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449205|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2015-11-06 12:11:44.0|^|TM100001683 Version: 7.0 / 24-JUL-2015|^|NB117593p1|^|CRO-017-02|^|05-NOV-2015|^|29329441|^|0|^|A|^|T|^|Rounding Interval|^|Rounding Interval|^|Rounding Interval|^|30|^|30|^||^|30|^||^|T|^|T|^||^|CABRII|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449205|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2015-11-06 12:11:44.0|^|TM100001683 Version: 7.0 / 24-JUL-2015|^|NB117593p1|^|CRO-017-02|^|05-NOV-2015|^|29329442|^|0|^|A|^|T|^|Total Time|^|Total Time|^|Total Time|^|150|^|150|^|s|^|150|^||^|T|^|T|^||^|CABRII|^|F|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449205|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2015-11-06 12:11:44.0|^|TM100001683 Version: 7.0 / 24-JUL-2015|^|NB117593p1|^|CRO-017-02|^|05-NOV-2015|^|29329443|^|0|^|A|^|T|^|Reconstitution Time|^|Reconstitution Time|^|Reconstitution Time|^|2 min 30 sec|^|2 min 30 sec|^||^||^||^|T|^|T|^|Report Results|^|CABRII|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449206|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777, 018-QA54699, SOP-68796|^|1|^|15|^|2015-11-30 10:55:50.0|^|TM100001777 Version 3.0 Effective Date 30 May 2015|^|NB111669 P6|^|CRO-017-02|^|29-NOV-2015|^|29329448|^|0|^|A|^|T|^|Peak 1 (% Area)|^|Monomer|^|Monomer|^|96.9|^|96.9|^|%|^|96.9|^||^|T|^|T|^|>= 95.0%|^|RYANP18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449206|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777, 018-QA54699, SOP-68796|^|1|^|15|^|2015-11-30 10:55:50.0|^|TM100001777 Version 3.0 Effective Date 30 May 2015|^|NB111669 P6|^|CRO-017-02|^|29-NOV-2015|^|29329449|^|0|^|A|^|T|^|Peak 2 (% Area)|^|HMMS|^|HMMS|^|2.9|^|2.9|^|%|^|2.9|^||^|T|^|F|^|<= 5.0%|^|RYANP18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449206|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777, 018-QA54699, SOP-68796|^|1|^|15|^|2015-11-30 10:55:50.0|^|TM100001777 Version 3.0 Effective Date 30 May 2015|^|NB111669 P6|^|CRO-017-02|^|29-NOV-2015|^|29329450|^|0|^|A|^|T|^|Peak 3 (% Area)|^|LMMS|^|LMMS|^|0.2|^|0.2|^|%|^|0.2|^||^|T|^|T|^||^|RYANP18|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449208|^|A|^|REGISTERED|^|TURBIDITY|^|Appearance (Clarity)|^|TM100002052, SOP-67108|^|1|^|2|^|2015-11-06 15:27:15.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB117594p1|^|CRO-017-02|^|06-NOV-2015|^|29329462|^|0|^|A|^|T|^|Turbidity - Rep|^|Turbidity - Rep|^|Turbidity - Rep|^|4|^|4|^|NTU|^|4|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428712|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-03 14:55:45.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449208|^|A|^|REGISTERED|^|TURBIDITY|^|Appearance (Clarity)|^|TM100002052, SOP-67108|^|1|^|2|^|2015-11-06 15:27:15.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB117594p1|^|CRO-017-02|^|06-NOV-2015|^|29329463|^|0|^|A|^|T|^|Turbidity|^|Turbidity|^|Turbidity|^|4|^|4|^|NTU|^|4|^||^|T|^|T|^|<= 18 NTU|^|CABRII|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428713|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-02 21:14:28.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449201|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405, SOP-68798|^|1|^|5|^|2015-12-02 15:51:29.0|^|TM000001405 v4.0|^|00709821-0280|^|Pfizer, QC, St. Louis, MO, US|^|02-DEC-2015|^|29329411|^|0|^|A|^|T|^|LOQ|^|LOQ|^|LOQ|^|0.2|^|0.2|^||^|0.2|^||^|T|^|T|^||^|BERESB|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428713|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-02 21:14:28.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449201|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405, SOP-68798|^|1|^|5|^|2015-12-02 15:51:29.0|^|TM000001405 v4.0|^|00709821-0280|^|Pfizer, QC, St. Louis, MO, US|^|02-DEC-2015|^|29329412|^|1|^|A|^|T|^|Moisture - Rep|^|Moisture - Rep|^|Moisture - Rep|^|0.668202633|^|0.7|^|%|^|0.7|^||^|T|^|T|^||^|BERESB|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428713|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-02 21:14:28.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449201|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405, SOP-68798|^|1|^|5|^|2015-12-02 15:51:29.0|^|TM000001405 v4.0|^|00709821-0280|^|Pfizer, QC, St. Louis, MO, US|^|02-DEC-2015|^|29329413|^|0|^|A|^|T|^|Moisture|^|Moisture|^|Moisture|^|0.668202633|^|0.7|^|%|^|0.7|^||^|T|^|T|^|<= 2%|^|BERESB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428714|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-17 17:38:23.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449207|^|A|^|REGISTERED|^|SPECIFIC_ACTIVITY|^|Potency Assay (Cell Based)|^|TM100001721, SOP-68246|^|1|^|11|^|2015-12-17 17:38:23.0|^|TM100001721 version 9.0 effective date 23OCT2015|^|ELN Batch: 11DEC2015 M7758 EJP2|^|CRO-017-01|^|11-DEC-2015|^|29329455|^|0|^|A|^|T|^|Relative Potency|^|Relative Potency|^|Relative Potency|^|97|^|97|^|%|^|97|^||^|T|^|T|^|55 - 158% potency relative to reference material|^|POSTE02|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|8|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_42|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_42|^|42 Months|^|42|^||^|2012-05-04 00:00:00.0|^|2015-11-04 00:00:00.0|^||^|428711|^|A|^|428714|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_42|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2015-10-28 00:01:20.0|^|2015-11-17 21:45:39.0|^|2015-11-17 21:45:40.0|^|2015-12-17 17:38:23.0|^|2016-01-28 18:40:16.0|^|F|^|F|^|2016-01-28 18:40:26.0|^|1449207|^|A|^|REGISTERED|^|SPECIFIC_ACTIVITY|^|Potency Assay (Cell Based)|^|TM100001721, SOP-68246|^|1|^|11|^|2015-12-17 17:38:23.0|^|TM100001721 version 9.0 effective date 23OCT2015|^|ELN Batch: 11DEC2015 M7758 EJP2|^|CRO-017-01|^|11-DEC-2015|^|29329456|^|0|^|A|^|T|^|Specific Activity|^|Specific Activity|^|Specific Activity|^|966|^|966|^|U/mg|^|966|^||^|T|^|T|^|550 - 1580 U/mg|^|POSTE02|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609648|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052, SOP-67108|^|1|^|3|^|2016-05-05 09:41:15.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB89575p38|^|CRO-017-02|^|04-MAY-2016|^|31564602|^|0|^|A|^|T|^|Appearance|^|Visual appearance|^|Visual appearance|^|White cake essentially free from visible particulates|^|White cake essentially free from visible particulates|^||^||^||^|T|^|T|^|White cake essentially free from visible particulates|^|CABRII|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609648|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052, SOP-67108|^|1|^|3|^|2016-05-05 09:41:15.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB89575p38|^|CRO-017-02|^|04-MAY-2016|^|31564604|^|0|^|A|^|T|^|Color|^|Color|^|Color|^|Y|^|Yes|^||^||^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609648|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052, SOP-67108|^|1|^|3|^|2016-05-05 09:41:15.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB89575p38|^|CRO-017-02|^|04-MAY-2016|^|31564605|^|0|^|A|^|T|^|Uniformity|^|Uniformity|^|Uniformity|^|Y|^|Yes|^||^||^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609648|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052, SOP-67108|^|1|^|3|^|2016-05-05 09:41:15.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB89575p38|^|CRO-017-02|^|04-MAY-2016|^|31564606|^|0|^|A|^|T|^|Absence of Foreign Matter|^|Absence of Foreign Matter|^|Absence of Foreign Matter|^|Y|^|Yes|^||^||^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609648|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052, SOP-67108|^|1|^|3|^|2016-05-05 09:41:15.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB89575p38|^|CRO-017-02|^|04-MAY-2016|^|31564607|^|0|^|A|^|T|^|Absence of Moisture|^|Absence of Moisture|^|Absence of Moisture|^|Y|^|Yes|^||^||^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609648|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052, SOP-67108|^|1|^|3|^|2016-05-05 09:41:15.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB89575p38|^|CRO-017-02|^|04-MAY-2016|^|31564608|^|0|^|A|^|T|^|Absence of Other Defects|^|Absence of Other Defects|^|Absence of Other Defects|^|Y|^|Yes|^||^||^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609649|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reducing)|^|TM100001851, SOP-68795|^|1|^|11|^|2016-05-16 10:10:17.0|^|TM100001851 Version 4.0 Effective Date 19 Aug 2013|^|NB81633 P38|^|CRO-017-02|^|13-MAY-2016|^|31794964|^|0|^|A|^|T|^|LOQ (% Area)|^|LOQ (% Area)|^|LOQ (% Area)|^|0.3|^|0.3|^||^|0.3|^||^|T|^|T|^||^|RYANP18|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609649|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reducing)|^|TM100001851, SOP-68795|^|1|^|11|^|2016-05-16 10:10:17.0|^|TM100001851 Version 4.0 Effective Date 19 Aug 2013|^|NB81633 P38|^|CRO-017-02|^|13-MAY-2016|^|31564613|^|0|^|A|^|T|^|Sum HC and LC|^|Heavy Chain + Light Chain|^|Heavy Chain + Light Chain|^|99.4|^|99.4|^|%|^|99.4|^||^|T|^|T|^|>= 95.0% IgG as heavy + light chain|^|RYANP18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609649|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reducing)|^|TM100001851, SOP-68795|^|1|^|11|^|2016-05-16 10:10:17.0|^|TM100001851 Version 4.0 Effective Date 19 Aug 2013|^|NB81633 P38|^|CRO-017-02|^|13-MAY-2016|^|31564614|^|0|^|A|^|T|^|Percent Fragment|^|Fragments|^|Fragments|^|0.3|^|NMT 0.3|^|%|^||^||^|T|^|T|^|Report Results|^|RYANP18|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609649|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reducing)|^|TM100001851, SOP-68795|^|1|^|11|^|2016-05-16 10:10:17.0|^|TM100001851 Version 4.0 Effective Date 19 Aug 2013|^|NB81633 P38|^|CRO-017-02|^|13-MAY-2016|^|31564615|^|0|^|A|^|T|^|Percent Other|^|Other|^|Other|^|0.3|^|NMT 0.3|^|%|^||^||^|T|^|T|^||^|RYANP18|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609650|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|11|^|2016-05-05 12:01:34.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB122262p15|^|CRO-017-02|^|05-MAY-2016|^|31564620|^|0|^|A|^|T|^|Color Hue|^|Color Hue|^|Color Hue|^|BY|^|BY|^||^||^||^|T|^|T|^||^|CABRII|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609650|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|11|^|2016-05-05 12:01:34.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB122262p15|^|CRO-017-02|^|05-MAY-2016|^|31564621|^|0|^|A|^|T|^|Color Intensity|^|Color Intensity|^|Color Intensity|^|6|^|6|^||^|6|^||^|T|^|T|^||^|CABRII|^|F|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609650|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|11|^|2016-05-05 12:01:34.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB122262p15|^|CRO-017-02|^|05-MAY-2016|^|31670977|^|0|^|A|^|T|^|Color Result|^|Color Result|^|Color Result|^|Not more intensely colored than level 6 of the color standard|^|Not more intensely colored than level 6 of the color standard|^||^||^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609650|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|11|^|2016-05-05 12:01:34.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB122262p15|^|CRO-017-02|^|05-MAY-2016|^|31670978|^|0|^|A|^|T|^|Color Description|^|Color Description|^|Color Description|^|Slightly Brownish-yellow|^|Slightly Brownish-yellow|^||^||^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609650|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|11|^|2016-05-05 12:01:34.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB122262p15|^|CRO-017-02|^|05-MAY-2016|^|31564622|^|0|^|A|^|T|^|Color|^|Coloration|^|Coloration|^|<=BY6|^|<=BY6|^||^||^||^|T|^|T|^|Not more intensely colored than level 5 of the color standard|^|CABRII|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609651|^|A|^|REGISTERED|^|CONCENTRATION_UV|^|Protein Concentration (UV)|^|TM100001683, TMC0085, SOP-68797|^|1|^|10|^|2016-05-09 16:31:00.0|^|TM100001683 Version: 7.0 / 24-JUL-2015|^|NB109693p19|^|CRO-017-02|^|09-MAY-2016|^|31564627|^|0|^|A|^|T|^|Protein Concentration|^|Protein Concentration - rep|^|Protein Concentration - rep|^|21.4|^|21.4|^|mg/mL|^|21.4|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609651|^|A|^|REGISTERED|^|CONCENTRATION_UV|^|Protein Concentration (UV)|^|TM100001683, TMC0085, SOP-68797|^|1|^|10|^|2016-05-09 16:31:00.0|^|TM100001683 Version: 7.0 / 24-JUL-2015|^|NB109693p19|^|CRO-017-02|^|09-MAY-2016|^|31564628|^|0|^|A|^|T|^|Protein Concentration - Average|^|Protein Concentration|^|Protein Concentration|^|21.4|^|21.4|^|mg/mL|^|21.4|^||^|T|^|T|^|Report Results|^|CABRII|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609652|^|A|^|REGISTERED|^|DYE_INGRESS|^|Container Closure|^|TM100002636, SOP-12349|^|1|^|1|^|2016-05-11 17:22:14.0|^|M8721.03 / 22-APR-2013|^|NB111671p26|^|CRO-017-02|^|12-MAY-2016|^|31564636|^|0|^|A|^|T|^|Dye Ingress|^|Dye Ingress|^|Dye Ingress|^|PASS|^|Pass|^||^||^||^|T|^|T|^|Pass|^|CABRII|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609653|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2016-05-13 09:31:41.0|^|TM100001681 Version 3.0 / 30MAY2012|^|89638 p 22|^|CRO-017-02|^|11-MAY-2016|^|31564641|^|0|^|A|^|T|^|Peak 1 (% Area)|^|% Acidic Peaks - rep|^|% Acidic Peaks - rep|^|20.6|^|20.6|^|%|^|20.6|^||^|T|^|T|^||^|CONMYS|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609653|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2016-05-13 09:31:41.0|^|TM100001681 Version 3.0 / 30MAY2012|^|89638 p 22|^|CRO-017-02|^|11-MAY-2016|^|31564642|^|0|^|A|^|T|^|Peak 1 (% Area) - Average|^|% Acidic Peaks|^|% Acidic Peaks|^|20.6|^|20.6|^|%|^|20.6|^||^|T|^|T|^|17.0 - 33.0%|^|CONMYS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609653|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2016-05-13 09:31:41.0|^|TM100001681 Version 3.0 / 30MAY2012|^|89638 p 22|^|CRO-017-02|^|11-MAY-2016|^|31564643|^|0|^|A|^|T|^|Peak 2 (% Area)|^|% Main Peak - rep|^|% Main Peak - rep|^|53.8|^|53.8|^|%|^|53.8|^||^|T|^|T|^||^|CONMYS|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609653|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2016-05-13 09:31:41.0|^|TM100001681 Version 3.0 / 30MAY2012|^|89638 p 22|^|CRO-017-02|^|11-MAY-2016|^|31564644|^|0|^|A|^|T|^|Peak 2 (% Area) - Average|^|% Main Peak|^|% Main Peak|^|53.8|^|53.8|^|%|^|53.8|^||^|T|^|T|^|>= 50.0%|^|CONMYS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609653|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2016-05-13 09:31:41.0|^|TM100001681 Version 3.0 / 30MAY2012|^|89638 p 22|^|CRO-017-02|^|11-MAY-2016|^|31564645|^|0|^|A|^|T|^|Peak 3 (% Area)|^|% Basic Peaks - rep|^|% Basic Peaks - rep|^|25.6|^|25.6|^|%|^|25.6|^||^|T|^|T|^||^|CONMYS|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609653|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2016-05-13 09:31:41.0|^|TM100001681 Version 3.0 / 30MAY2012|^|89638 p 22|^|CRO-017-02|^|11-MAY-2016|^|31564646|^|0|^|A|^|T|^|Peak 3 (% Area) - Average|^|% Basic Peaks|^|% Basic Peaks|^|25.6|^|25.6|^|%|^|25.6|^||^|F|^|F|^|7.0 - 24.0%|^|CONMYS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609654|^|A|^|ADDITIONAL|^|MAB_OXIDATION|^|Lys-C Digest|^|TM100001849, SOP-68792|^|1|^|11|^|2016-05-24 09:03:38.0|^|TM100001849 Version 3.0 / 28NOV2012|^|118110 p7|^|CRO-017-02|^|23-MAY-2016|^|31896615|^|0|^|A|^|T|^|LOQ|^|LOQ|^|LOQ|^|0.7|^|0.7|^|%|^|0.7|^||^|T|^|T|^||^|CONMYS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609654|^|A|^|ADDITIONAL|^|MAB_OXIDATION|^|Lys-C Digest|^|TM100001849, SOP-68792|^|1|^|11|^|2016-05-24 09:03:38.0|^|TM100001849 Version 3.0 / 28NOV2012|^|118110 p7|^|CRO-017-02|^|23-MAY-2016|^|31896616|^|0|^|A|^|T|^|LOQ (% Area)|^|LOQ (% Area)|^|LOQ (% Area)|^|0.7|^|0.7|^||^|0.7|^||^|T|^|T|^||^|CONMYS|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609654|^|A|^|ADDITIONAL|^|MAB_OXIDATION|^|Lys-C Digest|^|TM100001849, SOP-68792|^|1|^|11|^|2016-05-24 09:03:38.0|^|TM100001849 Version 3.0 / 28NOV2012|^|118110 p7|^|CRO-017-02|^|23-MAY-2016|^|31564651|^|0|^|A|^|T|^|Peak 1 (Relative Area %)|^|Oxidation at Fc-Met-1|^|Oxidation at Fc-Met-1|^|1.4|^|1.4|^|%|^|1.4|^||^|T|^|T|^||^|CONMYS|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609656|^|A|^|REGISTERED|^|PARTICULATE_BIO|^|Appearance (Visible Particulates)|^|TM100002052, SOP-67108|^|1|^|4|^|2016-05-05 09:43:08.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB89575p38|^|CRO-017-02|^|04-MAY-2016|^|31564663|^|0|^|A|^|T|^|Particles|^|Visible particulates|^|Visible particulates|^|FREE|^|Essentially Free of Visible Particles|^||^||^||^|T|^|T|^|Essentially Free of Visible Particles|^|CABRII|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609657|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2016-05-06 12:05:24.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|NB123958p11|^|CRO-017-02|^|05-MAY-2016|^|31684243|^|1|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|4864|^|4864|^|Particles/container|^|4864|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609657|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2016-05-06 12:05:24.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|NB123958p11|^|CRO-017-02|^|05-MAY-2016|^|31684244|^|2|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|5096|^|5096|^|Particles/container|^|5096|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609657|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2016-05-06 12:05:24.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|NB123958p11|^|CRO-017-02|^|05-MAY-2016|^|31684245|^|3|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|5144|^|5144|^|Particles/container|^|5144|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609657|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2016-05-06 12:05:24.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|NB123958p11|^|CRO-017-02|^|05-MAY-2016|^|31564668|^|0|^|A|^|T|^|Light Obscuration: >= 2µm|^|Light Obscuration: >= 2µm|^|Light Obscuration: >= 2µm|^|5034.6666667|^|5035|^|Particles/container|^|5035|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609657|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2016-05-06 12:05:24.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|NB123958p11|^|CRO-017-02|^|05-MAY-2016|^|31684246|^|1|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|1408|^|1408|^|Particles/container|^|1408|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609657|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2016-05-06 12:05:24.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|NB123958p11|^|CRO-017-02|^|05-MAY-2016|^|31684247|^|2|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|1364|^|1364|^|Particles/container|^|1364|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609657|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2016-05-06 12:05:24.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|NB123958p11|^|CRO-017-02|^|05-MAY-2016|^|31684248|^|3|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|1640|^|1640|^|Particles/container|^|1640|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609657|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2016-05-06 12:05:24.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|NB123958p11|^|CRO-017-02|^|05-MAY-2016|^|31564669|^|0|^|A|^|T|^|Light Obscuration: >= 5µm|^|Light Obscuration: >= 5µm|^|Light Obscuration: >= 5µm|^|1470.6666667|^|1471|^|Particles/container|^|1471|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609657|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2016-05-06 12:05:24.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|NB123958p11|^|CRO-017-02|^|05-MAY-2016|^|31684249|^|1|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|480|^|480|^|Particles/container|^|480|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609657|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2016-05-06 12:05:24.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|NB123958p11|^|CRO-017-02|^|05-MAY-2016|^|31684250|^|2|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|512|^|512|^|Particles/container|^|512|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609657|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2016-05-06 12:05:24.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|NB123958p11|^|CRO-017-02|^|05-MAY-2016|^|31684251|^|3|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|680|^|680|^|Particles/container|^|680|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609657|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2016-05-06 12:05:24.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|NB123958p11|^|CRO-017-02|^|05-MAY-2016|^|31564670|^|0|^|A|^|T|^|Light Obscuration: >= 8µm|^|Light Obscuration: >= 8µm|^|Light Obscuration: >= 8µm|^|557.33333333|^|557|^|Particles/container|^|557|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609657|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2016-05-06 12:05:24.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|NB123958p11|^|CRO-017-02|^|05-MAY-2016|^|31684252|^|1|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|236|^|236|^|Particles/container|^|236|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609657|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2016-05-06 12:05:24.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|NB123958p11|^|CRO-017-02|^|05-MAY-2016|^|31684253|^|2|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|224|^|224|^|Particles/container|^|224|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609657|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2016-05-06 12:05:24.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|NB123958p11|^|CRO-017-02|^|05-MAY-2016|^|31684254|^|3|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|396|^|396|^|Particles/container|^|396|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609657|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2016-05-06 12:05:24.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|NB123958p11|^|CRO-017-02|^|05-MAY-2016|^|31564671|^|0|^|A|^|T|^|Light Obscuration: >= 10µm|^|Light Obscuration: >= 10µm|^|Light Obscuration: >= 10µm|^|285.33333333|^|285|^|Particles/container|^|285|^||^|T|^|T|^|Report Results|^|CABRII|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609657|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2016-05-06 12:05:24.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|NB123958p11|^|CRO-017-02|^|05-MAY-2016|^|31684255|^|1|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|12|^|12|^|Particles/container|^|12|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609657|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2016-05-06 12:05:24.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|NB123958p11|^|CRO-017-02|^|05-MAY-2016|^|31684256|^|2|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|4|^|4|^|Particles/container|^|4|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609657|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2016-05-06 12:05:24.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|NB123958p11|^|CRO-017-02|^|05-MAY-2016|^|31684257|^|3|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|56|^|56|^|Particles/container|^|56|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609657|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2016-05-06 12:05:24.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|NB123958p11|^|CRO-017-02|^|05-MAY-2016|^|31564672|^|0|^|A|^|T|^|Light Obscuration: >= 25µm|^|Light Obscuration: >= 25µm|^|Light Obscuration: >= 25µm|^|24|^|24|^|Particles/container|^|24|^||^|T|^|T|^|Report Results|^|CABRII|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609657|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|7|^|2016-05-06 12:05:24.0|^|TM100002055 version 2.0 / 03-MAR-2014|^|NB123958p11|^|CRO-017-02|^|05-MAY-2016|^|31564673|^|0|^|A|^|T|^|Particulate Matter|^|Particulate Matter|^|Particulate Matter|^|Meets compendial requirements|^|Meets compendial requirements|^||^||^||^|T|^|T|^|Meets compendial requirements|^|CABRII|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609658|^|A|^|REGISTERED|^|PH|^|pH|^|M00125, TMS-000000862, SOP-67110|^|1|^|6|^|2016-05-06 12:10:28.0|^|M00125 Version 2.0 / 07-MAY-2012|^|NB120957p6|^|CRO-017-02|^|06-MAY-2016|^|31564678|^|0|^|A|^|T|^|pH|^|pH - rep|^|pH - rep|^|5.9|^|5.9|^||^|5.9|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609658|^|A|^|REGISTERED|^|PH|^|pH|^|M00125, TMS-000000862, SOP-67110|^|1|^|6|^|2016-05-06 12:10:28.0|^|M00125 Version 2.0 / 07-MAY-2012|^|NB120957p6|^|CRO-017-02|^|06-MAY-2016|^|31564679|^|0|^|A|^|T|^|pH - Average|^|pH|^|pH|^|5.9|^|5.9|^||^|5.9|^||^|T|^|T|^|6.0 +/- 0.5|^|CABRII|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609659|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2016-05-05 09:46:56.0|^|TM100001683 Version: 7.0 / 24-JUL-2015|^|NB89575p38|^|CRO-017-02|^|04-MAY-2016|^|31564684|^|0|^|A|^|T|^|Minutes|^|Minutes|^|Minutes|^|2|^|2|^|min|^|2|^||^|T|^|T|^||^|CABRII|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609659|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2016-05-05 09:46:56.0|^|TM100001683 Version: 7.0 / 24-JUL-2015|^|NB89575p38|^|CRO-017-02|^|04-MAY-2016|^|31564685|^|0|^|A|^|T|^|Seconds|^|Seconds|^|Seconds|^|27|^|27|^|s|^|27|^||^|T|^|T|^||^|CABRII|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609659|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2016-05-05 09:46:56.0|^|TM100001683 Version: 7.0 / 24-JUL-2015|^|NB89575p38|^|CRO-017-02|^|04-MAY-2016|^|31564686|^|0|^|A|^|T|^|Rounding Interval|^|Rounding Interval|^|Rounding Interval|^|30|^|30|^||^|30|^||^|T|^|T|^||^|CABRII|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609659|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2016-05-05 09:46:56.0|^|TM100001683 Version: 7.0 / 24-JUL-2015|^|NB89575p38|^|CRO-017-02|^|04-MAY-2016|^|31564687|^|0|^|A|^|T|^|Total Time|^|Total Time|^|Total Time|^|150|^|150|^|s|^|150|^||^|T|^|T|^||^|CABRII|^|F|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609659|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2016-05-05 09:46:56.0|^|TM100001683 Version: 7.0 / 24-JUL-2015|^|NB89575p38|^|CRO-017-02|^|04-MAY-2016|^|31564688|^|0|^|A|^|T|^|Reconstitution Time|^|Reconstitution Time|^|Reconstitution Time|^|2 min 30 sec|^|2 min 30 sec|^||^||^||^|T|^|T|^|Report Results|^|CABRII|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609660|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777, 018-QA54699, SOP-68796|^|1|^|15|^|2016-05-11 17:53:11.0|^|TM100001777 v3.0 / 30-MAY-2012|^|NB92114p20|^|CRO-017-02|^|08-MAY-2016|^|31564693|^|0|^|A|^|T|^|Peak 1 (% Area)|^|Monomer|^|Monomer|^|96.7|^|96.7|^|%|^|96.7|^||^|T|^|T|^|>= 95.0%|^|CABRII|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609660|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777, 018-QA54699, SOP-68796|^|1|^|15|^|2016-05-11 17:53:11.0|^|TM100001777 v3.0 / 30-MAY-2012|^|NB92114p20|^|CRO-017-02|^|08-MAY-2016|^|31564694|^|0|^|A|^|T|^|Peak 2 (% Area)|^|HMMS|^|HMMS|^|3.0|^|3.0|^|%|^|3|^||^|T|^|F|^|<= 5.0%|^|CABRII|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609660|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777, 018-QA54699, SOP-68796|^|1|^|15|^|2016-05-11 17:53:11.0|^|TM100001777 v3.0 / 30-MAY-2012|^|NB92114p20|^|CRO-017-02|^|08-MAY-2016|^|31564695|^|0|^|A|^|T|^|Peak 3 (% Area)|^|LMMS|^|LMMS|^|0.2|^|0.2|^|%|^|0.2|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609662|^|A|^|REGISTERED|^|TURBIDITY|^|Appearance (Clarity)|^|TM100002052, SOP-67108|^|1|^|2|^|2016-05-05 12:02:38.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB122262p15|^|CRO-017-02|^|05-MAY-2016|^|31564707|^|0|^|A|^|T|^|Turbidity - Rep|^|Turbidity - Rep|^|Turbidity - Rep|^|3|^|3|^|NTU|^|3|^||^|T|^|T|^||^|CABRII|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482520|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-24 09:03:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609662|^|A|^|REGISTERED|^|TURBIDITY|^|Appearance (Clarity)|^|TM100002052, SOP-67108|^|1|^|2|^|2016-05-05 12:02:38.0|^|TM100002052 Version 7.0 / 22-JUN-2015|^|NB122262p15|^|CRO-017-02|^|05-MAY-2016|^|31564708|^|0|^|A|^|T|^|Turbidity|^|Turbidity|^|Turbidity|^|3|^|3|^|NTU|^|3|^||^|T|^|T|^|<= 18 NTU|^|CABRII|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482521|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-23 20:10:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609655|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405, SOP-68798|^|1|^|5|^|2016-05-23 14:28:55.0|^|TM000001405 v4.0|^|00709821-0342|^|Pfizer, QC, St. Louis, MO, US|^|23-MAY-2016|^|31564656|^|0|^|A|^|T|^|LOQ|^|LOQ|^|LOQ|^|0.2|^|0.2|^||^|0.2|^||^|T|^|T|^||^|BERESB|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482521|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-23 20:10:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609655|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405, SOP-68798|^|1|^|5|^|2016-05-23 14:28:55.0|^|TM000001405 v4.0|^|00709821-0342|^|Pfizer, QC, St. Louis, MO, US|^|23-MAY-2016|^|31564657|^|1|^|A|^|T|^|Moisture - Rep|^|Moisture - Rep|^|Moisture - Rep|^|0.475981823|^|0.5|^|%|^|0.5|^||^|T|^|T|^||^|BERESB|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482521|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-05-23 20:10:38.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609655|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405, SOP-68798|^|1|^|5|^|2016-05-23 14:28:55.0|^|TM000001405 v4.0|^|00709821-0342|^|Pfizer, QC, St. Louis, MO, US|^|23-MAY-2016|^|31564658|^|0|^|A|^|T|^|Moisture|^|Moisture|^|Moisture|^|0.475981823|^|0.5|^|%|^|0.5|^||^|T|^|T|^|<= 2%|^|BERESB|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482522|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-06-10 16:39:12.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609661|^|A|^|REGISTERED|^|SPECIFIC_ACTIVITY|^|Potency Assay (Cell Based)|^|TM100001721, SOP-68246|^|1|^|11|^|2016-06-10 16:39:12.0|^|TM100001721 v9.0 / 23OCT2015|^|ELN: 03JUN2016 M7758 LMH|^|CRO-017-01|^|03-JUN-2016|^|31564700|^|0|^|A|^|T|^|Relative Potency|^|Relative Potency|^|Relative Potency|^|94|^|94|^|%|^|94|^||^|T|^|T|^|55 - 158% potency relative to reference material|^|HERNDL|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|9|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_48|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_48|^|48 Months|^|48|^||^|2012-05-04 00:00:00.0|^|2016-05-04 00:00:00.0|^||^|482519|^|A|^|482522|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_48|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2016-04-27 00:01:31.0|^|2016-05-04 12:47:02.0|^|2016-05-05 09:41:26.0|^|2016-06-10 16:39:12.0|^|2016-07-27 19:31:08.0|^|F|^|F|^|2016-07-27 19:31:15.0|^|1609661|^|A|^|REGISTERED|^|SPECIFIC_ACTIVITY|^|Potency Assay (Cell Based)|^|TM100001721, SOP-68246|^|1|^|11|^|2016-06-10 16:39:12.0|^|TM100001721 v9.0 / 23OCT2015|^|ELN: 03JUN2016 M7758 LMH|^|CRO-017-01|^|03-JUN-2016|^|31564701|^|0|^|A|^|T|^|Specific Activity|^|Specific Activity|^|Specific Activity|^|939|^|939|^|U/mg|^|939|^||^|T|^|T|^|550 - 1580 U/mg|^|HERNDL|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934306|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052, SOP-67108|^|1|^|3|^|2017-05-09 08:42:29.0|^|TM100002052 Version 9.0|^|NB101168p31|^|CRO-017-02|^|04-MAY-2017|^|36380732|^|0|^|A|^|T|^|Appearance|^|Visual appearance|^|Visual appearance|^|White cake essentially free from visible particulates|^|White cake essentially free from visible particulates|^||^||^||^|T|^|T|^|White cake essentially free from visible particulates|^|FLYNND14|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934306|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052, SOP-67108|^|1|^|3|^|2017-05-09 08:42:29.0|^|TM100002052 Version 9.0|^|NB101168p31|^|CRO-017-02|^|04-MAY-2017|^|36380734|^|0|^|A|^|T|^|Color|^|Color|^|Color|^|Y|^|Yes|^||^||^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934306|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052, SOP-67108|^|1|^|3|^|2017-05-09 08:42:29.0|^|TM100002052 Version 9.0|^|NB101168p31|^|CRO-017-02|^|04-MAY-2017|^|36380735|^|0|^|A|^|T|^|Uniformity|^|Uniformity|^|Uniformity|^|Y|^|Yes|^||^||^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934306|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052, SOP-67108|^|1|^|3|^|2017-05-09 08:42:29.0|^|TM100002052 Version 9.0|^|NB101168p31|^|CRO-017-02|^|04-MAY-2017|^|36380736|^|0|^|A|^|T|^|Absence of Foreign Matter|^|Absence of Foreign Matter|^|Absence of Foreign Matter|^|Y|^|Yes|^||^||^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934306|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052, SOP-67108|^|1|^|3|^|2017-05-09 08:42:29.0|^|TM100002052 Version 9.0|^|NB101168p31|^|CRO-017-02|^|04-MAY-2017|^|36380737|^|0|^|A|^|T|^|Absence of Moisture|^|Absence of Moisture|^|Absence of Moisture|^|Y|^|Yes|^||^||^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934306|^|A|^|REGISTERED|^|APPEARANCE_LYO|^|Appearance (Before Reconstitution)|^|TM100002052, SOP-67108|^|1|^|3|^|2017-05-09 08:42:29.0|^|TM100002052 Version 9.0|^|NB101168p31|^|CRO-017-02|^|04-MAY-2017|^|36380738|^|0|^|A|^|T|^|Absence of Other Defects|^|Absence of Other Defects|^|Absence of Other Defects|^|Y|^|Yes|^||^||^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934321|^|A|^|ADDITIONAL|^|CGE_NONREDUCED|^|CGE (non-reduced)|^|TM100001852, SOP-68794|^|1|^|10|^|2017-05-16 16:04:47.0|^|TM100001852 Version 5.0 Effective Date 19OCT2016|^|NB 109703 P30|^|CRO-017-02|^|15-MAY-2017|^|36713613|^|0|^|A|^|T|^|LOQ (% Area)|^|LOQ (% Area)|^|LOQ (% Area)|^|0.3|^|0.3|^||^|0.3|^||^|T|^|T|^||^|JAMESS17|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934321|^|A|^|ADDITIONAL|^|CGE_NONREDUCED|^|CGE (non-reduced)|^|TM100001852, SOP-68794|^|1|^|10|^|2017-05-16 16:04:47.0|^|TM100001852 Version 5.0 Effective Date 19OCT2016|^|NB 109703 P30|^|CRO-017-02|^|15-MAY-2017|^|36380854|^|0|^|A|^|T|^|IgG % Time Corrected Area|^|Intact IgG|^|Intact IgG|^|94.1|^|94.1|^|%|^|94.1|^||^|T|^|T|^||^|JAMESS17|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934321|^|A|^|ADDITIONAL|^|CGE_NONREDUCED|^|CGE (non-reduced)|^|TM100001852, SOP-68794|^|1|^|10|^|2017-05-16 16:04:47.0|^|TM100001852 Version 5.0 Effective Date 19OCT2016|^|NB 109703 P30|^|CRO-017-02|^|15-MAY-2017|^|36713614|^|0|^|A|^|T|^|Non-Reduced Percent Fragment|^|Non-Reduced Percent Fragment|^|Non-Reduced Percent Fragment|^|3.9|^|3.9|^|%|^|3.9|^||^|T|^|T|^||^|JAMESS17|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934321|^|A|^|ADDITIONAL|^|CGE_NONREDUCED|^|CGE (non-reduced)|^|TM100001852, SOP-68794|^|1|^|10|^|2017-05-16 16:04:47.0|^|TM100001852 Version 5.0 Effective Date 19OCT2016|^|NB 109703 P30|^|CRO-017-02|^|15-MAY-2017|^|36713615|^|0|^|A|^|T|^|Percent Other|^|Percent Other|^|Percent Other|^|2.0|^|2.0|^|%|^|2|^||^|T|^|T|^||^|JAMESS17|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934307|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reducing)|^|TM100001851, SOP-68795|^|1|^|11|^|2017-05-24 08:46:57.0|^|TM100001851 Version 5.0 Effective Date 19OCT2016|^|NB 118109 P34|^|CRO-017-02|^|22-MAY-2017|^|36860810|^|0|^|A|^|T|^|LOQ (% Area)|^|LOQ (% Area)|^|LOQ (% Area)|^|0.3|^|0.3|^||^|0.3|^||^|T|^|T|^||^|JAMESS17|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934307|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reducing)|^|TM100001851, SOP-68795|^|1|^|11|^|2017-05-24 08:46:57.0|^|TM100001851 Version 5.0 Effective Date 19OCT2016|^|NB 118109 P34|^|CRO-017-02|^|22-MAY-2017|^|36380743|^|0|^|A|^|T|^|Sum HC and LC|^|Heavy Chain + Light Chain|^|Heavy Chain + Light Chain|^|98.9|^|98.9|^|%|^|98.9|^||^|T|^|T|^|>= 95.0% IgG as heavy + light chain|^|JAMESS17|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934307|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reducing)|^|TM100001851, SOP-68795|^|1|^|11|^|2017-05-24 08:46:57.0|^|TM100001851 Version 5.0 Effective Date 19OCT2016|^|NB 118109 P34|^|CRO-017-02|^|22-MAY-2017|^|36380744|^|0|^|A|^|T|^|Percent Fragment|^|Fragments|^|Fragments|^|0.3|^|NMT 0.3|^|%|^||^||^|T|^|T|^|Report Results|^|JAMESS17|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934307|^|A|^|REGISTERED|^|CGE_REDUCED|^|CGE (reducing)|^|TM100001851, SOP-68795|^|1|^|11|^|2017-05-24 08:46:57.0|^|TM100001851 Version 5.0 Effective Date 19OCT2016|^|NB 118109 P34|^|CRO-017-02|^|22-MAY-2017|^|36380745|^|0|^|A|^|T|^|Percent Other|^|Other|^|Other|^|0.7|^|0.7|^|%|^|0.7|^||^|T|^|T|^||^|JAMESS17|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934308|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|11|^|2017-05-09 08:42:29.0|^|TM100002052 Version 9.0|^|NB127613 p15|^|CRO-017-02|^|05-MAY-2017|^|36380750|^|0|^|A|^|T|^|Color Hue|^|Color Hue|^|Color Hue|^|B|^|B|^||^||^||^|T|^|T|^||^|FLYNND14|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934308|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|11|^|2017-05-09 08:42:29.0|^|TM100002052 Version 9.0|^|NB127613 p15|^|CRO-017-02|^|05-MAY-2017|^|36380751|^|0|^|A|^|T|^|Color Intensity|^|Color Intensity|^|Color Intensity|^|8|^|8|^||^|8|^||^|T|^|T|^||^|FLYNND14|^|F|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934308|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|11|^|2017-05-09 08:42:29.0|^|TM100002052 Version 9.0|^|NB127613 p15|^|CRO-017-02|^|05-MAY-2017|^|36578947|^|0|^|A|^|T|^|Color Result|^|Color Result|^|Color Result|^|Not more intensely colored than level 8 of the color standard|^|Not more intensely colored than level 8 of the color standard|^||^||^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934308|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|11|^|2017-05-09 08:42:29.0|^|TM100002052 Version 9.0|^|NB127613 p15|^|CRO-017-02|^|05-MAY-2017|^|36578948|^|0|^|A|^|T|^|Color Description|^|Color Description|^|Color Description|^|Very Very Slightly Brown|^|Very Very Slightly Brown|^||^||^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934308|^|A|^|REGISTERED|^|COLOR_BIO|^|Appearance (Coloration)|^|TM100002052, SOP-67108|^|1|^|11|^|2017-05-09 08:42:29.0|^|TM100002052 Version 9.0|^|NB127613 p15|^|CRO-017-02|^|05-MAY-2017|^|36380752|^|0|^|A|^|T|^|Color|^|Coloration|^|Coloration|^|<=B8|^|<=B8|^||^||^||^|T|^|T|^|Not more intensely colored than level 5 of the color standard|^|FLYNND14|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934309|^|A|^|REGISTERED|^|CONCENTRATION_UV|^|Protein Concentration (UV)|^|TM100001683, TMC0085, SOP-68797|^|1|^|10|^|2017-05-16 14:34:39.0|^|TM100001683 Version: 8.0|^|NB101173 p33|^|CRO-017-02|^|11-MAY-2017|^|36380757|^|0|^|A|^|T|^|Protein Concentration|^|Protein Concentration - rep|^|Protein Concentration - rep|^|21.2|^|21.2|^|mg/mL|^|21.2|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934309|^|A|^|REGISTERED|^|CONCENTRATION_UV|^|Protein Concentration (UV)|^|TM100001683, TMC0085, SOP-68797|^|1|^|10|^|2017-05-16 14:34:39.0|^|TM100001683 Version: 8.0|^|NB101173 p33|^|CRO-017-02|^|11-MAY-2017|^|36380758|^|0|^|A|^|T|^|Protein Concentration - Average|^|Protein Concentration|^|Protein Concentration|^|21.2|^|21.2|^|mg/mL|^|21.2|^||^|T|^|T|^|Report Results|^|FLYNND14|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934322|^|A|^|REGISTERED|^|DYE_INGRESS|^|Container Closure|^|TM100002636, SOP-12349|^|1|^|1|^|2017-05-24 07:21:17.0|^|M8721 version 3|^|NB113972 p31|^|CRO-017-02|^|23-MAY-2017|^|36380859|^|0|^|A|^|T|^|Dye Ingress|^|Dye Ingress|^|Dye Ingress|^|PASS|^|Pass|^||^||^||^|T|^|T|^|Pass|^|FLYNND14|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934310|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2017-05-15 11:58:17.0|^|TM100001681 Version 4.0|^|NB89635 p29|^|CRO-017-02|^|12-MAY-2017|^|36380766|^|0|^|A|^|T|^|Peak 1 (% Area)|^|% Acidic Peaks - rep|^|% Acidic Peaks - rep|^|21.2|^|21.2|^|%|^|21.2|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934310|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2017-05-15 11:58:17.0|^|TM100001681 Version 4.0|^|NB89635 p29|^|CRO-017-02|^|12-MAY-2017|^|36380767|^|0|^|A|^|T|^|Peak 1 (% Area) - Average|^|% Acidic Peaks|^|% Acidic Peaks|^|21.2|^|21.2|^|%|^|21.2|^||^|T|^|T|^|17.0 - 33.0%|^|FLYNND14|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934310|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2017-05-15 11:58:17.0|^|TM100001681 Version 4.0|^|NB89635 p29|^|CRO-017-02|^|12-MAY-2017|^|36380768|^|0|^|A|^|T|^|Peak 2 (% Area)|^|% Main Peak - rep|^|% Main Peak - rep|^|52.3|^|52.3|^|%|^|52.3|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934310|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2017-05-15 11:58:17.0|^|TM100001681 Version 4.0|^|NB89635 p29|^|CRO-017-02|^|12-MAY-2017|^|36380769|^|0|^|A|^|T|^|Peak 2 (% Area) - Average|^|% Main Peak|^|% Main Peak|^|52.3|^|52.3|^|%|^|52.3|^||^|T|^|T|^|>= 50.0%|^|FLYNND14|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934310|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2017-05-15 11:58:17.0|^|TM100001681 Version 4.0|^|NB89635 p29|^|CRO-017-02|^|12-MAY-2017|^|36380770|^|0|^|A|^|T|^|Peak 3 (% Area)|^|% Basic Peaks - rep|^|% Basic Peaks - rep|^|26.5|^|26.5|^|%|^|26.5|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934310|^|A|^|REGISTERED|^|IEX_HPLC|^|Charge Isoforms (IEX)|^|TM100001681, SOP-68791|^|1|^|3|^|2017-05-15 11:58:17.0|^|TM100001681 Version 4.0|^|NB89635 p29|^|CRO-017-02|^|12-MAY-2017|^|36380771|^|0|^|A|^|T|^|Peak 3 (% Area) - Average|^|% Basic Peaks|^|% Basic Peaks|^|26.5|^|26.5|^|%|^|26.5|^||^|F|^|F|^|7.0 - 24.0%|^|FLYNND14|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934311|^|A|^|ADDITIONAL|^|MAB_OXIDATION|^|Lys-C Digest|^|TM100001849, SOP-68792|^|1|^|11|^|2017-05-19 11:02:06.0|^|TM100001849 Version 4.0 Effective Date 19OCT2016|^|NB 118107 P33|^|CRO-017-02|^|18-MAY-2017|^|36785087|^|0|^|A|^|T|^|LOQ|^|LOQ|^|LOQ|^|0.7|^|0.7|^|%|^|0.7|^||^|T|^|T|^||^|JAMESS17|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934311|^|A|^|ADDITIONAL|^|MAB_OXIDATION|^|Lys-C Digest|^|TM100001849, SOP-68792|^|1|^|11|^|2017-05-19 11:02:06.0|^|TM100001849 Version 4.0 Effective Date 19OCT2016|^|NB 118107 P33|^|CRO-017-02|^|18-MAY-2017|^|36785088|^|0|^|A|^|T|^|LOQ (% Area)|^|LOQ (% Area)|^|LOQ (% Area)|^|0.7|^|0.7|^||^|0.7|^||^|T|^|T|^||^|JAMESS17|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934311|^|A|^|ADDITIONAL|^|MAB_OXIDATION|^|Lys-C Digest|^|TM100001849, SOP-68792|^|1|^|11|^|2017-05-19 11:02:06.0|^|TM100001849 Version 4.0 Effective Date 19OCT2016|^|NB 118107 P33|^|CRO-017-02|^|18-MAY-2017|^|36380776|^|0|^|A|^|T|^|Peak 1 (Relative Area %)|^|Oxidation at Fc-Met-1|^|Oxidation at Fc-Met-1|^|1.7|^|1.7|^|%|^|1.7|^||^|T|^|T|^||^|JAMESS17|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934313|^|A|^|REGISTERED|^|PARTICULATE_BIO|^|Appearance (Visible Particulates)|^|TM100002052, SOP-67108|^|1|^|4|^|2017-05-09 08:42:29.0|^|TM100002052 Version 9.0|^|NB101168 p31|^|CRO-017-02|^|04-MAY-2017|^|36380788|^|0|^|A|^|T|^|Particles|^|Visible particulates|^|Visible particulates|^|FREE|^|Essentially Free of Visible Particles|^||^||^||^|T|^|T|^|Essentially Free of Visible Particles|^|FLYNND14|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934314|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|8|^|2017-05-11 15:03:46.0|^|TM100002055 version 3.0|^|NB128885p1|^|CRO-017-02|^|11-MAY-2017|^|36629760|^|1|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|8768|^|8768|^|Particles/container|^|8768|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934314|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|8|^|2017-05-11 15:03:46.0|^|TM100002055 version 3.0|^|NB128885p1|^|CRO-017-02|^|11-MAY-2017|^|36629761|^|2|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|8404|^|8404|^|Particles/container|^|8404|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934314|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|8|^|2017-05-11 15:03:46.0|^|TM100002055 version 3.0|^|NB128885p1|^|CRO-017-02|^|11-MAY-2017|^|36629762|^|3|^|A|^|T|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|Light Obscuration: >= 2µm - rep|^|8376|^|8376|^|Particles/container|^|8376|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934314|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|8|^|2017-05-11 15:03:46.0|^|TM100002055 version 3.0|^|NB128885p1|^|CRO-017-02|^|11-MAY-2017|^|36380793|^|0|^|A|^|T|^|Light Obscuration: >= 2µm|^|Light Obscuration: >= 2µm|^|Light Obscuration: >= 2µm|^|8516|^|8516|^|Particles/container|^|8516|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934314|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|8|^|2017-05-11 15:03:46.0|^|TM100002055 version 3.0|^|NB128885p1|^|CRO-017-02|^|11-MAY-2017|^|36629763|^|1|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|1460|^|1460|^|Particles/container|^|1460|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934314|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|8|^|2017-05-11 15:03:46.0|^|TM100002055 version 3.0|^|NB128885p1|^|CRO-017-02|^|11-MAY-2017|^|36629764|^|2|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|1396|^|1396|^|Particles/container|^|1396|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934314|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|8|^|2017-05-11 15:03:46.0|^|TM100002055 version 3.0|^|NB128885p1|^|CRO-017-02|^|11-MAY-2017|^|36629765|^|3|^|A|^|T|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|Light Obscuration: >= 5µm - rep|^|1388|^|1388|^|Particles/container|^|1388|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934314|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|8|^|2017-05-11 15:03:46.0|^|TM100002055 version 3.0|^|NB128885p1|^|CRO-017-02|^|11-MAY-2017|^|36380794|^|0|^|A|^|T|^|Light Obscuration: >= 5µm|^|Light Obscuration: >= 5µm|^|Light Obscuration: >= 5µm|^|1414.6666667|^|1415|^|Particles/container|^|1415|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934314|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|8|^|2017-05-11 15:03:46.0|^|TM100002055 version 3.0|^|NB128885p1|^|CRO-017-02|^|11-MAY-2017|^|36629766|^|1|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|416|^|416|^|Particles/container|^|416|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934314|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|8|^|2017-05-11 15:03:46.0|^|TM100002055 version 3.0|^|NB128885p1|^|CRO-017-02|^|11-MAY-2017|^|36629767|^|2|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|344|^|344|^|Particles/container|^|344|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934314|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|8|^|2017-05-11 15:03:46.0|^|TM100002055 version 3.0|^|NB128885p1|^|CRO-017-02|^|11-MAY-2017|^|36629768|^|3|^|A|^|T|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|Light Obscuration: >= 8µm - rep|^|320|^|320|^|Particles/container|^|320|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934314|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|8|^|2017-05-11 15:03:46.0|^|TM100002055 version 3.0|^|NB128885p1|^|CRO-017-02|^|11-MAY-2017|^|36380795|^|0|^|A|^|T|^|Light Obscuration: >= 8µm|^|Light Obscuration: >= 8µm|^|Light Obscuration: >= 8µm|^|360|^|360|^|Particles/container|^|360|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934314|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|8|^|2017-05-11 15:03:46.0|^|TM100002055 version 3.0|^|NB128885p1|^|CRO-017-02|^|11-MAY-2017|^|36629769|^|1|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|224|^|224|^|Particles/container|^|224|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934314|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|8|^|2017-05-11 15:03:46.0|^|TM100002055 version 3.0|^|NB128885p1|^|CRO-017-02|^|11-MAY-2017|^|36629770|^|2|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|168|^|168|^|Particles/container|^|168|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934314|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|8|^|2017-05-11 15:03:46.0|^|TM100002055 version 3.0|^|NB128885p1|^|CRO-017-02|^|11-MAY-2017|^|36629771|^|3|^|A|^|T|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|Light Obscuration: >= 10µm - rep|^|156|^|156|^|Particles/container|^|156|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934314|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|8|^|2017-05-11 15:03:46.0|^|TM100002055 version 3.0|^|NB128885p1|^|CRO-017-02|^|11-MAY-2017|^|36380796|^|0|^|A|^|T|^|Light Obscuration: >= 10µm|^|Light Obscuration: >= 10µm|^|Light Obscuration: >= 10µm|^|182.66666667|^|183|^|Particles/container|^|183|^||^|T|^|T|^|Report Results|^|FLYNND14|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934314|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|8|^|2017-05-11 15:03:46.0|^|TM100002055 version 3.0|^|NB128885p1|^|CRO-017-02|^|11-MAY-2017|^|36629772|^|1|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|12|^|12|^|Particles/container|^|12|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934314|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|8|^|2017-05-11 15:03:46.0|^|TM100002055 version 3.0|^|NB128885p1|^|CRO-017-02|^|11-MAY-2017|^|36629773|^|2|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|4|^|4|^|Particles/container|^|4|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934314|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|8|^|2017-05-11 15:03:46.0|^|TM100002055 version 3.0|^|NB128885p1|^|CRO-017-02|^|11-MAY-2017|^|36629774|^|3|^|A|^|T|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|Light Obscuration: >= 25µm - rep|^|0|^|0|^|Particles/container|^|0|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934314|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|8|^|2017-05-11 15:03:46.0|^|TM100002055 version 3.0|^|NB128885p1|^|CRO-017-02|^|11-MAY-2017|^|36380797|^|0|^|A|^|T|^|Light Obscuration: >= 25µm|^|Light Obscuration: >= 25µm|^|Light Obscuration: >= 25µm|^|5.3333333333|^|5|^|Particles/container|^|5|^||^|T|^|T|^|Report Results|^|FLYNND14|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934314|^|A|^|REGISTERED|^|PARTICULATE_MATTER_USP788|^|Subvisible Particles|^|USP <788>, TM100002055, SOP-13114|^|1|^|8|^|2017-05-11 15:03:46.0|^|TM100002055 version 3.0|^|NB128885p1|^|CRO-017-02|^|11-MAY-2017|^|36380798|^|0|^|A|^|T|^|Particulate Matter|^|Particulate Matter|^|Particulate Matter|^|Meets compendial requirements|^|Meets compendial requirements|^||^||^||^|T|^|T|^|Meets compendial requirements|^|FLYNND14|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934315|^|A|^|REGISTERED|^|PH|^|pH|^|M00125, TMS-000000862, SOP-67110|^|1|^|7|^|2017-05-09 08:42:29.0|^|M00125 Version 2.0|^|NB120955 p16|^|CRO-017-02|^|08-MAY-2017|^|36380803|^|0|^|A|^|T|^|pH|^|pH - rep|^|pH - rep|^|5.9|^|5.9|^||^|5.9|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934315|^|A|^|REGISTERED|^|PH|^|pH|^|M00125, TMS-000000862, SOP-67110|^|1|^|7|^|2017-05-09 08:42:29.0|^|M00125 Version 2.0|^|NB120955 p16|^|CRO-017-02|^|08-MAY-2017|^|36380804|^|0|^|A|^|T|^|pH - Average|^|pH|^|pH|^|5.9|^|5.9|^||^|5.9|^||^|T|^|T|^|6.0 +/- 0.5|^|FLYNND14|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934316|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2017-05-09 08:42:29.0|^|TM100001683 Version: 8.0|^|NB101168p31|^|CRO-017-02|^|04-MAY-2017|^|36380809|^|0|^|A|^|T|^|Minutes|^|Minutes|^|Minutes|^|3|^|3|^|min|^|3|^||^|T|^|T|^||^|FLYNND14|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934316|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2017-05-09 08:42:29.0|^|TM100001683 Version: 8.0|^|NB101168p31|^|CRO-017-02|^|04-MAY-2017|^|36380810|^|0|^|A|^|T|^|Seconds|^|Seconds|^|Seconds|^|42|^|42|^|s|^|42|^||^|T|^|T|^||^|FLYNND14|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934316|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2017-05-09 08:42:29.0|^|TM100001683 Version: 8.0|^|NB101168p31|^|CRO-017-02|^|04-MAY-2017|^|36380811|^|0|^|A|^|T|^|Rounding Interval|^|Rounding Interval|^|Rounding Interval|^|30|^|30|^||^|30|^||^|T|^|T|^||^|FLYNND14|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934316|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2017-05-09 08:42:29.0|^|TM100001683 Version: 8.0|^|NB101168p31|^|CRO-017-02|^|04-MAY-2017|^|36380812|^|0|^|A|^|T|^|Total Time|^|Total Time|^|Total Time|^|240|^|240|^|s|^|240|^||^|T|^|T|^||^|FLYNND14|^|F|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934316|^|A|^|REGISTERED|^|RECON_TIME|^|Reconstitution Time|^|TM100001683, TM100002052, SOP-67108|^|1|^|5|^|2017-05-09 08:42:29.0|^|TM100001683 Version: 8.0|^|NB101168p31|^|CRO-017-02|^|04-MAY-2017|^|36380813|^|0|^|A|^|T|^|Reconstitution Time|^|Reconstitution Time|^|Reconstitution Time|^|4 min |^|4 min |^||^||^||^|T|^|T|^|Report Results|^|FLYNND14|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934317|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777, 018-QA54699, SOP-68796|^|1|^|17|^|2017-05-11 13:30:33.0|^|TM100001777 v3.0|^|NB111516 p46|^|CRO-017-02|^|10-MAY-2017|^|36380820|^|0|^|A|^|T|^|Peak 1 (% Area)|^|Monomer|^|Monomer|^|96.4|^|96.4|^|%|^|96.4|^||^|T|^|T|^|>= 95.0%|^|FLYNND14|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934317|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777, 018-QA54699, SOP-68796|^|1|^|17|^|2017-05-11 13:30:33.0|^|TM100001777 v3.0|^|NB111516 p46|^|CRO-017-02|^|10-MAY-2017|^|36380821|^|0|^|A|^|T|^|Peak 2 (% Area)|^|HMMS|^|HMMS|^|3.4|^|3.4|^|%|^|3.4|^||^|T|^|F|^|<= 5.0%|^|FLYNND14|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934317|^|A|^|REGISTERED|^|SEC|^|Size Exclusion HPLC|^|TM100001777, 018-QA54699, SOP-68796|^|1|^|17|^|2017-05-11 13:30:33.0|^|TM100001777 v3.0|^|NB111516 p46|^|CRO-017-02|^|10-MAY-2017|^|36380822|^|0|^|A|^|T|^|Peak 3 (% Area)|^|LMMS|^|LMMS|^|0.2|^|0.2|^|%|^|0.2|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934320|^|A|^|REGISTERED|^|TURBIDITY|^|Appearance (Clarity)|^|TM100002052, SOP-67108|^|1|^|2|^|2017-05-09 08:42:29.0|^|TM100002052 Version 9.0|^|NB127613 p15|^|CRO-017-02|^|05-MAY-2017|^|36380848|^|0|^|A|^|T|^|Turbidity - Rep|^|Turbidity - Rep|^|Turbidity - Rep|^|3.20|^|3|^|NTU|^|3|^||^|T|^|T|^||^|FLYNND14|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595974|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-05-24 08:46:57.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934320|^|A|^|REGISTERED|^|TURBIDITY|^|Appearance (Clarity)|^|TM100002052, SOP-67108|^|1|^|2|^|2017-05-09 08:42:29.0|^|TM100002052 Version 9.0|^|NB127613 p15|^|CRO-017-02|^|05-MAY-2017|^|36380849|^|0|^|A|^|T|^|Turbidity|^|Turbidity|^|Turbidity|^|3.2|^|3|^|NTU|^|3|^||^|T|^|T|^|<= 18 NTU|^|FLYNND14|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-06-23 12:50:02.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934312|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405, SOP-68798|^|1|^|5|^|2017-06-22 17:02:29.0|^|TM000001405 v 4.0|^|00710916-0042|^|Pfizer, QC, St. Louis, MO, US|^|22-JUN-2017|^|36380781|^|0|^|A|^|T|^|LOQ|^|LOQ|^|LOQ|^|0.2|^|0.2|^||^|0.2|^||^|T|^|T|^||^|NELSOA16|^|F|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-06-23 12:50:02.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934312|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405, SOP-68798|^|1|^|5|^|2017-06-22 17:02:29.0|^|TM000001405 v 4.0|^|00710916-0042|^|Pfizer, QC, St. Louis, MO, US|^|22-JUN-2017|^|36380782|^|1|^|A|^|T|^|Moisture - Rep|^|Moisture - Rep|^|Moisture - Rep|^|0.554879035|^|0.6|^|%|^|0.6|^||^|T|^|T|^||^|NELSOA16|^|T|^|F|^|NO
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595975|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-06-23 12:50:02.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934312|^|A|^|REGISTERED|^|MOISTURE_KARL_FISCHER|^|Residual Moisture|^|TM000001405, SOP-68798|^|1|^|5|^|2017-06-22 17:02:29.0|^|TM000001405 v 4.0|^|00710916-0042|^|Pfizer, QC, St. Louis, MO, US|^|22-JUN-2017|^|36380783|^|0|^|A|^|T|^|Moisture|^|Moisture|^|Moisture|^|0.554879035|^|0.6|^|%|^|0.6|^||^|T|^|T|^|<= 2%|^|NELSOA16|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595976|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-06-12 17:52:07.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1942078|^|A|^|REGISTERED|^|ENDOTOXIN|^|Endotoxin|^|USP <85>, TM100001884, SOP-12810,TMM0077|^|1|^|12|^|2017-05-25 20:25:31.0|^|M14522.00|^|NB 137701 P9-12|^|CRO-017-01|^|25-MAY-2017|^|36505066|^|0|^|A|^|T|^|Endotoxin - rep|^|Endotoxin - rep|^|Endotoxin - rep|^|<0.0023|^|0.00|^|EU/mg|^|0|^||^|T|^|T|^||^|CLARKR37|^|T|^|F|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595976|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-06-12 17:52:07.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1942078|^|A|^|REGISTERED|^|ENDOTOXIN|^|Endotoxin|^|USP <85>, TM100001884, SOP-12810,TMM0077|^|1|^|12|^|2017-05-25 20:25:31.0|^|M14522.00|^|NB 137701 P9-12|^|CRO-017-01|^|25-MAY-2017|^|36505067|^|0|^|A|^|T|^|Endotoxin|^|Endotoxin|^|Endotoxin|^|0.0023|^|0.00|^|EU/mg|^|0|^||^|T|^|T|^|<= 0.63 EU/mg|^|CLARKR37|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595976|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-06-12 17:52:07.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934318|^|A|^|REGISTERED|^|SPECIFIC_ACTIVITY|^|Potency Assay (Cell Based)|^|TM100001721, SOP-68246|^|1|^|11|^|2017-06-09 16:07:59.0|^|TM100001721v10 effective 17FEB2017|^|ELN: 02JUN2017 M7758 EJP2|^|CRO-017-01|^|02-JUN-2017|^|36380836|^|0|^|A|^|T|^|Relative Potency|^|Relative Potency|^|Relative Potency|^|125|^|125|^|%|^|125|^||^|T|^|T|^|55 - 158% potency relative to reference material|^|OCONNR24|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595976|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-06-12 17:52:07.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1934318|^|A|^|REGISTERED|^|SPECIFIC_ACTIVITY|^|Potency Assay (Cell Based)|^|TM100001721, SOP-68246|^|1|^|11|^|2017-06-09 16:07:59.0|^|TM100001721v10 effective 17FEB2017|^|ELN: 02JUN2017 M7758 EJP2|^|CRO-017-01|^|02-JUN-2017|^|36380837|^|0|^|A|^|T|^|Specific Activity|^|Specific Activity|^|Specific Activity|^|1246|^|1246|^|U/mg|^|1246|^||^|T|^|T|^|550 - 1580 U/mg|^|OCONNR24|^|T|^|T|^|YES
|^||^||^|527|^|PF-05280014|^|PF-05280014 (Trastuzumab)|^|Trastuzumab (Biosimilar 2, PF8)|^|D1100333|^|10|^|PF-05280014 Powder for Injection, 440 mg/vial|^|DP|^|Z00514|^|12410|^|2012-01-27 00:00:00.0|^||^|PF-05280014:1-007 / MONTH_60|^|Z00514|^|PF-05280014:1-007|^|INVERTED|^|30C_75RH|^|MONTH_60|^|60 Months|^|60|^||^|2012-05-04 00:00:00.0|^|2017-05-04 00:00:00.0|^||^|595973|^|A|^|595976|^|A|^|Z00514 / INVERTED / 30C_75RH / MONTH_60|^|STB|^|STABILITY_ALIQUOT|^|FINAL|^|STB_CLINICAL_HUMAN|^|2017-04-27 00:00:45.0|^|2018-09-13 15:56:15.0|^|2018-09-13 15:56:15.0|^|2017-06-12 17:52:07.0|^|2018-09-13 17:01:00.0|^|F|^|F|^|2018-09-13 17:01:08.0|^|1942077|^|A|^|REGISTERED|^|STERILITY|^|Sterility|^|USP <71>,TMS-000001008,TTM0072,SOP-12269|^|1|^|4|^|2017-06-12 17:52:07.0|^|USP 40 <71>, M12543.01|^|ELN Batch: 24May2017 Sterility|^|CRO-017-01|^|24-MAY-2017|^|36505061|^|0|^|A|^|T|^|Sterility|^|Sterility|^|Sterility|^|NO_GROWTH|^|No growth detected|^||^||^||^|T|^|T|^|No growth detected|^|CLARKR37|^|T|^|F|^|YES
